,index,pmid,rpsid,pmidlink,components_type,rna_id,rna_id_interface,rnas,rna_length,rna_sequence,rna_classification,source,protein_sequence,protein_name,protein_region,protein_modification,protein_sequence_length,Uniprot ID,mark,link,IDR,low complexity domain,In_vitrovivo,solute_concentration,salt_concentration,buffer,temperature,incubation_time,other_requirement,detection_method,morphology,description,rna_length_num
0,0,PMID: 22398450,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/22398450,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,136 µM [PTBP1];|80 µM RNA,"170 mM NaCl, 30 mM KCl, 1 mM MgCl2","170 mM NaCl, 30 mM KCl, 1 mM MgCl2",RT,"imme diately,> 2day s",other_molecular:1 mM ATP,Differential interference contrast microscopy,liquid,"Analogous droplets were also observed for an unrelated SH35-ligand5 pair and for the tetravalent RNA binding protein PTB interacting with an RNA oligonucleotide. Thus, liquid-liquiddemixing phase transitions may occur in many multivalent intracellular systems.",50
1,1,PMID: 22579282,RNAPS0000052,https://pubmed.ncbi.nlm.nih.gov/22579282,RNA + protein,-;|-,-;|-,"MS2 hairpin RNA (Han,2012);|Saccharomyces cerevisiae tRNA",31nt;|-,UAGAAAACAUGAGGAUCACCCAUGUCUGCAG;|-,irregular RNA;|tRNA,-;|Saccharomyces cerevisiae,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1 µM[RNA];|2.5 µM yeast tRNA,"50 mM KCl, 5 mM MgCl2","50 mM KCl, 5 mM MgCl2",0˚C,30 min,"other_molecular:0.5% NP-40, 20 mM BME, 1:500 Rnasin",Confocal microscopy,gel,"Gel retention assay performed with both CFP tagged protein and Cy5.5-labeled hairpin RNA. The MS2 RNA hairpin is only recruited into the hydrogel when incubated with CFP-FUS214-MS2, which contains both the capacity for binding RNA as well as LC elements required for gel retention.",31
2,2,PMID: 26015579,RNAPS0000090,https://pubmed.ncbi.nlm.nih.gov/26015579,RNA + protein,-,-,polyU(50),50nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1|length=708aa|residues=1-708
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,0-8 µM [laf-1];|5 µM polyU,100-400 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",20˚C,> 1 h,-,FRAP,"solute, liquid","RNA is recruited to droplets but does not shift the phase boundary. Addition of 5 µM RNA has no effect on the phase diagram of LAF-1. RNA concentration in the dilute phase vs. total LAF-1 concentration at 250 mM NaCl. Unlike LAF-1, which is in equilibrium with a constant saturation concentration in the dilute phase (Fig. 2D), the RNA concentration in the dilute phase decreases as total protein concentration increases. RNA concentration was directly measured using absorbance at A260 in the bulk phase after centrifugation of droplets.",50
3,3,PMID: 26351690,RNAPS0000159,https://pubmed.ncbi.nlm.nih.gov/26351690,RNAs + protein,-,-,Caenorhabditis elegans rRNA,50nt,-,rRNA,Caenorhabditis elegans,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib-1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,5.5 µM [fib1];|5 µM rRNA,250 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Microscopy,liquid,"RNA specificity did not increase the magnitude of phase separation. We found quantitatively similar results with an in vitro-transcribed segment of C. elegans rRNA that is a direct substrate of FIB-1. Moreover, in addition to shifting the phase boundary, RNA accelerated droplet coarsening.",50
4,5,PMID: 26406374,RNAPS0000173,https://pubmed.ncbi.nlm.nih.gov/26406374,RNA + protein,-,-,"a random oligonucleotide RNA (Molliex,2015)",44nt,GGGCCCCCGGGUACCGAGCUGCUAAUCAAAACAAAACAAAAGCU,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=135aa|residues=186-320
MASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGSGDGYN
GFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY
GGSSSSSSYGSGRRF",HNRNPA1,LCD,-,135aa(186-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[186-196],[197-208],[309-318]",[190-320],In vitro,100 µM [HNRNPA1 LCD];|100 µM RNA,150 mM NaCl,"50 mM HEPES(pH 7.5), 5 mM DTT",10˚C,-,crowding agent:150 mg/ml Ficoll,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"The two RRM domains and multiple binding motifs for RRMs on the RNA likely mediate weak multivalent interactions that lead to LLPS. Droplets formed by A1-LCD also recruited RNA (Figure 4C), indicating that the LCD of hnRNPA1 binds RNA, as shown previously.",44
5,6,PMID: 26406374,RNAPS0000173,https://pubmed.ncbi.nlm.nih.gov/26406374,RNA + protein,-,-,"a random oligonucleotide RNA (Molliex,2015)",44nt,GGGCCCCCGGGUACCGAGCUGCUAAUCAAAACAAAACAAAAGCU,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,0.05-100 µM [HNRNPA1];|0-100 µM RNA,150 mM NaCl,"50 mM HEPES(pH 7.5), 5 mM DTT",10˚C,-,crowding agent:150 mg/ml Ficoll,"Differential interference contrast microscopy,Fluorescence microscopy","solute, liquid","Fluorescently labeled RNA (flfl-RNA44) was recruited into the protein-dense droplets formed by hnRNPA1 (Figure 4A). Notably, the addition of RNA substantially decreased the hnRNPA1 concentration required for phase separation to as low as 500 nM, well within the estimated intracellular concentration of hnRNPA1.",44
6,7,PMID: 26406374,RNAPS0000173,https://pubmed.ncbi.nlm.nih.gov/26406374,RNA + protein,-,-,"a random oligonucleotide RNA (Molliex,2015)",44nt,GGGCCCCCGGGUACCGAGCUGCUAAUCAAAACAAAACAAAAGCU,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=186aa|residues=1-186
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEM",HNRNPA1,RRM,-,186aa(1-186),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-186]",-,In vitro,100 µM [HNRNPA1 RRM];|100 µM RNA,150 mM NaCl,"50 mM HEPES(pH 7.5), 5 mM DTT",10˚C,-,crowding agent:150 mg/ml Ficoll,Fluorescence microscopy,liquid,"The increased propensity for LLPS in the presence of RNA suggested the formation of larger hetero-oligomers. Indeed, despite our previous results that A1-RRM alone was not able to undergo LLPS under any conditions when tested in isolation, it readily phase separated in the presence of RNA.",44
7,8,PMID: 26412307,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,2.5-12.5 µM [PTBP1];|0.4-2 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,liquid,"An important point is that, even when insufficient in themselves to promote LLPS, promiscuous IDRs can decrease the critical concentration for phase separation driven by more specific interactions. We demonstrate this phenomenon for phase separation of PTB and RNA in vitro (Figure 4) and for P-body assembly in vivo (Figure 6).",50
8,9,PMID: 26412307,RNAPS0000175,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P39936|IF4F2_YEAST Eukaryotic initiation factor 4F subunit p130 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=TIF4632 PE=1 SV=1|length=85aa|residues=13-97
QQANGYKKFPPHDNQYSGANNSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRN
NSQGNAQYYNNRFNNGYRLNNNDYN",elF4GII,IDR,-,85aa(13-97),P39936,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P39936,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0420,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0006,http://db.phasep.pro/browse/","[14-15],[17-19],[32-44],[64-66],[86-97]",-,In vitro,30 µM [elF4GII IDR];|0.1-4 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,liquid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM).",50
9,10,PMID: 26412307,RNAPS0000175,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P39936|IF4F2_YEAST Eukaryotic initiation factor 4F subunit p130 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=TIF4632 PE=1 SV=1|length=85aa|residues=13-97
QQANGYKKFPPHDNQYSGANNSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRN
NSQGNAQYYNNRFNNGYRLNNNDYN",elF4GII,IDR,-,85aa(13-97),P39936,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P39936,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0420,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0006,http://db.phasep.pro/browse/","[14-15],[17-19],[32-44],[64-66],[86-97]",-,In vitro,30 µM [elF4GII IDR];|4-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,liquid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM).",50
10,11,PMID: 26412307,RNAPS0000176,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=237aa|residues=1-237
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",FUS,IDR,-,237aa(1-237),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[1-237],"[17-104],[106-237]",In vitro,30 µM [FUS IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,solid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM).",50
11,12,PMID: 26412307,RNAPS0000177,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=135aa|residues=186-320
MASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGSGDGYN
GFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY
GGSSSSSSYGSGRRF",HNRNPA1,IDR,-,135aa(186-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[186-196],[197-208],[309-318]",[190-320],In vitro,10 µM [HNRNPA1 IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,liquid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM).",50
12,13,PMID: 26412307,RNAPS0000179,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P40070|LSM4_YEAST U6 snRNA-associated Sm-like protein LSm4 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=LSM4 PE=1 SV=1|length=97aa|residues=91-187
QQINSNNNSNSNGPGHKRYYNNRDSNNNRGNYNRRNNNNGNSNRRPYSQNRQYNNSNSSN
INNSINSINSNNQNMNNGLGGSVQHHFNSSSPQKVEF",LSM4,IDR,-,97aa(91-187),P40070,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0005,http://db.phasep.pro/browse/",-,"[94-102],[108-135],[138-167]",In vitro,30 µM [Lsm4 IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Electron microscopy,solid,"A range of RNA concentrations (0.1–10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10–30 uM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 uM).",50
13,14,PMID: 26412307,RNAPS0000367,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[elF4GII IDR] with PTB residues 1-531 fused to elF4GII residues 13-97|Linker is missing|length=616aa|residues=1-531/13-97
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIQQANGYKKF
PPHDNQYSGANNSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRNNSQGNAQYY
NNRFNNGYRLNNNDYN",PTBP1-TIF4632,IDR,-,"616aa(1-531,13-97)","P26599,P39936","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
TIF4632:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P39936,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0420,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0006,http://db.phasep.pro/browse/","-;|[14-15],[17-19],[32-44],[64-66],[86-97]","[32-44],[162-179],[306-335];|-",In vitro,1.25 µM [PTBP1]-[TIF4632 IDR];|0.4 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 1 h;24 h,-,Electron microscopy,liquid,"All six PTB-IDR fusions phase separated upon addition of RNA, producing droplets that concentrated both molecules. At 1 hr after RNA addition, droplets formed by the eIF4GII IDR, Pub1 IDR, and Fus IDR fusions were relatively large, round, and separated into discrete structures. By contrast, the Lsm4 IDR, Tia1 IDR, and hnRNPA1 IDR fusions created droplets that were smaller, and often attached to each other in long irregular chains, as though coalescence into larger structures had been aborted.",50
14,15,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,≥125 nM [PTBP1]-[FUS IDR];|≥20 nM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,liquid,"Adding BSA can greatly reduce the concentration threshold of proteins and RNA for phase transition.Performing the experiment in the presence of 100 mg/ml BSA to mimic protein-crowding effects within the cell allowed the detection of RNA-driven LLPS of the SNAP-PTB-FusIDR at concentrations below 10 nM (Figure 2D), which is below the cellular concentration of many of the abundant components of mRNP granules.",50
15,16,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,≤62.5 nM [PTBP1]-[FUS IDR];|≤10 nM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,solute,"Adding BSA can greatly reduce the concentration threshold of proteins and RNA for phase transition.Performing the experiment in the presence of 100 mg/ml BSA to mimic protein-crowding effects within the cell allowed the detection of RNA-driven LLPS of the SNAP-PTB-FusIDR at concentrations below 10 nM (Figure 2D), which is below the cellular concentration of many of the abundant components of mRNP granules.",50
16,17,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,1-250 nM [PTBP1]-[FUS IDR];|1-40 nM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,other_molecular:100 mg/ml BSA,Electron microscopy,liquid,"Adding BSA can greatly reduce the concentration threshold of proteins and RNA for phase transition.Performing the experiment in the presence of 100 mg/ml BSA to mimic protein-crowding effects within the cell allowed the detection of RNA-driven LLPS of the SNAP-PTB-FusIDR at concentrations below 10 nM (Figure 2D), which is below the cellular concentration of many of the abundant components of mRNP granules.",50
17,18,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,3 µM [PTBP1]-[FUS IDR];|0.5 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,-,-,Electron microscopy,liquid,"At 100 mM NaCl and protein concentrations of 1.25–2.5 mM, all six SNAP-PTB-IDR fusions phase separated upon addition of 0.4–0.8 mM RNA, producing droplets that concentrated both molecules (Figures 2 and S2A, showing RNA enrichment).",50
18,19,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,0.5-12.5 µM [PTBP1]-[FUS IDR];|0.1-2 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 12 h,-,Electron microscopy,"solute, liquid","At 100 mM NaCl and protein concentrations of 1.25–2.5 mM, all six SNAP-PTB-IDR fusions phase separated upon addition of 0.4–0.8 mM RNA, producing droplets that concentrated both molecules (Figures 2 and S2A, showing RNA enrichment).",50
19,20,PMID: 26412307,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[FUS IDR] with PTB residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,1.25 µM [PTBP1]-[FUS IDR];|0.4 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 1 h;24 h,-,Electron microscopy,liquid,"All six PTB-IDR fusions phase separated upon addition of RNA, producing droplets that concentrated both molecules. At 1 hr after RNA addition, droplets formed by the eIF4GII IDR, Pub1 IDR, and Fus IDR fusions were relatively large, round, and separated into discrete structures. By contrast, the Lsm4 IDR, Tia1 IDR, and hnRNPA1 IDR fusions created droplets that were smaller, and often attached to each other in long irregular chains, as though coalescence into larger structures had been aborted.",50
20,21,PMID: 26412307,RNAPS0000048,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[Pub1 IDR] with PTB residues 1-531 fused to Pub1 residues 243-327|Linker is missing|length=616aa|residues=1-531;243-327
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTINNNNNNYQQ
RRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMPIGAMPLPSQGQ
PQQSQTIGLPPQVNPQ",PTBP1-PUB1,IDR,-,"616aa(1-531,243-327)","P26599,P32588","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/,https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/",-;|[243-262],"[32-44],[162-179],[306-335];|[243-297],[307-316]",In vitro,2.5 µM [PTBP1]-[PUB1 IDR];|0.8 µM RNA,100 mM NaCl,"20 mM imidazole, pH 7.0, 1 mM DTT, 10% glycerol",RT,> 1 h;24 h,-,Electron microscopy,liquid,"All six PTB-IDR fusions phase separated upon addition of RNA, producing droplets that concentrated both molecules. At 1 hr after RNA addition, droplets formed by the eIF4GII IDR, Pub1 IDR, and Fus IDR fusions were relatively large, round, and separated into discrete structures. By contrast, the Lsm4 IDR, Tia1 IDR, and hnRNPA1 IDR fusions created droplets that were smaller, and often attached to each other in long irregular chains, as though coalescence into larger structures had been aborted.",50
21,22,PMID: 26412307,RNAPS0000049,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P32588|PUB1_YEAST Nuclear and cytoplasmic polyadenylated RNA-binding protein PUB1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PUB1 PE=1 SV=4|length=85aa|residues=243-327
NNNNNNYQQRRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMPIG
AMPLPSQGQPQQSQTIGLPPQVNPQ",PUB1,IDR,-,85aa(243-327),P32588,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/",[243-262],"[243-297],[307-316]",In vitro,30 µM [PUB1 IDR];|0.1-10 µM RNA,100 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,-,Fluorescence microscopy,liquid,"A range of RNA concentrations (0.1-10 mM) did not promote phase separation of the IDR proteins up to protein concentrations of 10-30 µM, SNAP-eIF4GII IDR, which did phase separate upon addition of RNA (0.1~4 µM).",50
22,23,PMID: 26412307,RNAPS0000050,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,"hnRNPA1_ligand RNA (Lin,2015)",46nt,UAGGGACUUAGGGUUCUCUCUAGGGACUUAGGGUUCUCUCUAGGGA,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,50 µM [HNRNPA1];|100 µM RNA,300 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,> 1 h,crowding agent:100 mg/ml Ficoll400,Electron microscopy,liquid,"If we added PEG as a crowding agent, we observed phase separation of hnRNPA1 without RNA at high protein concentrations, and stimulation of LLPS with RNA addition at lower protein concentrations, demonstrating that RNA can promote LLPS of hnRNPA1. Similar results were observed with Ficoll as a crowding agent.",46
23,24,PMID: 26412307,RNAPS0000050,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,"hnRNPA1_ligand RNA (Lin,2015)",46nt,UAGGGACUUAGGGUUCUCUCUAGGGACUUAGGGUUCUCUCUAGGGA,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,5 µM [HNRNPA1];|10 µM RNA,175 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,crowding agent:100 mg/ml PEG 3350,Electron microscopy,liquid,"If we added PEG as a crowding agent, we observed phase separation of hnRNPA1 without RNA at high protein concentrations, and stimulation of LLPS with RNA addition at lower protein concentrations, demonstrating that RNA can promote LLPS of hnRNPA1. Similar results were observed with Ficoll as a crowding agent.",46
24,25,PMID: 26412307,RNAPS0000050,https://pubmed.ncbi.nlm.nih.gov/26412307,RNA + protein,-,-,"hnRNPA1_ligand RNA (Lin,2015)",46nt,UAGGGACUUAGGGUUCUCUCUAGGGACUUAGGGUUCUCUCUAGGGA,irregular RNA,-,"sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens OX=9606 GN=HNRNPA1|length=320aa|residues=1-320
MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFV
TYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHH
LRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKA
LSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGS
GDGYNGFGNDGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPR
NQGGYGGSSSSSSYGSGRRF",HNRNPA1,-,-,320aa(1-320),P09651,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/P09651,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2438","[1-8],[92-102],[182-196],[197-208],[309-318]",[190-320],In vitro,30 µM [HNRNPA1];|60 µM RNA,175 mM NaCl,"20 mM Tris pH 7.4, 1 mM DTT",RT,-,crowding agent:100 mg/ml PEG 3350,Electron microscopy,liquid,"If we added PEG as a crowding agent, we observed phase separation of hnRNPA1 without RNA at high protein concentrations, and stimulation of LLPS with RNA addition at lower protein concentrations, demonstrating that RNA can promote LLPS of hnRNPA1. Similar results were observed with Ficoll as a crowding agent.",46
25,70,PMID: 27212236,RNAPS0000058,https://pubmed.ncbi.nlm.nih.gov/27212236,RNA + protein,-,-,polyU(50),50nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|Q22053|FBRL_CAEEL rRNA 2'-O-methyltransferase fibrillarin OS=Caenorhabditis elegans OX=6239 GN=fib-1 PE=2 SV=1|length=352aa|residues=1-352
MGRPEFNRGGGGGGFRGGRGGDRGGSRGGFGGGGRGGYGGGDRGSFGGGDRGGFRGGRGG
GDRGGFRGGRGGGDRGGFGGRGSPRGGFGGRGSPRGGRGSPRGGRGGAGGMRGGKTVVVE
PHRLGGVFIVKGKEDALATKNMVVGESVYGEKRVSVDDGAGSIEYRVWNPFRSKLAASIM
GGLENTHIKPGTKLLYLGAASGTTVSHCSDVVGPEGIVYAVEFSHRSGRDLLGVAKKRPN
VVPIVEDARHPHKYRMLVGMVDVIFSDVAQPDQARIVALNAQNFLRNGGHAVISIKANCI
DSTAEPEAVFAGEVNKLKEEKFKPLEQVTLEPYERDHAVVVAVYRPVKGKKV",fib1,-,-,352aa(1-352),Q22053,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q22053,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0032,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0019,http://db.phasep.pro/browse/",[1-115],[8-114],In vitro,600 nM [fib1];|5 µM polyU,150 mM NaCl,"20 mM Tris, pH 7.5, 1 mM DTT",RT,> 30 min,-,Microscopy,liquid,"Indeed, in the presence of 5 mg/ml rRNA and 150 mM NaCl, FIB1 condenses into droplets at a protein concentration of 600 nM. FIB1 can phase separate even in the presence of non-specific poly-U50 and heparin, suggesting that electrostatic interactions contribute to droplet assembly.",50
26,89,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,6.2 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,> 20 min,-,Wide-field fluorescence microscopy,solute,"Dhh1 liquid droplet formation requires ATP binding. Dhh1 droplets did not form in the absence of ATP, demonstrating that Dhh1 in its ATP-bound form promotes liquid droplet formation.",0
27,90,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506|mutation=F66R
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGREKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,protein_mutation:F66R,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/","[22-39],[61-85],[323-328],[411-453],[464-504]",-,In vitro,6.2 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,> 1 h,other_molecular:5 mM ATP,Wide-field fluorescence microscopy,solute,"Dhh1_M(F66R) showed only a minor defect in PB localization following glucose starvation, this mutant showed a dramatic loss of droplet formation in vitro.",0
28,91,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,6.2 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,≤ 20 min,"other_molecular:5 mM ATP,5 μM RNase A",Wide-field fluorescence microscopy,liquid,"Remarkably, recombinant Dhh1, in the presence of RNA and ATP, readily formed droplets in solution. These droplets showed hallmarks of liquid-liquid phase separation, undergoing growth and fusion events and reversible deformation, consistent with the reported biophysical behavior of PBs. Dhh1 droplet formation was RNA-dependent, as no droplets formed when RNA was omitted, and the number and size of droplets rapidly decreased upon addition of RNase A, but not with buffer alone.",0
29,92,PMID: 27692063,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/27692063,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.5-12.5 µM [DHH1];|0.075 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,4˚C,> 1 h,other_molecular:5 mM ATP,Wide-field fluorescence microscopy,liquid,"Remarkably, recombinant Dhh1, in the presence of RNA and ATP, readily formed droplets in solution. These droplets showed hallmarks of liquid-liquid phase separation, undergoing growth and fusion events and reversible deformation, consistent with the reported biophysical behavior of PBs. Dhh1 droplet formation was RNA-dependent, as no droplets formed when RNA was omitted, and the number and size of droplets rapidly decreased upon addition of RNase A, but not with buffer alone. Dhh1 droplets did not form in the absence of ATP, demonstrating that Dhh1 in its ATP-bound form promotes liquid droplet formation.",0
30,95,PMID: 27914198,RNAPS0000091,https://pubmed.ncbi.nlm.nih.gov/27914198,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=544aa|residues=1-544
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSS",meg-3,IDR,-,544aa(1-544),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492]",In vitro,0.1-5 µM [MEG3 IDR];|0.1-10 µM polyU,150 mM NaCl,"25 mM HEPES, pH7.4",RT,≤ 10 min,-,Confocal microscopy,liquid,"MEG-3 and MEG-3IDR behaved similarly to each other, except that in the low concentration range (<5 mM), MEG-3 formed more condensates than MEG-3IDR, and in the high concentration range (>5 mM) MEG-3IDR tended to form larger condensates.",30
31,96,PMID: 27914198,RNAPS0000091,https://pubmed.ncbi.nlm.nih.gov/27914198,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1|length=862aa|residues=1-862
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,0.1-5 µM [MEG3];|0.1-10 µM polyU,150 mM NaCl,"25 mM HEPES, pH7.4",RT,≤ 10 min,-,Confocal microscopy,liquid,"We pre-incubated recombinant MEX-5 with poly-U in buffer for 30 min before adding MEG-3. We found that MEX-5 strongly inhibited MEG-3 phase separation induced by RNA. Addition of excess RNA (3-fold increase) restored robust phase separation in the presence of MEX-5. Additionally, MEX-5 had no effect on the phase separation of MEG-3 in the absence of RNA. MEG-3 and MEG-3IDR behaved similarly to each other, except that in the low concentration range (<5 mM), MEG-3 formed more condensates than MEG-3IDR, and in the high concentration range (>5 mM) MEG-3IDR tended to form larger condensates.",30
32,97,PMID: 28283059,RNAPS0000093,https://pubmed.ncbi.nlm.nih.gov/28283059,RNA + protein,-,-,polyA(19),19nt,AAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|P04147|PABP_YEAST Polyadenylate-binding protein, cytoplasmic and nuclear OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAB1 PE=1 SV=4|length=597aa|residues=2-577
MGSSHHHHHHHHASENLYFQSADITDKTAEQLENLNIQDDQKQAATGSESQSVENSSASL
YVGDLEPSVSEAHLYDIFSPIGSVSSIRVCRDAITKTSLGYAYVNFNDHEAGRKAIEQLN
YTPIKGRLCRIMWSQRDPSLRKKGSGNIFIKNLHPDIDNKALYDTFSVFGDILSSKIATD
ENGKSKGFGFVHFEEEGAAKEAIDALNGMLLNGQEIYVAPHLSRKERDSQLEETKAHYTN
LYVKNINSETTDEQFQELFAKFGPIVSASLEKDADGKLKGFGFVNYEKHEDAVKAVEALN
DSELNGEKLYVGRAQKKNERMHVLKKQYEAYRLEKMAKYQGVNLFVKNLDDSVDDEKLEE
EFAPYGTITSAKVMRTENGKSKGFGFVCFSTPEEATKAITEKNQQIVAGKPLYVAIAQRK
DVRRSQLAQQIQARNQMRYQQATAAAAAAAAGMPGQFMPPMFYGVMPPRGVPFNGPNPQQ
MNPMGGMPKNGMPPQFRNGPVYGVPPQGGFPRNANDNNQFYQQKQRQALGEQLYKKVSAK
TSNEEAAGKITGMILDLPPQEVFPLLESDELFEQHYKEASAAYESFKKEQEQQTEQA",Pab1,-,-,597aa(1-597),P04147,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P04147,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0254,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0048,http://db.phasep.pro/browse/","[1-12],[29-65],[118-118],[130-143],[199-207],[217-231],[307-327],[357-357],[414-450],[471-501],[549-566],[588-596]",-,In vitro,15 µM [Pab1 2-577];|100 µg/ml polyA,"150 mM KCl, 2.5 mM MgCl2",20 mM HEPES pH 6.4,46˚C,> 30 min,-,Gel filtration,solute,"Adding RNA increasingly inhibited Pab1 demixing. Pab1 releases RNA and demixes, forming particles stabilized by protein-protein interactions, consistent with its behavior in vivo.",19
33,98,PMID: 28306503,RNAPS0000094,https://pubmed.ncbi.nlm.nih.gov/28306503,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)20,-,-,[PR]20:40aa,-,-,-,-,-,In vitro,0-250 µM [PR]20;|0-1 µg/µl polyU,-,100mM K2HPO4/KH2PO4 buffer,RT,-,-,"Turbidity measurement,FRAP,Cryo-EM",liquid,"This raised the idea that biological anions could support PR LLPS as well. Indeed, addition of polyU RNA promoted LLPS in a dose-dependent manner even without molecular crowders being present.",30
34,99,PMID: 28306503,RNAPS0000095,https://pubmed.ncbi.nlm.nih.gov/28306503,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|Q96LT7|CI072_HUMAN Guanine nucleotide exchange C9orf72 OS=Homo sapiens OX=9606 GN=C9orf72 PE=1 SV=2
MSTLCPPPSPAVAKTEIALSGKSPLLAATFAYWDNILGPRVRHIWAPKTEQVLLSDGEIT
FLANHTLNGEILRNAESGAIDVKFFVLSEKGVIIVSLIFDGNWNGDRSTYGLSIILPQTE
LSFYLPLHRVCVDRLTHIIRKGRIWMHKERQENVQKIILEGTERMEDQGQSIIPMLTGEV
IPVMELLSSMKSHSVPEEIDIADTVLNDDDIGDSCHEGFLLNAISSHLQTCGCSVVVGSS
AEKVNKIVRTLCLFLTPAERKCSRLCEAESSFKYESGLFVQGLLKDSTGSFVLPFRQVMY
APYPTTHIDVDVNTVKQMPPCHEHIYNQRRYMRSELTAFWRATSEEDMAQDTIIYTDESF
TPDLNIFQDVLHRDTLVKAFLDQVFQLKPGLSLRSTFLAQFLLVLHRKALTLIKYIEDDT
QKGKKPFKSLRNLKIDLDLTAEGDLNIIMALAEKIKPGLHSFIFGRPFYTSVQERDVLMT
F",C9orf72,-,-,481aa(1-481),Q96LT7,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0616,http://db.phasep.pro/browse/",-,-,In vitro,0.05-0.25 µg/µL [polyU];|20 µM [C9orf72],200 µM NaCl,"50mM MES,pH 5",RT,≤ 200 min,-,FRAP,liquid,"Similar to the PEG-induced LLPS, PR20-RNA droplets were highly circular (Figure 4A). They also continuously increased in size over time, as measured by dynamic light scattering (DLS).",30
35,100,PMID: 28306503,RNAPS0000095,https://pubmed.ncbi.nlm.nih.gov/28306503,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|Q96LT7|CI072_HUMAN Guanine nucleotide exchange C9orf72 OS=Homo sapiens OX=9606 GN=C9orf72 PE=1 SV=2
MSTLCPPPSPAVAKTEIALSGKSPLLAATFAYWDNILGPRVRHIWAPKTEQVLLSDGEIT
FLANHTLNGEILRNAESGAIDVKFFVLSEKGVIIVSLIFDGNWNGDRSTYGLSIILPQTE
LSFYLPLHRVCVDRLTHIIRKGRIWMHKERQENVQKIILEGTERMEDQGQSIIPMLTGEV
IPVMELLSSMKSHSVPEEIDIADTVLNDDDIGDSCHEGFLLNAISSHLQTCGCSVVVGSS
AEKVNKIVRTLCLFLTPAERKCSRLCEAESSFKYESGLFVQGLLKDSTGSFVLPFRQVMY
APYPTTHIDVDVNTVKQMPPCHEHIYNQRRYMRSELTAFWRATSEEDMAQDTIIYTDESF
TPDLNIFQDVLHRDTLVKAFLDQVFQLKPGLSLRSTFLAQFLLVLHRKALTLIKYIEDDT
QKGKKPFKSLRNLKIDLDLTAEGDLNIIMALAEKIKPGLHSFIFGRPFYTSVQERDVLMT
F",C9orf72,-,-,481aa(1-481),Q96LT7,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0616,http://db.phasep.pro/browse/",-,-,In vitro,0-1 µg/µL [polyU];|0-250 µm [C9orf72],-,"100mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Turbidity measurement,FRAP,Cryo-EM",liquid,"This raised the idea that biological anions could support PR LLPS as well. Indeed, addition of polyU RNA promoted LLPS in a dose-dependent manner even without molecular crowders being present (Figures 3F, 4A, and S1E); and this was also the case for other arginine-rich peptides.",30
36,101,PMID: 28472520,RNAPS0000097,https://pubmed.ncbi.nlm.nih.gov/28472520,RNA + protein,-,-,(GA-rich U5)30,30nt,GGAGUGAGAGGAAGGAAGGGAAGAAAGAAG,nucleotide rich RNA,-,"sp|O94752|EDC3_SCHPO Enhancer of mRNA-decapping protein 3 OS=Schizosaccharomyces pombe (strain 972 / ATCC 24843) OX=284812 GN=edc3 PE=1 SV=1|length=331aa|residues=1-71,195-454
MSVADFYGSNVEVLLNNDSKARGVITNFDSSNSILQLRLANDSTKSIVTKDIKDLRILPK
NEIMPKNGTKSKPFVDENIPAELHTTTGDILKPITPEQLSQGIALAIAKTSTDIVVENAA
QLLSQFVFSVLGGHKRLSSRNHNSQPLVCILVGSHDHASAAVAAGRRLCAIGIKVVLRLL
TPFNVDNRQLLMFQAAGGYIPTENFDQFLNKLTSPIELVVDVLTGFHPSIDKNSHALIQW
ANDLNVLILSVDIPSGYTVQKKNTAILPKWTLALGAVTTTLAQAALVKQAAGVSVFVGNL
GTGSQTWAELGILESQVTGQYLAQISCTSTN",edc3,-,-,"331aa(1-71,195-454)",O94752,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/O94752,http://llps.biocuckoo.cn/view.php?id=LLPS-Scp-0071,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0103,http://db.phasep.pro/browse/",-,[394-415],In vitro,0-60 µM [edc3△IDR];|0.00-15.0 µM RNA,125 mM NaCl,"25 mM HEPES, pH 7.3, 1 mM DTT",30˚C,immediately,-,Turbidity measurement,solute,"This effect is even more prominent in RNA:Edc3 phase diagrams, where the removal of the IDR results in the almost complete loss of LLPS (Figure4B). These data indicate that the IDR in Edc3 is an important RNA interaction site.",30
37,102,PMID: 28472520,RNAPS0000097,https://pubmed.ncbi.nlm.nih.gov/28472520,RNA + protein,-,-,(GA-rich U5)30,30nt,GGAGUGAGAGGAAGGAAGGGAAGAAAGAAG,nucleotide rich RNA,-,"sp|O94752|EDC3_SCHPO Enhancer of mRNA-decapping protein 3 OS=Schizosaccharomyces pombe (strain 972 / ATCC 24843) OX=284812 GN=edc3 PE=1 SV=1|length=454aa|residues=1-454
MSVADFYGSNVEVLLNNDSKARGVITNFDSSNSILQLRLANDSTKSIVTKDIKDLRILPK
NEIMPKNGTKSPSTNSTKLKSAETYSSKNKWSMDCDEEFDFAANLEKFDKKQVFAEFREK
DKKDPAKLLVSHNKSPNRNYHHKQNVLGPSVKDEFVDLPSAGSQINGIDAVLSSSSNGHV
TPGSKKGSRETLKKKPFVDENIPAELHTTTGDILKPITPEQLSQGIALAIAKTSTDIVVE
NAAQLLSQFVFSVLGGHKRLSSRNHNSQPLVCILVGSHDHASAAVAAGRRLCAIGIKVVL
RLLTPFNVDNRQLLMFQAAGGYIPTENFDQFLNKLTSPIELVVDVLTGFHPSIDKNSHAL
IQWANDLNVLILSVDIPSGYTVQKKNTAILPKWTLALGAVTTTLAQAALVKQAAGVSVFV
GNLGTGSQTWAELGILESQVTGQYLAQISCTSTN",edc3,-,-,454aa(1-454),O94752,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/O94752,http://llps.biocuckoo.cn/view.php?id=LLPS-Scp-0071,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0103,http://db.phasep.pro/browse/",[173-192],[394-415],In vitro,0-60 µM [edc3];|0.00-15.0 µM RNA,125 mM NaCl,"25 mM HEPES, pH 7.3, 1 mM DTT",30˚C,immediately,-,Turbidity measurement,"solute, liquid","This effect is even more prominent in RNA:Edc3 phase diagrams, where the removal of the IDR results in the almost complete loss of LLPS (Figure4B). These data indicate that the IDR in Edc3 is an important RNA interaction site.",30
38,130,PMID: 28924037,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/28924037,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=533aa|residues=1-531
GHMDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPS
RVIHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVT
PVLRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMA
GQSPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAK
LSLDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFG
LSVPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILF
GVYGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPR
EGQEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNG
GVVKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,3.75-6.25 µM [PTBP1];|0.2-1.0 µM RNA,"150 mM KCl, 1 mM MgCl2","10 mM imidazole (pH 7.0), 1 mM EGTA, 1 mM DTT",22˚C,-,-,"Fluorescence microscopy,Turbidity measurement",liquid,"PTB undergoes LLPS when mixed with RNA and that fusion of PTB to FUS(WT) promotes this behavior. In contrast, attachment of FUS(27S) opposed LLPS of PTB + RNA. FUS(27S) is not a highly specific LLPS inhibitor but may be able to generally reduce the self-association of tethered proteins and thus oppose their LLPS.",50
39,131,PMID: 28924037,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/28924037,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTBP1]-[FUS IDR] with PTBP1 residues 1-531 fused to FUS residues 1-214||length=756aa|residues=1-531/1-214|mutation= FUS IDR(27S)
GHMDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPS
RVIHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVT
PVLRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMA
GQSPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAK
LSLDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFG
LSVPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILF
GVYGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPR
EGQEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNG
GVVKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIGGSAAAG
GSMASNDSTQQATQSSGASPTQPGQGSSQQSSQPSGQQSSSGSSQSTDTSGSGQSSSSSS
GQSQNTGSGTQSTPQGSGSTGGSGSSQSSQSSSGQQSSSPGSGQQPAPSSTSGSSGSSSQ
SSSSGQPQSGSSSQQPSSGGQQQSSGQQQSSNPPQGSGQQNQSNSSSGGGGGGGGGGNSG
QDQSSMSSGGGSGGGSGNQDQSGGGGSGGSGQQDRG",PTBP1-FUS,IDR,protein_mutation:FUS IDR(27S),"756aa(1-531,1-214)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-214],"[32-44],[162-179],[306-335];|-",In vitro,3.75-6.25 µM [PTBP1]-[FUS IDR];|0-1.0 µM RNA,"150 mM KCl, 1 mM MgCl2","10 mM imidazole (pH 7.0), 1 mM EGTA, 1 mM DTT",22˚C,-,-,"Fluorescence microscopy,Turbidity measurement",solute,"PTB undergoes LLPS when mixed with RNA and that fusion of PTB to FUS(WT) promotes this behavior. In contrast, attachment of FUS(27S) opposed LLPS of PTB + RNA. FUS(27S) is not a highly specific LLPS inhibitor but may be able to generally reduce the self-association of tethered proteins and thus oppose their LLPS.",50
40,134,PMID: 29064502,RNAPS0000124,https://pubmed.ncbi.nlm.nih.gov/29064502,RNA + protein,-,-,polyA(30),30nt,AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1|length=708aa|residues=1-708
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,0-9 mg/ml [laf-1];|7.5 µM polyA,0-500 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Confocal microscopy,"solute, liquid","In the presence of polyadenylate RNA (poly-rA) of various lengths, the low-concentration arm of the LAF-1 binodal and the concentrations corresponding to the critical region remain essentially invariant. However, upon addition of RNA we observe a marked shift of the high-concentration arm of the LAF-1 binodal, toward lower values of dense phase concentration.",30
41,135,PMID: 29064502,RNAPS0000125,https://pubmed.ncbi.nlm.nih.gov/29064502,RNA + protein,-,-,polyA(15),15nt,AAAAAAAAAAAAAAA,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1|length=708aa|residues=1-708
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,0-9 mg/ml [laf-1];|15 µM polyA,0-500 mM NaCl,"20 mM Tris, pH 7.4, 1 mM DTT",RT,-,-,Confocal microscopy,"solute, liquid","In the presence of polyadenylate RNA (poly-rA) of various lengths, the low-concentration arm of the LAF-1 binodal and the concentrations corresponding to the critical region remain essentially invariant. However, upon addition of RNA we observe a marked shift of the high-concentration arm of the LAF-1 binodal, toward lower values of dense phase concentration.",15
42,140,PMID: 29314832,RNAPS0000142,https://pubmed.ncbi.nlm.nih.gov/29314832,RNA + protein,-,-,luciferase_antisense_siRNA,21nt,UCGAAGUACUCAGCGUAAGUU,siRNA,Photinus pyralis,KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK,50 aa pLys,-,-,50aa,-,-,-,[1-50],-,In vitro,5 mM([RNA phosphate] + [pLys amine]),18.2 MΩ water and concentrated NaCl solutions,pH 7,RT,4 h,-,-,liquid,"Single- and double-stranded RNA oligonucleotides displayed the same phase behavior as DNA: single-stranded RNA formed coacervates and double-stranded RNA formed precipitates. When mixed with 50 aa pLys, ssRNA forms coacervates while dsRNA forms solid precipitates, just as for DNA.",21
43,141,PMID: 29314832,RNAPS0000143,https://pubmed.ncbi.nlm.nih.gov/29314832,RNA + protein,-,-,luciferase_dsRNA_siRNA,42nt,UCGAAGUACUCAGCGUAAGUUUUAGCUUCAUGAGUCGCAUUC,siRNA,Photinus pyralis,KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK,50 aa pLys,-,-,50aa,-,-,-,[1-50],-,In vitro,5 mM([RNA phosphate] + [pLys amine]),18.2 MΩ water and concentrated NaCl solutions,pH 7,RT,4 h,-,-,solid,"Single- and double-stranded RNA oligonucleotides displayed the same phase behavior as DNA: single-stranded RNA formed coacervates and double-stranded RNA formed precipitates. When mixed with 50 aa pLys, ssRNA forms coacervates while dsRNA forms solid precipitates, just as for DNA.",42
44,142,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,20 µM [PTBP1];|1.6 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,liquid,"While SNAP-tagged PTB and RNA showed limited assembly when mixed together at concentrations of 20 mM and 1.6 mM, respectively, the addition of 100 mg/mL BSA induced robust phase separation at these concentrations. Consistent with this effect being due to molecular crowding, PTB-RNA LLPS is also stimulated by PEG or Ficoll, additional crowding agents.",50
45,143,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,20 µM [PTBP1];|1.6 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,crowding agent:100 mg/ml Ficoll,Confocal microscopy,liquid,"While SNAP-tagged PTB and RNA showed limited assembly when mixed together at concentrations of 20 mM and 1.6 mM, respectively, the addition of 100 mg/mL BSA induced robust phase separation at these concentrations. Consistent with this effect being due to molecular crowding, PTB-RNA LLPS is also stimulated by PEG or Ficoll, additional crowding agents.",50
46,144,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,20 µM [PTBP1];|1.6 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,crowding agent:100 mg/ml PEG,Confocal microscopy,liquid,"While SNAP-tagged PTB and RNA showed limited assembly when mixed together at concentrations of 20 mM and 1.6 mM, respectively, the addition of 100 mg/mL BSA induced robust phase separation at these concentrations. Consistent with this effect being due to molecular crowding, PTB-RNA LLPS is also stimulated by PEG or Ficoll, additional crowding agents.",50
47,145,PMID: 29425497,RNAPS0000051,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"sp|P26599|PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens OX=9606 GN=PTBP1 PE=1 SV=1|length=531aa|residues=1-531
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTI",PTBP1,-,-,531aa(1-531),P26599,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/",-,"[32-44],[162-179],[306-335]",In vitro,4 µM [PTBP1];|0.32 µM RNA ,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,solute,"4 µM PTB and 0.32 µM RNA do not phase separate in 100 mg/mL BSA. However, we observed LLPS with identical concentrations of RNA and PTB, when PTB was fused to either the FUS or Pub1 IDRs. PTB fused to either IDR showed an increase in both the number and size of the assemblies visualized. Therefore, weak interactions of IDRs can enhance phase separation in the presence of competitor proteins, when present in molecules that also contain specific interactions which are less susceptible to competition from cellular macromolecules.",50
48,146,PMID: 29425497,RNAPS0000369,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTBP1]-[FUS IDR] with PTBP1 residues 1-531 fused to FUS residues 1-237|Linker is missing|length=768aa|residues=1-531/1-237
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTIMASNDYTQQ
ATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQ
STPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGS
YSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGG
SGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSG",PTBP1-FUS,IDR,-,"768aa(1-531,1-237)","P26599,P35637","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",-;|[1-237],"[32-44],[162-179],[306-335];|[17-104],[106-237]",In vitro,4 µM [PTBP1]-[FUS IDR];|0.32 µM RNA,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,liquid,"4 uM PTB and 0.32 μM RNA do not phase separate in 100 mg/mL BSA. However, we observed LLPS with identical concentrations of RNA and PTB, when PTB was fused to either the FUS or Pub1 IDRs. PTB fused to either IDR showed an increase in both the number and size of the assemblies visualized. Therefore, weak interactions of IDRs can enhance phase separation in the presence of competitor proteins, when present in molecules that also contain specific interactions which are less susceptible to competition from cellular macromolecules.",50
49,147,PMID: 29425497,RNAPS0000048,https://pubmed.ncbi.nlm.nih.gov/29425497,RNA + protein,-,-,(UCUCUAAAAA)5,50nt,UCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAAUCUCUAAAAA,repeat RNA,-,"A fusion protein construct [PTB]-[Pub1 IDR] with PTB residues 1-531 fused to Pub1 residues 243-327|Linker is missing|length=616aa|residues=1-531;243-327
MDGIVPDIAVGTKRGSDELFSTCVTNGPFIMSSNSASAANGNDSKKFKGDSRSAGVPSRV
IHIRKLPIDVTEGEVISLGLPFGKVTNLLMLKGKNQAFIEMNTEEAANTMVNYYTSVTPV
LRGQPIYIQFSNHKELKTDSSPNQARAQAALQAVNSVQSGNLALAASAAAVDAGMAMAGQ
SPVLRIIVENLFYPVTLDVLHQIFSKFGTVLKIITFTKNNQFQALLQYADPVSAQHAKLS
LDGQNIYNACCTLRIDFSKLTSLNVKYNNDKSRDYTRPDLPSGDSQPSLDQTMAAAFGLS
VPNVHGALAPLAIPSAAAAAAAAGRIAIPGLAGAGNSVLLVSNLNPERVTPQSLFILFGV
YGDVQRVKILFNKKENALVQMADGNQAQLAMSHLNGHKLHGKPIRITLSKHQNVQLPREG
QEDQGLTKDYGNSPLHRFKKPGSKNFQNIFPPSATLHLSNIPPSVSEEDLKVLFSSNGGV
VKGFKFFQKDRKMALIQMGSVEEAVQALIDLHNHDLGENHHLRVSFSKSTINNNNNNYQQ
RRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMPIGAMPLPSQGQ
PQQSQTIGLPPQVNPQ",PTBP1-PUB1,IDR,-,"616aa(1-531,243-327)","P26599,P32588","PTBP1:DrLLPS,LLPSDB,PhaSepDB,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0970,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0010,http://db.phasep.pro/browse/,https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/",-;|[243-262],"[32-44],[162-179],[306-335];|[243-297],[307-316]",In vitro,4 µM [PTBP1]-[PUB1 IDR];|0.32 µM RNA,100 mM NaCl,"20 mM imidazole pH 7.0, 1 mM DTT, 10% glycerol",RT,-,other_molecular:100 mg/ml BSA,Confocal microscopy,liquid,"4 µM PTB and 0.32 µM RNA do not phase separate in 100 mg/mL BSA. However, we observed LLPS with identical concentrations of RNA and PTB, when PTB was fused to either the FUS or Pub1 IDRs. PTB fused to either IDR showed an increase in both the number and size of the assemblies visualized. Therefore, weak interactions of IDRs can enhance phase separation in the presence of competitor proteins, when present in molecules that also contain specific interactions which are less susceptible to competition from cellular macromolecules.",50
50,199,PMID: 29898402,RNAPS0000030,https://pubmed.ncbi.nlm.nih.gov/29898402,RNA + protein,NCBI ID: 850499,https://www.ncbi.nlm.nih.gov/gene/850499,SEC53,350nt(416-765),CUAUAAGUUGAAUAGUUCAGUCAAAAUUUUGACGGUGUCAUCAGGGGAUUGUACUGAAUGUCCGAUGGUUCUUUCAUCGACAAAAAUUUCGUAAUCGUUACCACCGACCAUAGUCUUGUCACCAAAGAAAUGAAUUUCCUUGAAACCAUCUUUUUCAACGUGUUGCAAACAGUAGGUCUUAUCCCAACCAGCGGGGAAAACGUCGAAAGAGAUUUGGCCACCAAUGGAGAAAGUCAAACCGUAGUCUGGGAAUUCCUUUUUCAAAGCUUCAACGAACUUGGCUCUGAUUUGGUGUUCCUUAUCGUAUCUUUCGAAUUCGUUUCUUUCCUCAGUAGAAGCAUUUCUACCAA,mRNA,yeast,"sp|P32588|PUB1_YEAST Nuclear and cytoplasmic polyadenylated RNA-binding protein PUB1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PUB1 PE=1 SV=4|length=453aa|residues=1-453
MSENNEEQHQQQQQQQPVAVETPSAVEAPASADPSSEQSVAVEGNSEQAEDNQGENDPSV
VPANAITGGRETSDRVLYVGNLDKAITEDILKQYFQVGGPIANIKIMIDKNNKNVNYAFV
EYHQSHDANIALQTLNGKQIENNIVKINWAFQSQQSSSDDTFNLFVGDLNVNVDDETLRN
AFKDFPSYLSGHVMWDMQTGSSRGYGFVSFTSQDDAQNAMDSMQGQDLNGRPLRINWAAK
RDNNNNNNYQQRRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMP
IGAMPLPSQGQPQQSQTIGLPPQVNPQAVDHIIRSAPPRVTTAYIGNIPHFATEADLIPL
FQNFGFILDFKHYPEKGCCFIKYDTHEQAAVCIVALANFPFQGRNLRTGWGKERSNFMPQ
QQQQGGQPLIMNDQQQPVMSEQQQQQQQQQQQQ",PUB1,-,-,453aa(1-453),P32588,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/","[1-67],[241-262],[418-453]","[8-16],[103-116],[152-158],[243-297],[307-316],[420-427],[434-452]",In vitro,20 µM [PUB1];|0-183 nM mRNA,183 mM NaCl,"200 mM phosphate buffer (with pH 6.5), 1 mM TCEP",46˚C,> 10 min,crowding agent:20% Ficoll,Fluorescence microscopy,liquid,"When we mixed Pub1 with this RNA and induced phase separation by lowering the pH, we observed that the RNA reduced the number and size of Pub1 condensates (Figures S2J and S2L). Similar findings were made for heat-induced Pub1 assemblies (Figures S2K and S2L).",350
51,200,PMID: 29898402,RNAPS0000030,https://pubmed.ncbi.nlm.nih.gov/29898402,RNA + protein,NCBI ID: 850499,https://www.ncbi.nlm.nih.gov/gene/850499,SEC53,350nt(416-765),CUAUAAGUUGAAUAGUUCAGUCAAAAUUUUGACGGUGUCAUCAGGGGAUUGUACUGAAUGUCCGAUGGUUCUUUCAUCGACAAAAAUUUCGUAAUCGUUACCACCGACCAUAGUCUUGUCACCAAAGAAAUGAAUUUCCUUGAAACCAUCUUUUUCAACGUGUUGCAAACAGUAGGUCUUAUCCCAACCAGCGGGGAAAACGUCGAAAGAGAUUUGGCCACCAAUGGAGAAAGUCAAACCGUAGUCUGGGAAUUCCUUUUUCAAAGCUUCAACGAACUUGGCUCUGAUUUGGUGUUCCUUAUCGUAUCUUUCGAAUUCGUUUCUUUCCUCAGUAGAAGCAUUUCUACCAA,mRNA,yeast,"sp|P32588|PUB1_YEAST Nuclear and cytoplasmic polyadenylated RNA-binding protein PUB1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PUB1 PE=1 SV=4|length=453aa|residues=1-453
MSENNEEQHQQQQQQQPVAVETPSAVEAPASADPSSEQSVAVEGNSEQAEDNQGENDPSV
VPANAITGGRETSDRVLYVGNLDKAITEDILKQYFQVGGPIANIKIMIDKNNKNVNYAFV
EYHQSHDANIALQTLNGKQIENNIVKINWAFQSQQSSSDDTFNLFVGDLNVNVDDETLRN
AFKDFPSYLSGHVMWDMQTGSSRGYGFVSFTSQDDAQNAMDSMQGQDLNGRPLRINWAAK
RDNNNNNNYQQRRNYGNNNRGGFRQYNSNNNNNMNMGMNMNMNMNMNNSRGMPPSSMGMP
IGAMPLPSQGQPQQSQTIGLPPQVNPQAVDHIIRSAPPRVTTAYIGNIPHFATEADLIPL
FQNFGFILDFKHYPEKGCCFIKYDTHEQAAVCIVALANFPFQGRNLRTGWGKERSNFMPQ
QQQQGGQPLIMNDQQQPVMSEQQQQQQQQQQQQ",PUB1,-,-,453aa(1-453),P32588,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P32588,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0524,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0004,http://db.phasep.pro/browse/","[1-67],[241-262],[418-453]","[8-16],[103-116],[152-158],[243-297],[307-316],[420-427],[434-452]",In vitro,20 µM [PUB1];|0-183 nM mRNA,183 mM NaCl,"200 mM phosphate buffer (with pH 6.2), 1 mM TCEP",25˚C,-,crowding agent:20% Ficoll,Fluorescence microscopy,liquid,"When we mixed Pub1 with this RNA and induced phase separation by lowering the pH, we observed that the RNA reduced the number and size of Pub1 condensates (Figures S2J and S2L). Similar findings were made for heat-induced Pub1 assemblies (Figures S2K and S2L).",350
52,203,PMID: 30110628,RNAPS0000236,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(UC-rich A4)50,50nt,UUUAUUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCCUCCUUCCU,nucleotide rich RNA,-,RRRR,poly(R)4,-,-,4aa,-,-,-,-,-,In vitro,25 µM [polyR];|1 µM (UC-rich A4)50,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"In vitro, R4 peptide formed droplets in the presence of low-, but not high-, complexity rIGSRNA (Figure 3E). Increasing [NaCl] to 250 mM was sufficient to rapidly dissolve R4-GFP nucleolar foci and R4 peptide droplets in vivo and in vitro (Figures 3F and S3H).",50
53,204,PMID: 30110628,RNAPS0000236,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(UC-rich A4)50,50nt,UUUAUUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCUUCCCUCCUUCCU,nucleotide rich RNA,-,RRRR,poly(R)4,-,-,4aa,-,-,-,-,-,In vitro,25 µM [polyR];|1 µM (UC-rich A4)50,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"In vitro, R4 peptide formed droplets in the presence of low-, but not high-, complexity rIGSRNA (Figure 3E). Increasing [NaCl] to 250 mM was sufficient to rapidly dissolve R4-GFP nucleolar foci and R4 peptide droplets in vivo and in vitro (Figures 3F and S3H).",50
54,205,PMID: 30110628,RNAPS0000237,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (CU-rich)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
55,206,PMID: 30110628,RNAPS0000237,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (CU-rich)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
56,207,PMID: 30110628,RNAPS0000238,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (AG-rich U89)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
57,208,PMID: 30110628,RNAPS0000238,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM (AG-rich U89)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
58,209,PMID: 30110628,RNAPS0000239,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (CU-rich)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
59,210,PMID: 30110628,RNAPS0000239,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(CU-rich)100,100nt,UCUGUCUCUGUCUUUGUCUCUCUCUCUCCCUCUCUGCCUGUCUCACUGUGUCUGUCUUCUGUCUUACUCUCUUUCUCUCCCCGUCUGUCUCUCUCUCUCU,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (CU-rich)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
60,211,PMID: 30110628,RNAPS0000240,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (AG-rich U89)100,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,liquid,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
61,212,PMID: 30110628,RNAPS0000240,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,(AG-rich U89)100,100nt,AGAGAGAGAGACAGAGAGAGACAGAGAGAGAGAGAGAGGAGGGAGAGAGAAAAAAGAAAGAAAAAAAGAAAAGAAAAGAAAGAGAAAAUGAAAGAAAAGG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM (AG-rich U89)100,250 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
62,213,PMID: 30110628,RNAPS0000241,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"rIGS16RNA-Low complexity (Wang,2018)",50nt,CGAUUGAUUGCGAUCUCAAUUGCCUUUUAGCUUCAUUCAUACCCUGUUAU,irregular RNA,-,RRRR,poly(R)4,-,-,4aa,-,-,-,-,-,In vitro,25 µM [polyR];|1 µM irregular RNA 12,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"In vitro, R4 peptide formed droplets in the presence of low-, but not high-, complexity rIGSRNA (Figure 3E). Increasing [NaCl] to 250 mM was sufficient to rapidly dissolve R4-GFP nucleolar foci and R4 peptide droplets in vivo and in vitro (Figures 3F and S3H).",50
63,214,PMID: 30110628,RNAPS0000242,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"High complexity-rIGSRNA2 (Wang,2018)",100nt,CCGGGAUUUCAGCCUUUAAAAGCGCGGGCCCUGCCACCUUUCGCUGUGGCCCUUACGCUCAGAAUGACGUGUCCUCUCUGCCGUAGGUUGACUCCUUGAG,irregular RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,25 µM [APP ACM];|1 µM irregular RNA 18,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
64,215,PMID: 30110628,RNAPS0000243,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"High complexity-rIGSRNA2 (Wang,2018)",100nt,CCGGGAUUUCAGCCUUUAAAAGCGCGGGCCCUGCCACCUUUCGCUGUGGCCCUUACGCUCAGAAUGACGUGUCCUCUCUGCCGUAGGUUGACUCCUUGAG,irregular RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,25 µM [β-amyloid 672-688];|1 µM irregular RNA 18,150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
65,216,PMID: 30110628,RNAPS0000244,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"UC RNA(Loughlin,2021)",100nt,CCGGCCCGCCUGGUCUUCUGUCUCUGCGCUCUGGUGACCUCAGCCUCCCAAAUAGCUGGGACUACAGGGAUCUCUUAAGCCCGGGAGGGAGAGGUUAACG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=16aa|residues=104-119
GTGRRIHSYRGHLWLF",APP,ACM,-,16aa(104-119),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",-,-,In vitro,"25 µM [APP ACM];|1 µM UC RNA(Loughlin,2021)",150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
66,217,PMID: 30110628,RNAPS0000245,https://pubmed.ncbi.nlm.nih.gov/30110628,RNA + protein,-,-,"UC RNA(Loughlin,2021)",100nt,CCGGCCCGCCUGGUCUUCUGUCUCUGCGCUCUGGUGACCUCAGCCUCCCAAAUAGCUGGGACUACAGGGAUCUCUUAAGCCCGGGAGGGAGAGGUUAACG,nucleotide rich RNA,-,"sp|P05067|A4_HUMAN Amyloid-beta A4 protein OS=Homo sapiens OX=9606 GN=APP PE=1 SV=3|length=17aa|residues=672-688
DAEFRHDSGYEVHHQKL",β-amyloid,ACM,-,17aa(672-688),P05067,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P05067,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2530,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0179,http://db.phasep.pro/browse/",[672-688],-,In vitro,"25 µM [β-amyloid 672-688];|1 µM UC RNA(Loughlin,2021)",150 mM NaCl,50mM nuclease-free-water,RT,> 10 min,-,Microscopy,solute,"Mixing of 5’FAM labeled low-complexity RNA derived from rIGSRNA CU or AG repeats with unlabeled peptides containing the short cationic domain of VHL ACM or β-amyloid resulted in numerous liquid droplets observable by differential interference contrast and fluorescence microscopy. In contrast, two independent RNA derived from high-complexity regions of rIGSRNA failed to form droplets under identical conditions. Interactions between the short cationic domain of VHL ACM or β-amyloid and low-complexity rIGSRNA were disrupted by salts. Increasing salt concentration from 150 to 250 mM rapidly dissolved the liquid droplets in vitro.",100
67,218,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|10 µg/mL polyA,≤25 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Because in vivo RNase E foci required the presence of RNA, whether addition of RNA could induce LLPS of the CTD-YFP protein in vitro was tested. Addition of 5–175 mg/mL poly-A RNA at a low concentration (12.4 mM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble",0
68,219,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|10 µg/mL polyA,≥200 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Because in vivo RNase E foci required the presence of RNA, whether addition of RNA could induce LLPS of the CTD-YFP protein in vitro was tested. Addition of 5–175 mg/mL poly-A RNA at a low concentration (12.4 mM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble",0
69,220,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|5-175 µg/mL polyA,100 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,liquid,"Addition of 5-175 µg/mL poly-A RNA at a low concentration (12.4 µM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble. Interestingly, addition of excess poly-A RNA above 175 µg/mL prevented the assembly of condensates.",0
70,221,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|0-5 µg/mL polyA,100 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Addition of 5-175 µg/mL poly-A RNA at a low concentration (12.4 µM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble. Interestingly, addition of excess poly-A RNA above 175 µg/mL prevented the assembly of condensates.",0
71,222,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|175-250 µg/mL polyA,100 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,solute,"Addition of 5-175 µg/mL poly-A RNA at a low concentration (12.4 µM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble. Interestingly, addition of excess poly-A RNA above 175 µg/mL prevented the assembly of condensates.",0
72,223,PMID: 30197298,RNAPS0000246,https://pubmed.ncbi.nlm.nih.gov/30197298,RNA + protein,-,-,polyA,-,-,poly RNA,-,"tr|Q9A749|Q9A749_CAUVC Ribonuclease E OS=Caulobacter vibrioides (strain ATCC 19089 / CB15) OX=190650 GN=rne PE=1 SV=1|length=448aa|residues=451-898
TGVLEGTTHVCEHCEGTGRVRSVESSALAALRAVEAEALKGSGSVILKVSRSVGLYILNE
KRDYLQRLLTTHGLFVSVVVDDSLHAGDQEIERTELGERIAVAPPPFVEEDDDFDPNAYD
DEEEEDDVILDDEDDTDREDTDDDDATTRKSARDDERGDRKGRRGRRDRNRGRGRRDERD
GETESEDEDVVAEGADEDRGEFGDDDEGGRRRRRRGRRGGRRGGREDGDRPTDAFVWIRP
RVPFGENVFTWHDPAALVGGGESRRQAPEPRVDAATEAAPRPERAEREERPGRERGRRGR
DRGRRQRDEAPVAEMTSVESATVEAAEPFEAPILAPPVIAGPPADVWVELPEVEEAPKKP
KRSRARGKKATETSVEAIDTVTEVAAEAPAPETAEPEAVEVAPPAPTVEAAPEPGPVVEA
VEEAQPAEPDPNEITAPPEKPRRGWWRR",rne,CTD,-,448aa(451-898),Q9A749,"PhaSePro,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9A749,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0174,http://db.phasep.pro/browse/","[545-686],[706-774],[802-828],[856-884],[890-892],[898-898]","[469-489],[554-680],[727-761],[830-879]",In vitro,12.4 µM [rne CTD];|10 µg/mL polyA,50-175 mM NaCl,20 mM Tris-Cl pH 7.4,4˚C,≤ 1 h,-,Microscopy,liquid,"Because in vivo RNase E foci required the presence of RNA, whether addition of RNA could induce LLPS of the CTD-YFP protein in vitro was tested. Addition of 5–175 mg/mL poly-A RNA at a low concentration (12.4 mM) of CTD-YFP induced LLPS condensates and broadened the range in salt concentration over which they assemble",0
73,229,PMID: 30442662,RNAPS0000254,https://pubmed.ncbi.nlm.nih.gov/30442662,RNA + protein,-,-,polyU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526|mutation=R244C
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGCGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,protein_mutation:R244C,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[3-251],[284-292],[332-338],[375-415],[451-499],[501-501],[503-505],[507-526]",-,In vitro,1 µM [FUS];|1 µM polyU,100 mM NaCl,"50 mM Tris·HCl (pH 7.4), 1 mM EDTA, 1 mM DTT",RT,≤ 20 h,-,Microscopy,"liquid, solid","Within a period of 20 h, FUS_M(R244C)-RNA droplets formed and increased in both size and number. When UBQLN2 was present, the FUS_M(R244C)-RNA droplets formed were smaller in size but more numerous compared with those formed in the absence of UBQLN2. Notably, the FUS_M(R244C)-RNA droplets in the absence of UBQLN2 displayed nonspherical, irregular patterns, whereas those in the presence of UBQLN2 remained highly spherical over the entire time course. These nonspherical irregular droplets may represent the transition from the reversible liquid-like, phase-separated state of FUS to a more stable, solid state of FUS.",40
74,230,PMID: 30648970,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,2 µM [DHH1];|0.1 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:5 mM ATP,Fluorescence microscopy,liquid,"We found a stoichiometric ratio of 2.7:1 ± 0.13 of Dhh1 to Pat1 in the in vitro phase-separated droplets, closely resembling the Dhh1:Pat1 ratio of mature PBs in vivo.",0
75,231,PMID: 30648970,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,4 µM [DHH1];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,liquid,"We therefore next analyzed whether the Pat1-Dhh1 droplets are still responsive to Not1. Similar to what we observed in vivo (Figure 5), Not1MIF4G also diminishes formation Dhh1 droplets in the presence of Pat1 in vitro (Figure 6B).",0
76,232,PMID: 30648970,RNAPS0000257,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|length=419aa|residues=5-79,456-787|mutation=D39A,E40A,T41A,F42A
GLENSGNARDGPLDFEESYKGYGEHELEENDYLNAAAAGDNVQVGTDFDFGNPHSSGSSG
NAIGGNGVGATARSYGGSGGSGGSGGSSSYAFNNGNGATNLNKSGGKKFILELIETVYEE
ILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIFNFLDKQQK
LKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLSNNSNFIEI
MGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEISTWNEIYDK
LFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQRIIIDEVR
DEIFATINEAETLQKKEKELSVLPQRSQELDTELKSIIYNKEKLYQDLNLFLNVMGLVY",PAT1,NC,"protein_mutation:D39A,E40A,T41A,F42A","419aa(5-79,456-787)",P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[5-16],[63-79],[456-475],[501-510],[660-667],[742-748],[756-771]",-,In vitro,2-8 µM [PAT1 NC];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,solute,"While no LLPS of Pat1 NC alone was detected, addition of increasing concentrations of wild-type Pat1 NC strongly enhanced the LLPS of Dhh1 in the presence of ATP and RNA as judged by an increase in the area * intensity of Dhh1 droplets. Furthermore, Pat1 NC itself enriched in Dhh1 droplets, suggesting that Pat1 and Dhh1 co-oligomerize with RNA to form a composite phase-separated compartment. Dhh1-RNA droplet formation was either not at all or only mildly stimulated upon addition of these Pat1 variants.",0
77,233,PMID: 30648970,RNAPS0000257,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|length=419aa|residues=5-79,456-787|mutation=S456E,S457E
GLENSGNARDGPLDFEESYKGYGEHELEENDYLNDETFGDNVQVGTDFDFGNPHSSGSSG
NAIGGNGVGATARSYGGSGGSGGSGGSAAYAFNNGNGATNLNKSGGKKFILELIETVYEE
ILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIFNFLDKQQK
LKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLSNNSNFIEI
MGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEISTWNEIYDK
LFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQRIIIDEVR
DEIFATINEAETLQKKEKELSVLPQRSQELDTELKSIIYNKEKLYQDLNLFLNVMGLVY",PAT1,NC,"protein_mutation:S456E,S457E","419aa(5-79,456-787)",P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[5-16],[63-79],[456-473],[501-510],[660-667],[742-748],[756-771]",-,In vitro,2-8 µM [PAT1 NC];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,solute,"While no LLPS of Pat1 NC alone was detected, addition of increasing concentrations of wild-type Pat1 NC strongly enhanced the LLPS of Dhh1 in the presence of ATP and RNA as judged by an increase in the area * intensity of Dhh1 droplets. Furthermore, Pat1 NC itself enriched in Dhh1 droplets, suggesting that Pat1 and Dhh1 co-oligomerize with RNA to form a composite phase-separated compartment. Dhh1-RNA droplet formation was either not at all or only mildly stimulated upon addition of these Pat1 variants.",0
78,234,PMID: 30648970,RNAPS0000257,https://pubmed.ncbi.nlm.nih.gov/30648970,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|length=419aa|residues=5-79,456-787
GLENSGNARDGPLDFEESYKGYGEHELEENDYLNDETFGDNVQVGTDFDFGNPHSSGSSG
NAIGGNGVGATARSYGGSGGSGGSGGSSSYAFNNGNGATNLNKSGGKKFILELIETVYEE
ILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIFNFLDKQQK
LKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLSNNSNFIEI
MGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEISTWNEIYDK
LFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQRIIIDEVR
DEIFATINEAETLQKKEKELSVLPQRSQELDTELKSIIYNKEKLYQDLNLFLNVMGLVY",PAT1,NC,-,"419aa(5-79,456-787)",P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[5-24],[55-79],[456-469]","[59-74],[545-555],[571-583]",In vitro,2-8 µM [PAT1 NC];|0.2 mg/ml polyU,"150 mM KCl, 2 mM MgCl2",30 mM HEPES-KOH pH 7.4,RT,> 20 min,other_molecular:3.2 mM ATP,Fluorescence microscopy,solute,"While no LLPS of Pat1 NC alone was detected, addition of increasing concentrations of wild-type Pat1 NC strongly enhanced the LLPS of Dhh1 in the presence of ATP and RNA as judged by an increase in the area * intensity of Dhh1 droplets. Furthermore, Pat1 NC itself enriched in Dhh1 droplets, suggesting that Pat1 and Dhh1 co-oligomerize with RNA to form a composite phase-separated compartment. Dhh1-RNA droplet formation was either not at all or only mildly stimulated upon addition of these Pat1 variants.",0
79,237,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"150 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,"Differential interference contrast microscopy,FRAP",liquid,"This suggests that binding between FMRPLCR and sc1 RNA may be more dynamic than the stable interaction depicted by the crystal structure of a small RGG peptide in complex with sc1 (Protein Data Bank ID codes 5DE5, 5DE8, and 5DEA)",36
80,238,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"10-500 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",0-150 mM NaCl,"10 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Differential interference contrast microscopy,"solute, liquid","By using DIC microscopy to map a phase diagram in varying protein and salt concentrations, we found that increasing salt concentrations disfavor FMRPLCR droplet formation in the presence of sc1 RNA.",36
81,239,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,protein_ptm:Methylation,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|≥2.5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,Me-FMRP LCR and FMRP LCR_M(RtoK) have a dramatic decrease in phase-separation propensity compared with FMRP LCR.,36
82,240,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632|mutation=all R to K
GASSKPPPNKTDKEKSYVTDDGQGMGKGSKPYKNKGHGKKGPGYTSGTNSEASNASETES
DHKDELSDWSLAPTEEEKESFLKKGDGKKKGGGGKGQGGKGKGGGFKGNDDHSKTDNKPK
NPKEAKGKTTDGSLQIKVDCNNEKSVHTKTLQNTSSEGSKLKTGKDKNQKKEKPDSVDGQ
QPLVNGVP",FMR1,-,protein_mutation:all R to K,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-458],[473-488],[490-515],[530-544],[558-570],[606-631]",-,In vitro,"100 µM [FMR1 LCR];|≥1.5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,Me-FMRP LCR and FMRP LCR_M(RtoK) have a dramatic decrease in phase-separation propensity compared with FMRP LCR.,36
83,241,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|≥0.15 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,Me-FMRP LCR and FMRP LCR_M(RtoK) have a dramatic decrease in phase-separation propensity compared with FMRP LCR.,36
84,242,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=632aa|residues=1-632
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,"50-250 µM [FMR1];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,Microscopy,"liquid, gel","Representative images of increasing FMRP concentration from 50 to 250 μM in the presence of Cy3-labeled sc1 RNA (5 μM) at room temperature, showing spherical droplets at the lower FMRP concentration and non-spherical gel assemblies enriched with sc1 RNA at the higher concentrations.",36
85,243,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"25 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"10 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Differential interference contrast microscopy,liquid,FMRP LCR phase separates without any additives and that addition of RNA increases its phase-separation propensity at protein concentrations closer to physiological levels,36
86,244,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"500 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"10 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Differential interference contrast microscopy,liquid,FMRP LCR phase separates without any additives and that addition of RNA increases its phase-separation propensity at protein concentrations closer to physiological levels,36
87,245,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-200 mM NaCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
88,246,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 300 mM NaCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
89,247,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-200 mM KCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
90,248,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 300 mM KCl","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
91,249,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-200 mM MgCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
92,250,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 300 mM MgCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
93,251,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 10-150 mM CaCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,liquid,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
94,252,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"100 µM [FMR1 LCR];|2.5 µM sc1 G quadruplex RNA (Tsang,2019)","30 mM NaCl, 200-300 mM CaCl2","25 mM Na2PO4 pH 7.4, 2 mM DTT",RT,-,-,Differential interference contrast microscopy,solute,"Identical ionic strengths of different salt solutions disrupt droplet formation to a similar degree. However, the divalent ions Mg2+ and Ca2+ qualitatively appear to have a slightly stronger ability to disrupt droplet formation.",36
95,253,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"250 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 30 min,other_molecular:500 nM Cy3 dye,Sedimentation assay,liquid,"Cy3-labeled sc1 G quadruplex RNA (Tsang,2019) and miRNA125b are nearly completely sequestered into droplets (>90%), whereas 4EBP2 strongly partitions into the droplet (∼60%). In contrast, the free Cy3 dye and Cy3- BSA exhibit negligible partitioning.",36
96,254,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"250 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",-,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 30 min,other_molecular:500 nM Cy3 BSA,Sedimentation assay,liquid,"Cy3-labeled sc1 G quadruplex RNA (Tsang,2019) and miRNA125b are nearly completely sequestered into droplets (>90%), whereas 4EBP2 strongly partitions into the droplet (∼60%). In contrast, the free Cy3 dye and Cy3- BSA exhibit negligible partitioning.",36
97,255,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=455aa|residues=1-455
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRT",FMR1,△LCR,-,455aa(1-455),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-455]",-,In vitro,"50 µM [FMR1△LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",solute,"Upon addition of Cy3-labeled sc1 G quadruplex RNA (Tsang,2019), droplets were formed with FMRP and FMRP LCR, but not with FMRPΔLCR. Our results show that FMRP LCR alone is necessary and sufficient to drive phase separation with sc1 G quadruplex RNA (Tsang,2019) in vitro. After 30 minutes of incubation on ice, FMRP wild type gel assemblies stick together with non-spherical morphology.",36
98,256,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"50 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Upon addition of Cy3-labeled sc1 G quadruplex RNA (Tsang,2019), droplets were formed with FMRP and FMRP LCR, but not with FMRPΔLCR. Our results show that FMRP LCR alone is necessary and sufficient to drive phase separation with sc1 G quadruplex RNA (Tsang,2019) in vitro. After 30 minutes of incubation on ice, FMRP wild type gel assemblies stick together with non-spherical morphology.",36
99,257,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=632aa|residues=1-632
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,"50 µM [FMR1];|5 µM sc1 G quadruplex RNA (Tsang,2019)",30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,≤ 30 min,-,"Differential interference contrast microscopy,Fluorescence microscopy","liquid, gel","Upon addition of Cy3-labeled sc1 G quadruplex RNA (Tsang,2019), droplets were formed with FMRP and FMRP LCR, but not with FMRPΔLCR. Our results show that FMRP LCR alone is necessary and sufficient to drive phase separation with sc1 G quadruplex RNA (Tsang,2019) in vitro. After 30 minutes of incubation on ice, FMRP wild type gel assemblies stick together with non-spherical morphology.",36
100,258,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"0-300 µM [FMR1 LCR];|0-5 µM sc1 G quadruplex RNA (Tsang,2019)",100 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,Microscopy,"solute, liquid","At room temperature, and in the absence of RNA and crowding reagents, we observed that phospho-FMRP LCR (containing 8–10 phosphate groups added) readily phase separates at ∼250 μM, whereas FMRP LCR does not. Furthermore, by using microscopy to map and compare the phase diagrams of phospho-FMRP LCR and FMRP LCR (pH 7.4 and 150 mM KCl), we found that moderately phosphorylated FMRP LCR (ranging from three to five groups, reflective of the phosphorylation state in vivo) increases its propensity to form liquid-like droplets with sc1 G quadruplex RNA (Tsang,2019) at lower protein concentrations.",36
101,259,PMID: 30765518,RNAPS0000261,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,"sc1 G quadruplex RNA (Tsang,2019)",36nt,GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG,irregular RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,protein_ptm:Phosphorylation,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"0-300 µM [FMR1 LCR];|0-5 µM sc1 G quadruplex RNA (Tsang,2019)",100 mM KCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",RT,-,-,Microscopy,"solute, liquid","At room temperature, and in the absence of RNA and crowding reagents, we observed that phospho-FMRP LCR (containing 8–10 phosphate groups added) readily phase separates at ∼250 μM, whereas FMRP LCR does not. Furthermore, by using microscopy to map and compare the phase diagrams of phospho-FMRP LCR and FMRP LCR (pH 7.4 and 150 mM KCl), we found that moderately phosphorylated FMRP LCR (ranging from three to five groups, reflective of the phosphorylation state in vivo) increases its propensity to form liquid-like droplets with sc1 G quadruplex RNA (Tsang,2019) at lower protein concentrations.",36
102,260,PMID: 30765518,RNAPS0000263,https://pubmed.ncbi.nlm.nih.gov/30765518,RNAs + protein,-;|-,-;|-,"sc1 G quadruplex RNA (Tsang,2019);|miR-125b",36nt;|22nt(1-22),GCUGCGGUGUGGAAGGAGUGGUCGGGUUGCGCAGCG;|UCACAAGUUAGGGUCUCAGGGA,irregular RNA;|miRNA,-;|Mus musculus,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,"250 µM [FMR1 LCR];|5 µM sc1 G quadruplex RNA (Tsang,2019);|500 nM miRNA125b",-,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 30 min,-,Sedimentation assay,liquid,"Cy3-labeled sc1 G quadruplex RNA (Tsang,2019) and miRNA125b are nearly completely sequestered into droplets (>90%), whereas 4EBP2 strongly partitions into the droplet (∼60%). In contrast, the free Cy3 dye and Cy3- BSA exhibit negligible partitioning.",36
103,261,PMID: 30765518,RNAPS0000264,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyA,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyA,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions.",0
104,262,PMID: 30765518,RNAPS0000265,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyU,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions.",0
105,263,PMID: 30765518,RNAPS0000266,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyC,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyC,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions.",0
106,264,PMID: 30765518,RNAPS0000267,https://pubmed.ncbi.nlm.nih.gov/30765518,RNA + protein,-,-,polyG,-,-,poly RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1|length=188aa|residues=445-632
GASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETES
DHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPR
NPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSSEGSRLRTGKDRNQKKEKPDSVDGQ
QPLVNGVP",FMR1,LCR,-,188aa(445-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[445-515],[516-632]","[492-504],[527-549]",In vitro,125 µM [FMR1 LCR];|0.05 mg/mL polyG,30 mM NaCl,"25 mM Na2PO4, pH 7.4, 2 mM DTT",4˚C,> 5 min,-,Microscopy,liquid,"By mixing different RNA sequences with FMRP LCR, we showed that FMRP LCR-RNA phase separation is not sequence-specific and does not require sequences capable of G-quadruplex formation. FMRPLCR:RNA phase separation is not dependent on RNA sequence or structure but is likely driven by protein:RNA electrostatic and pi-pi interactions.",0
107,282,PMID: 30926670,RNAPS0000272,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrU,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|0-1.5 µg/µL [poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,"crowding agent:,30%PEG","Microscopy,FRAP",liquid,"Increasing the concentration of poly-rU in PEG-induced PR droplets decreases PR dynamics, even at lower RNA concentrations than used for PR-RNA droplet formation in the absence of PEG.",0
108,283,PMID: 30926670,RNAPS0000272,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrU,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|0.5-8 µg/µL [poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"As can be seen in Fig. 2 A and B (and Movie S1), mixing of PR with homopolymeric RNAs (except poly-rG) results in the formation of liquid-like condensates.",0
109,284,PMID: 30926670,RNAPS0000273,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrA,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"As can be seen in Fig. 2 A and B (and Movie S1), mixing of PR with homopolymeric RNAs (except poly-rG) results in the formation of liquid-like condensates.",0
110,285,PMID: 30926670,RNAPS0000274,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrC,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,"As can be seen in Fig. 2 A and B (and Movie S1), mixing of PR with homopolymeric RNAs (except poly-rG) results in the formation of liquid-like condensates.",0
111,286,PMID: 30926670,RNAPS0000275,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrG,-,-,poly RNA,-,PRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPRPR,poly(proline−arginine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PR30];|1 µg/µL [poly-rG],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",-,"In contrast, poly-rG is known to form G quadruplexes, and these structural elements are highly stable. Interestingly, unlike the spherical coacervates formed by complexation of each of poly-rA, poly-rC, and poly-rU with PR, the assemblies formed by poly-rG and PR peptides are characterized by an open, fractal-like network structure that is resistant to thermal denaturation at high salt concentrations.",0
112,287,PMID: 30926670,RNAPS0000279,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrA,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline-lysine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PK30];|1 µg/µL [poly-rA],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,PK−polynucleotide droplets are uniformly less viscous than PR−polynucleotide droplets as assayed by spontaneous fusion events,0
113,288,PMID: 30926670,RNAPS0000280,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrU,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline-lysine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PK30];|1 µg/µL [poly-rU],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,PK−polynucleotide droplets are uniformly less viscous than PR−polynucleotide droplets as assayed by spontaneous fusion events,0
114,289,PMID: 30926670,RNAPS0000281,https://pubmed.ncbi.nlm.nih.gov/30926670,RNA + protein,-,-,polyrC,-,-,poly RNA,-,PKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPKPK,poly(proline-lysine)30,-,-,60aa,-,-,-,[1-60],-,In vitro,250 µM [PK30];|1 µg/µL [poly-rC],-,"1 μg/μL in 100 mM K2HPO4/KH2PO4,pH 7",RT,-,-,"Microscopy,FRAP",liquid,PK−polynucleotide droplets are uniformly less viscous than PR−polynucleotide droplets as assayed by spontaneous fusion events,0
115,310,PMID: 33290746,RNAPS0000420,https://pubmed.ncbi.nlm.nih.gov/33290746,RNA + protein,-,-,"H20 RNA(Chen,2020)",20nt,AGAUUCAACUGGCAGUAACC,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,4 µM[SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,RT,20 min,-,Fluorescence microscopy,"liquid, solute","Pure N-protein demixed into droplets (consistent with results from the Morgan [Carlson et al., 2020] and Fawzi [Myrto Perdikari et al., 2020] labs) and LLPS was enhanced by RNA extracted from the culture medium supernatant of infected cells containing full-length SARS-CoV-2 genome",20
116,312,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=267aa|residues=1-267
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGG",FUS,NTD,-,267aa(1-267),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[1-267],"[17-104],[106-261]",In vitro,20µM [FUS NTD];|40 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"Like ATP, RNA and two ssDNA molecules also induced the same monotonic dissolution of LLPS of NTD. Briefly, a ratio of 1:2 was required for RNA, but only a ratio of 1:1 was sufficient for two ssDNA molecules to significantly disrupt LLPS to reduce the sizes of droplets, with the maximal diameter reduced from approximately 7.6 to < 3.0 μm. Furthermore, a ratio of 1:5 was required for RNA (0.1 mM), but only a ratio of 1:2 was sufficient for two ssDNA molecules (0.04 mM) to completely dissolve LLPS of the NTD.",12
117,313,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=267aa|residues=1-267
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGG",FUS,NTD,-,267aa(1-267),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[1-267],"[17-104],[106-261]",In vitro,20µM [FUS NTD];|100 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,solute,"Like ATP, RNA and two ssDNA molecules also induced the same monotonic dissolution of LLPS of NTD. Briefly, a ratio of 1:2 was required for RNA, but only a ratio of 1:1 was sufficient for two ssDNA molecules to significantly disrupt LLPS to reduce the sizes of droplets, with the maximal diameter reduced from approximately 7.6 to < 3.0 μm. Furthermore, a ratio of 1:5 was required for RNA (0.1 mM), but only a ratio of 1:2 was sufficient for two ssDNA molecules (0.04 mM) to completely dissolve LLPS of the NTD.",12
118,314,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=156aa|residues=371-526
RRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN
PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD
RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,CTD,-,156aa(371-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[371-507],[508-512]","[371-425],[450-507]",In vitro,20µM [FUS CTD];|40 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"Upon adding RNA at a molar ratio of 1:2, many small droplets formed with a maximal diameter of approximately 1.1 μm. However, at 1:5, droplets were significantly dissolved, with only a small number of droplets left with a maximal diameter <1.0 μm, and at 1:10, all droplets dissolved. Interestingly, for TssDNA, even at 1:1, many large droplets formed with a maximal diameter of approximately 4.0 μm, while at 1:2, droplets were significantly dissolved, with only several droplets left with a maximal diameter <1.0 μm. At 1:5, all droplets were dissolved. T24 has a similar effect as TssDNA: at 1:1, many large droplets formed with a maximal diameter of approximately 5.0 μm, while at 1:2, droplets were significantly dissolved, with several droplets left with a maximal diameter <1.0 μm. Strikingly, three oligonucleic acids also have the same two-stage effect on the FUS U-CTD.",12
119,315,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=156aa|residues=371-526
RRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN
PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD
RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,CTD,-,156aa(371-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[371-507],[508-512]","[371-425],[450-507]",In vitro,20µM [FUS CTD];|100 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"Upon adding RNA at a molar ratio of 1:2, many small droplets formed with a maximal diameter of approximately 1.1 μm. However, at 1:5, droplets were significantly dissolved, with only a small number of droplets left with a maximal diameter <1.0 μm, and at 1:10, all droplets dissolved. Interestingly, for TssDNA, even at 1:1, many large droplets formed with a maximal diameter of approximately 4.0 μm, while at 1:2, droplets were significantly dissolved, with only several droplets left with a maximal diameter <1.0 μm. At 1:5, all droplets were dissolved. T24 has a similar effect as TssDNA: at 1:1, many large droplets formed with a maximal diameter of approximately 5.0 μm, while at 1:2, droplets were significantly dissolved, with several droplets left with a maximal diameter <1.0 μm. Strikingly, three oligonucleic acids also have the same two-stage effect on the FUS U-CTD.",12
120,316,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=156aa|residues=371-526
RRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPN
PTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGD
RGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,CTD,-,156aa(371-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[371-507],[508-512]","[371-425],[450-507]",In vitro,20µM [FUS CTD];|200 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,solute,"Upon adding RNA at a molar ratio of 1:2, many small droplets formed with a maximal diameter of approximately 1.1 μm. However, at 1:5, droplets were significantly dissolved, with only a small number of droplets left with a maximal diameter <1.0 μm, and at 1:10, all droplets dissolved. Interestingly, for TssDNA, even at 1:1, many large droplets formed with a maximal diameter of approximately 4.0 μm, while at 1:2, droplets were significantly dissolved, with only several droplets left with a maximal diameter <1.0 μm. At 1:5, all droplets were dissolved. T24 has a similar effect as TssDNA: at 1:1, many large droplets formed with a maximal diameter of approximately 5.0 μm, while at 1:2, droplets were significantly dissolved, with several droplets left with a maximal diameter <1.0 μm. Strikingly, three oligonucleic acids also have the same two-stage effect on the FUS U-CTD.",12
121,317,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,20µM [FUS];|40 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"In the absence of nucleic acids, FUS itself was able to undergo LLPS to form only a small number of droplets with a maximal diameter of approximately 3.7 μm. By contrast, addition of RNA at a ratio of 1:2 significantly enhanced LLPS by mainly increasing the numbers of droplets with a maximal diameter of approximately 4.0 μm. Further addition to 1:10 led to significant dissolution of liquid droplets by reducing both numbers and sizes of droplets with a maximal diameter of only approximately 2.5 μm.  For TssDNA, at a molar ratio of 1:1 (FUS:TssDNA), LLPS of FUS appeared to be significantly enhanced by forming a large number of droplets with a maximal diameter up to 5.4 μm. Further addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to only approximately 1.6 μm, and at 1:10, all droplets were completely dissolved. Interestingly, T24 showed the same two stage effect on LLPS of FUS as TssDNA. At a molar ratio of 1:1, LLPS of FUS was significantly enhanced by forming a large number of droplets with a maximal diameter up to approximately 6.2 μm. Similarly, addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to approximately 1.2 μm, and at 1:10, all droplets were also dissolved.",12
122,318,PMID: 31188823,RNAPS0000300,https://pubmed.ncbi.nlm.nih.gov/31188823,RNA + protein,-,-,"12-mer RNA (Kang,2019)",12nt,UAGUUUGGUGAU,irregular RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|length=526aa|residues=1-526
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,20µM [FUS];|200 µM RNA,"150 mM NaCl, 1 mM MgCl2, 4 mM ZnCl2",5 mM sodium phosphate buffer at pH 6.0,25˚C,-,-,Differential interference contrast microscopy,liquid,"In the absence of nucleic acids, FUS itself was able to undergo LLPS to form only a small number of droplets with a maximal diameter of approximately 3.7 μm. By contrast, addition of RNA at a ratio of 1:2 significantly enhanced LLPS by mainly increasing the numbers of droplets with a maximal diameter of approximately 4.0 μm. Further addition to 1:10 led to significant dissolution of liquid droplets by reducing both numbers and sizes of droplets with a maximal diameter of only approximately 2.5 μm.  For TssDNA, at a molar ratio of 1:1 (FUS:TssDNA), LLPS of FUS appeared to be significantly enhanced by forming a large number of droplets with a maximal diameter up to 5.4 μm. Further addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to only approximately 1.6 μm, and at 1:10, all droplets were completely dissolved. Interestingly, T24 showed the same two stage effect on LLPS of FUS as TssDNA. At a molar ratio of 1:1, LLPS of FUS was significantly enhanced by forming a large number of droplets with a maximal diameter up to approximately 6.2 μm. Similarly, addition to 1:5 led to significant dissolution of droplets with the maximal diameter reduced to approximately 1.2 μm, and at 1:10, all droplets were also dissolved.",12
123,346,PMID: 31292544,RNAPS0000315,https://pubmed.ncbi.nlm.nih.gov/31292544,RNA + protein,-,-,"m6A RNA(Ries,2019)",65nt,CCAGAGCCAGAACCAGAGACCAGAAACCAGAACCAGAACCAGAAGCCAGAGCCAGAAACCAGA,irregular RNA,-,"sp|Q9Y5A9|YTHD2_HUMAN YTH domain-containing family protein 2 OS=Homo sapiens OX=9606 GN=YTHDF2 PE=1 SV=2
MSASSLLEQRPKGQGNKVQNGSVHQKDGLNDDDFEPYLSPQARPNNAYTAMSDSYLPSYY
SPSIGFSYSLGEAAWSTGGDTAMPYLTSYGQLSNGEPHFLPDAMFGQPGALGSTPFLGQH
GFNFFPSGIDFSAWGNNSSQGQSTQSSGYSSNYAYAPSSLGGAMIDGQSAFANETLNKAP
GMNTIDQGMAALKLGSTEVASNVPKVVGSAVGSGSITSNIVASNSLPPATIAPPKPASWA
DIASKPAKQQPKLKTKNGIAGSSLPPPPIKHNMDIGTWDNKGPVAKAPSQALVQNIGQPT
QGSPQPVGQQANNSPPVAQASVGQQTQPLPPPPPQPAQLSVQQQAAQPTRWVAPRNRGSG
FGHNGVDGNGVGQSQAGSGSTPSEPHPVLEKLRSINNYNPKDFDWNLKHGRVFIIKSYSE
DDIHRSIKYNIWCSTEHGNKRLDAAYRSMNGKGPVYLLFSVNGSGHFCGVAEMKSAVDYN
TCAGVWSQDKWKGRFDVRWIFVKDVPNSQLRHIRLENNENKPVTNSRDTQEVPLEKAKQV
LKIIASYKHTTSIFDDFSHYEKRQEEEESVKKERQGRGK",YTHDF2,-,-,579aa(1-579),Q9Y5A9,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/Q9Y5A9,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1477","[1-45],[247-382]","[52-63],[135-153],[324-349]",In vitro,570 nM [RNA];|25  µM [DF2],-,-,-,-,-,Differential interference contrast microscopy,solute,"We next asked whether the binding of m6 A-RNA to the YTH domain  regulates LLPS of DF proteins. We chose a buffer and protein concen tration in which LLPS does not occur. Addition of a 65-nucleotide-long  RNA containing either zero m6 A nucleotides or one m6 A nucleotide  did not induce LLPS of DF2 (Fig. 1f, Extended Data Fig. 1f). However,  an RNA that contained ten m6 A nucleotides triggered LLPS within  minutes",65
124,347,PMID: 31292544,RNAPS0000315,https://pubmed.ncbi.nlm.nih.gov/31292544,RNA + protein,-,-,"m6A RNA(Ries,2019)",65nt,CCUGAGCCUGAACCUGAGACCUGAAACCUGAACCUGAACCUGAAGCCUGAGCCUGAAACCUGA,irregular RNA,-,"sp|Q9Y5A9|YTHD2_HUMAN YTH domain-containing family protein 2 OS=Homo sapiens OX=9606 GN=YTHDF2 PE=1 SV=2
MSASSLLEQRPKGQGNKVQNGSVHQKDGLNDDDFEPYLSPQARPNNAYTAMSDSYLPSYY
SPSIGFSYSLGEAAWSTGGDTAMPYLTSYGQLSNGEPHFLPDAMFGQPGALGSTPFLGQH
GFNFFPSGIDFSAWGNNSSQGQSTQSSGYSSNYAYAPSSLGGAMIDGQSAFANETLNKAP
GMNTIDQGMAALKLGSTEVASNVPKVVGSAVGSGSITSNIVASNSLPPATIAPPKPASWA
DIASKPAKQQPKLKTKNGIAGSSLPPPPIKHNMDIGTWDNKGPVAKAPSQALVQNIGQPT
QGSPQPVGQQANNSPPVAQASVGQQTQPLPPPPPQPAQLSVQQQAAQPTRWVAPRNRGSG
FGHNGVDGNGVGQSQAGSGSTPSEPHPVLEKLRSINNYNPKDFDWNLKHGRVFIIKSYSE
DDIHRSIKYNIWCSTEHGNKRLDAAYRSMNGKGPVYLLFSVNGSGHFCGVAEMKSAVDYN
TCAGVWSQDKWKGRFDVRWIFVKDVPNSQLRHIRLENNENKPVTNSRDTQEVPLEKAKQV
LKIIASYKHTTSIFDDFSHYEKRQEEEESVKKERQGRGK",YTHDF2,-,-,579aa(1-579),Q9Y5A9,"PhaSePro,DrLLPS","https://phasepro.elte.hu/entry/Q9Y5A9,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1477","[1-45],[247-382]","[52-63],[135-153],[324-349]",In vitro,570 nM [RNA];|25  µM [DF2],-,-,-,≤ min,-,Differential interference contrast microscopy,liquid,"We next asked whether the binding of m6 A-RNA to the YTH domain  regulates LLPS of DF proteins. We chose a buffer and protein concen tration in which LLPS does not occur. Addition of a 65-nucleotide-long  RNA containing either zero m6 A nucleotides or one m6 A nucleotide  did not induce LLPS of DF2 (Fig. 1f, Extended Data Fig. 1f). However,  an RNA that contained ten m6 A nucleotides triggered LLPS within  minutes",65
125,348,PMID: 31334587,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31334587,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|length=506aa|residues=1-506
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.2 mg/ml[polyU];|5µM[DHH1],2 mM MgCl2,30 mM HEPES-KOH pH 7.4,RT,60-200 s,other_molecular:50 mM ATP,Turbidity measurement,"solute, liquid","In the first junction, liquid-liquid phase separation (LLPS) is triggered by mixing a one-phase protein solution of Dhh1 with ATP and polyU.",0
126,349,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.25 µl 1mg/ml[polyU](final concentration 0.05 mg/ml);|3 µl[DHH1],-,"13.4 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2.1 µl 0.5M KCl (final KCl concentration 100mM) ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix ,1.25 µl 100mM ATP/MgCl2 (final concentration 5mM) ,1 µl 10 mg/ml BSA, 2 µl 1M Hepes of the respective pH ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicated,pH=6.2-7.2",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different pH conditions.,0
127,350,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.25 µl 1mg/ml[polyU];|3 µl[DHH1],-,"12.5 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),3 µl mix of 0.5M KCl / water to the final KCl concentration as indicated ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix ,1.25 µl 100mM ATP/MgCl2 (final concentration 5 mM) ,1 µl 10 mg/ml BSA, 2 µl 1M Hepes of the respective pH ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicated,0-15mM ATP",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different ATP concentrations.,0
128,351,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.05-0.5mg/ml[polyU](final concentration 0.05 mg/ml);|3 µl[DHH1],-,"13.4 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2.1 µl 0.5M KCl (final KCl concentration 100 mM) ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix .1.25 µl 100mM ATP/MgCl2 (final concentration 5 mM) ,1 µl 10 mg/ml BSA, 2 µl 1M Hepes ofthe respective pH .1.25 µl mix of water / 10mg/ml polyU to the final concentration as indicated ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicate",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different polyU concentrations,0
129,352,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,1.25 µl 1mg/ml[polyU](final concentration 0.05 mg/ml);|3 µl[DHH1],-,"13.4 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2.1 µl 0.5M KCl (final KCl concentration 100mM) ,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）mix ,1.5 µl mix of ATP/MgCl2 (250mM stock) and H2O to the final concentration as indicated ,1 µl 10 mg/ml BSA ,2 µl 1M Hepes of the respective pH ,3 µl mix of MH200G and Dhh1 stock to the final concentration as indicated",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",-,Phase separation behaviour of full-length and tail-less (core) Dhh1 in different salt concentrations.,0
130,353,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1
MGSINNNFNTNNNSNTDLDRDWKTALNIPKKDTRPQTDDVLNTKGNTFEDFYLKRELLMG
IFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATIDKSLYVA
ENDETVPVPFPIEQQSYHQQAIPQQQLPSQQQFAIPPQQHHPQFMVPPSHQQQQAYPPPQ
MPSQQGYPPQQEHFMAMPPGQSQPQY",DHH1,-,-,506aa(1-506),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.25µl 10mg/ml[polyU];|5.25µl 50µM[DHH1],-,"15.75 µl LSB-150 (150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl 10 mg/ml BSA,1 µl Hepes,pH 6.4 ",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA. To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human, both recombinant DDX6 and DDX3X still form phase separated droplets in vitro.",0
131,354,PMID: 31435012,RNAPS0000087,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P39517|DHH1_YEAST ATP-dependent RNA helicase DHH1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DHH1 PE=1 SV=1|residue=48-425
FEDFYLKRELLMGIFEAGFEKPSPIQEEAIPVAITGRDILARAKNGTGKTAAFVIPTLEKVKPKLNKIQALIM
VPTRELALQTSQVVRTLGKHCGISCMVTTGGTNLRDDILRLNETVHILVGTPGRVLDLAS
RKVADLSDCSLFIMDEADKMLSRDFKTIIEQILSFLPPTHQSLLFSATFPLTVKEFMVKH
LHKPYEINLMEELTLKGITQYYAFVEERQKLHCLNTLFSKLQINQAIIFCNSTNRVELLA
KKITDLGYSCYYSHARMKQQERNKVFHEFRQGKVRTLVCSDLLTRGIDIQAVNVVINFDF
PKTAETYLHRIGRSGRFGHLGLAINLINWNDRFNLYKIEQELGTEIAAIPATI
",DHH1,-,-,378aa(48-425),P39517,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0503,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0168,http://db.phasep.pro/browse/",-,-,In vitro,0.25µl 10mg/ml[polyU];|5.25µl 50µM[DHH1-core],-,"15.75 µl LSB-150 (150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl 10 mg/ml BSA,1 µl Hepes,pH 6.4 ",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA. To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human, both recombinant DDX6 and DDX3X still form phase separated droplets in vitro.",0
132,355,PMID: 31435012,RNAPS0000326,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P06634|DED1_YEAST ATP-dependent RNA helicase DED1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DED1 PE=1 SV=2
MAELSEQVQNLSINDNNENGYVPPHLRGKPRSARNNSSNYNNNNGGYNGGRGGGSFFSNN
RRGGYGNGGFFGGNNGGSRSNGRSGGRWIDGKHVPAPRNEKAEIAIFGVPEDPNFQSSGI
NFDNYDDIPVDASGKDVPEPITEFTSPPLDGLLLENIKLARFTKPTPVQKYSVPIVANGR
DLMACAQTGSGKTGGFLFPVLSESFKTGPSPQPESQGSFYQRKAYPTAVIMAPTRELATQ
IFDEAKKFTYRSWVKACVVYGGSPIGNQLREIERGCDLLVATPGRLNDLLERGKISLANV
KYLVLDEADRMLDMGFEPQIRHIVEDCDMTPVGERQTLMFSATFPADIQHLARDFLSDYI
FLSVGRVGSTSENITQKVLYVENQDKKSALLDLLSASTDGLTLIFVETKRMADQLTDFLI
MQNFRATAIHGDRTQSERERALAAFRSGAATLLVATAVAARGLDIPNVTHVINYDLPSDV
DDYVHRIGRTGRAGNTGLATAFFNSENSNIVKGLHEILTEANQEVPSFLKDAMMSAPGSR
SNSRRGGFGRNNNRDYRKAGGASAGGWGSSRSRDNSFRGGSGWGSDSKSSGWGNSGGSNN
SSWW",DED1,-,-,604aa(1-604),P06634,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0016,http://db.phasep.pro/browse/",-,"[34-87],[385-403],[449-460],[538-554],[559-570],[579-604]",In vitro,1.5µl 1mg/ml[polyU];|2.5µl 50µM[DED1],-,"13ul LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1ul CK mix,2ul Hepes pH 6.8,1ul 10mg/ml BSA",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
133,356,PMID: 31435012,RNAPS0000327,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P24784|DBP1_YEAST ATP-dependent RNA helicase DBP1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DBP1 PE=1 SV=2
MADLPQKVSNLSINNKENGGGGGKSSYVPPHLRSRGKPSFERSTPKQEDKVTGGDFFRRA
GRQTGNNGGFFGFSKERNGGTSANYNRGGSSNYKSSGNRWVNGKHIPGPKNAKLEAELFG
VHDDPDYHSSGIKFDNYDNIPVDASGKDVPEPILDFSSPPLDELLMENIKLASFTKPTPV
QKYSIPIVTKGRDLMACAQTGSGKTGGFLFPLFTELFRSGPSPVPEKAQSFYSRKGYPSA
LVLAPTRELATQIFEEARKFTYRSWVRPCVVYGGAPIGNQMREVDRGCDLLVATPGRLND
LLERGKVSLANIKYLVLDEADRMLDMGFEPQIRHIVEECDMPSVENRQTLMFSATFPVDI
QHLARDFLDNYIFLSVGRVGSTSENITQRILYVDDMDKKSALLDLLSAEHKGLTLIFVET
KRMADQLTDFLIMQNFKATAIHGDRTQAERERALSAFKANVADILVATAVAARGLDIPNV
THVINYDLPSDIDDYVHRIGRTGRAGNTGVATSFFNSNNQNIVKGLMEILNEANQEVPTF
LSDLSRQNSRGGRTRGGGGFFNSRNNGSRDYRKHGGNGSFGSTRPRNTGTSNWGSIGGGF
RNDNEKNGYGNSNASWW",DBP1,-,-,617aa(1-617),P24784,"LLPSDB,PhaSepDB","http://bio-comp.org.cn/llpsdb/protein.php?protein=p0221,http://db.phasep.pro/browse/",-,"[19-23],[545-569]",In vitro,1µl 1mg/ml[polyU];|3µl 50µM[DBP1],-,"14 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,2 µl Hepes pH 6.4,1 µl 10mg/ml BSA",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
134,357,PMID: 31435012,RNAPS0000328,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P24783|DBP2_YEAST ATP-dependent RNA helicase DBP2 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DBP2 PE=1 SV=1
MTYGGRDQQYNKTNYKSRGGDFRGGRNSDRNSYNDRPQGGNYRGGFGGRSNYNQPQELIK
PNWDEELPKLPTFEKNFYVEHESVRDRSDSEIAQFRKENEMTISGHDIPKPITTFDEAGF
PDYVLNEVKAEGFDKPTGIQCQGWPMALSGRDMVGIAATGSGKTLSYCLPGIVHINAQPL
LAPGDGPIVLVLAPTRELAVQIQTECSKFGHSSRIRNTCVYGGVPKSQQIRDLSRGSEIV
IATPGRLIDMLEIGKTNLKRVTYLVLDEADRMLDMGFEPQIRKIVDQIRPDRQTLMWSAT
WPKEVKQLAADYLNDPIQVQVGSLELSASHNITQIVEVVSDFEKRDRLNKYLETASQDNE
YKTLIFASTKRMCDDITKYLREDGWPALAIHGDKDQRERDWVLQEFRNGRSPIMVATDVA
ARGIDVKGINYVINYDMPGNIEDYVHRIGRTGRAGATGTAISFFTEQNKGLGAKLISIMR
EANQNIPPELLKYDRRSYGGGHPRYGGGRGGRGGYGRRGGYGGGRGGYGGNRQRDGGWGN
RGRSNY",DBP2,-,-,546aa(1-546),P24783,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0566,-,"[39-53],[447-461],[495-543]",In vitro,1µl 1mg/ml[polyU];|2.5µl 50µM[DBP2],-,"11.5 µl MH200G,1 µl 1M phosphate pH 6.0,1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,2 µl Hepes pH 6.0,1 µl 10mg/ml BSA",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
135,358,PMID: 31435012,RNAPS0000329,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P60842|IF4A1_HUMAN Eukaryotic initiation factor 4A-I OS=Homo sapiens OX=9606 GN=EIF4A1 PE=1 SV=1
MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQ
RAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVV
MALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFV
LDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEE
LTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTVS
AMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRI
GRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI",EIF4A1,-,-,406aa(1-406),P60842,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2247,[20-21],[359-370],In vitro,2µl 1mg/ml[polyU];|2µl 500µM[EIF4A1],100 mM NaCl,"9µl LSB-150(150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1µl BSA 10mg/ml,1µl Hepes pH 6.6,3µl 1x ATPase buffer(30 mM HEPES-KOH pH 7.5, 100 mM NaCl, 2 mM MgCl2)",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
136,359,PMID: 31435012,RNAPS0000330,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q07478|SUB2_YEAST ATP-dependent RNA helicase SUB2 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=SUB2 PE=1 SV=1
MSHEGEEDLLEYSDNEQEIQIDASKAAEAGETGAATSATEGDNNNNTAAGDKKGSYVGIH
STGFKDFLLKPELSRAIIDCGFEHPSEVQQHTIPQSIHGTDVLCQAKSGLGKTAVFVLST
LQQLDPVPGEVAVVVICNARELAYQIRNEYLRFSKYMPDVKTAVFYGGTPISKDAELLKN
KDTAPHIVVATPGRLKALVREKYIDLSHVKNFVIDECDKVLEELDMRRDVQEIFRATPRD
KQVMMFSATLSQEIRPICRRFLQNPLEIFVDDEAKLTLHGLQQYYIKLEEREKNRKLAQL
LDDLEFNQVIIFVKSTTRANELTKLLNASNFPAITVHGHMKQEERIARYKAFKDFEKRIC
VSTDVFGRGIDIERINLAINYDLTNEADQYLHRVGRAGRFGTKGLAISFVSSKEDEEVLA
KIQERFDVKIAEFPEEGIDPSTYLNN",SUB2,-,-,446aa(1-446),Q07478,PhaSepDB,http://db.phasep.pro/browse/,-,[23-41],In vitro,2µl 1mg/ml[polyU];|2µl 500µM[SUB2],100 mM NaCl,"9µl LSB-150(150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1µl BSA 10mg/ml,1µl Hepes pH 6.6,3µl 1x ATPase buffer(30 mM HEPES-KOH pH 7.5, 100 mM NaCl, 2 mM MgCl2)",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
137,360,PMID: 31435012,RNAPS0000331,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P20449|DBP5_YEAST ATP-dependent RNA helicase DBP5 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=DBP5 PE=1 SV=2
MSDTKRDPADLLASLKIDNEKEDTSEVSTKETVKSQPEKTADSIKPAEKLVPKVEEKKTK
QEDSNLISSEYEVKVKLADIQADPNSPLYSAKSFDELGLAPELLKGIYAMKFQKPSKIQE
RALPLLLHNPPRNMIAQSQSGTGKTAAFSLTMLTRVNPEDASPQAICLAPSRELARQTLE
VVQEMGKFTKITSQLIVPDSFEKNKQINAQVIVGTPGTVLDLMRRKLMQLQKIKIFVLDE
ADNMLDQQGLGDQCIRVKRFLPKDTQLVLFSATFADAVRQYAKKIVPNANTLELQTNEVN
VDAIKQLYMDCKNEADKFDVLTELYGLMTIGSSIIFVATKKTANVLYGKLKSEGHEVSIL
HGDLQTQERDRLIDDFREGRSKVLITTNVLARGIDIPTVSMVVNYDLPTLANGQADPATY
IHRIGRTGRFGRKGVAISFVHDKNSFNILSAIQKYFGDIEMTRVPTDDWDEVEKIVKKVL
KD",DBP5,-,-,482aa(1-482),P20449,-,-,-,-,In vitro,2µl 1mg/ml[polyU];|2µl 500µM[DBP5],100 mM NaCl,"9µl LSB-150(150 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1µl BSA 10mg/ml,1µl Hepes pH 6.6,3µl 1x ATPase buffer(30 mM HEPES-KOH pH 7.5, 100 mM NaCl, 2 mM MgCl2)",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
138,361,PMID: 31435012,RNAPS0000332,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P26196|DDX6_HUMAN Probable ATP-dependent RNA helicase DDX6 OS=Homo sapiens OX=9606 GN=DDX6 PE=1 SV=2
MSTARTENPVIMGLSSQNGQLRGPVKPTGGPGGGGTQTQQQMNQLKNTNTINNGTQQQAQ
SMTTTIKPGDDWKKTLKLPPKDLRIKTSDVTSTKGNEFEDYCLKRELLMGIFEMGWEKPS
PIQEESIPIALSGRDILARAKNGTGKSGAYLIPLLERLDLKKDNIQAMVIVPTRELALQV
SQICIQVSKHMGGAKVMATTGGTNLRDDIMRLDDTVHVVIATPGRILDLIKKGVAKVDHV
QMIVLDEADKLLSQDFVQIMEDIILTLPKNRQILLYSATFPLSVQKFMNSHLQKPYEINL
MEELTLKGVTQYYAYVTERQKVHCLNTLFSRLQINQSIIFCNSSQRVELLAKKISQLGYS
CFYIHAKMRQEHRNRVFHDFRNGLCRNLVCTDLFTRGIDIQAVNVVINFDFPKLAETYLH
RIGRSGRFGHLGLAINLITYDDRFNLKSIEEQLGTEIKPIPSNIDKSLYVAEYHSEPVED
EKP",DDX6,-,-,483aa(1-483),P26196,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0982,http://db.phasep.pro/browse/",-,-,In vitro,3µl 2mg/ml[polyU];|2.5µl 50µM[DDX6],-,"14.5 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
139,362,PMID: 31435012,RNAPS0000333,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|O00571|DDX3X_HUMAN ATP-dependent RNA helicase DDX3X OS=Homo sapiens OX=9606 GN=DDX3X PE=1 SV=3
MSHVAVENALGLDQQFAGLDLNSSDNQSGGSTASKGRYIPPHLRNREATKGFYDKDSSGW
SSSKDKDAYSSFGSRSDSRGKSSFFSDRGSGSRGRFDDRGRSDYDGIGSRGDRSGFGKFE
RGGNSRWCDKSDEDDWSKPLPPSERLEQELFSGGNTGINFEKYDDIPVEATGNNCPPHIE
SFSDVEMGEIIMGNIELTRYTRPTPVQKHAIPIIKEKRDLMACAQTGSGKTAAFLLPILS
QIYSDGPGEALRAMKENGRYGRRKQYPISLVLAPTRELAVQIYEEARKFSYRSRVRPCVV
YGGADIGQQIRDLERGCHLLVATPGRLVDMMERGKIGLDFCKYLVLDEADRMLDMGFEPQ
IRRIVEQDTMPPKGVRHTMMFSATFPKEIQMLARDFLDEYIFLAVGRVGSTSENITQKVV
WVEESDKRSFLLDLLNATGKDSLTLVFVETKKGADSLEDFLYHEGYACTSIHGDRSQRDR
EEALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEYVHRIGRTGRVGNLGL
ATSFFNERNINITKDLLDLLVEAKQEVPSWLENMAYEHHYKGSSRGRSKSSRFSGGFGAR
DYRQSSGASSSSFSSSRASSSRSGGGGHGSSRGFGGGGYGGFYNSDGYGGNYNSQGVDWW
GN",DDX3X,-,-,662aa(1-662),O00571,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/O00571,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1500,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0261,http://db.phasep.pro/browse/","[1-167],[256-263],[407-411],[437-437],[439-441],[473-480],[500-506],[535-536],[576-584]",-,In vitro,2µl 2mg/ml[polyU];|3µl 50µM[DDX3X],-,"14 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes pH 6.8",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
140,363,PMID: 31435012,RNAPS0000334,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P21693|DBPA_ECOLI ATP-dependent RNA helicase DbpA OS=Escherichia coli (strain K12) OX=83333 GN=dbpA PE=1 SV=2
MTAFSTLNVLPPAQLTNLNELGYLTMTPVQAAALPAILAGKDVRVQAKTGSGKTAAFGLG
LLQQIDASLFQTQALVLCPTRELADQVAGELRRLARFLPNTKILTLCGGQPFGMQRDSLQ
HAPHIIVATPGRLLDHLQKGTVSLDALNTLVMDEADRMLDMGFSDAIDDVIRFAPASRQT
LLFSATWPEAIAAISGRVQRDPLAIEIDSTDALPPIEQQFYETSSKGKIPLLQRLLSLHQ
PSSCVVFCNTKKDCQAVCDALNEVGQSALSLHGDLEQRDRDQTLVRFANGSARVLVATDV
AARGLDIKSLELVVNFELAWDPEVHVHRIGRTARAGNSGLAISFCAPEEAQRANIISDML
QIKLNWQTPPANSSIATLEAEMATLCIDGGKKAKMRPGDVLGALTGDIGLDGADIGKIAV
HPAHVYVAVRQAVAHKAWKQLQGGKIKGKTCRVRLLK",dbpA,-,-,457aa(1-457),P21693,-,-,-,-,In vitro,2µl 2mg/ml[polyU];|3µl 50µM[dbpA],-,"16 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10 mg/ml,1 µl 1M Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
141,364,PMID: 31435012,RNAPS0000335,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0A8J8|RHLB_ECOLI ATP-dependent RNA helicase RhlB OS=Escherichia coli (strain K12) OX=83333 GN=rhlB PE=1 SV=2
MSKTHLTEQKFSDFALHPKVVEALEKKGFHNCTPIQALALPLTLAGRDVAGQAQTGTGKT
MAFLTSTFHYLLSHPAIADRKVNQPRALIMAPTRELAVQIHADAEPLAEATGLKLGLAYG
GDGYDKQLKVLESGVDILIGTTGRLIDYAKQNHINLGAIQVVVLDEADRMYDLGFIKDIR
WLFRRMPPANQRLNMLFSATLSYRVRELAFEQMNNAEYIEVEPEQKTGHRIKEELFYPSN
EEKMRLLQTLIEEEWPDRAIIFANTKHRCEEIWGHLAADGHRVGLLTGDVAQKKRLRILD
EFTRGDLDILVATDVAARGLHIPAVTHVFNYDLPDDCEDYVHRIGRTGRAGASGHSISLA
CEEYALNLPAIETYIGHSIPVSKYNPDALMTDLPKPLRLTRPRTGNGPRRTGAPRNRRRS
G",RhlB,-,-,421aa(1-421),P0A8J8,PhaSepDB,http://db.phasep.pro/browse/,-,[398-419],In vitro,2µl 2mg/ml[polyU];|3µl 50µM[RhlB],-,"16 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),2 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10 mg/ml,1 µl 1M Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",solute,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
142,365,PMID: 31435012,RNAPS0000336,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0A9P6|DEAD_ECOLI ATP-dependent RNA helicase DeaD OS=Escherichia coli (strain K12) OX=83333 GN=deaD PE=1 SV=2
MAEFETTFADLGLKAPILEALNDLGYEKPSPIQAECIPHLLNGRDVLGMAQTGSGKTAAF
SLPLLQNLDPELKAPQILVLAPTRELAVQVAEAMTDFSKHMRGVNVVALYGGQRYDVQLR
ALRQGPQIVVGTPGRLLDHLKRGTLDLSKLSGLVLDEADEMLRMGFIEDVETIMAQIPEG
HQTALFSATMPEAIRRITRRFMKEPQEVRIQSSVTTRPDISQSYWTVWGMRKNEALVRFL
EAEDFDAAIIFVRTKNATLEVAEALERNGYNSAALNGDMNQALREQTLERLKDGRLDILI
ATDVAARGLDVERISLVVNYDIPMDSESYVHRIGRTGRAGRAGRALLFVENRERRLLRNI
ERTMKLTIPEVELPNAELLGKRRLEKFAAKVQQQLESSDLDQYRALLSKIQPTAEGEELD
LETLAAALLKMAQGERTLIVPPDAPMRPKREFRDRDDRGPRDRNDRGPRGDREDRPRRER
RDVGDMQLYRIEVGRDDGVEVRHIVGAIANEGDISSRYIGNIKLFASHSTIELPKGMPGE
VLQHFTRTRILNKPMNMQLLGDAQPHTGGERRGGGRGFGGERREGGRNFSGERREGGRGD
GRRFSGERREGRAPRRDDSTGRRRFGGDA",DeaD,-,-,629aa(1-629),P0A9P6,-,-,-,-,In vitro,1.5µl 2mg/ml[polyU];|3µl 50µM[DeaD],-,"17.5 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes pH 6.4",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
143,366,PMID: 31435012,RNAPS0000337,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P21507|SRMB_ECOLI ATP-dependent RNA helicase SrmB OS=Escherichia coli (strain K12) OX=83333 GN=srmB PE=1 SV=1
MTVTTFSELELDESLLEALQDKGFTRPTAIQAAAIPPALDGRDVLGSAPTGTGKTAAYLL
PALQHLLDFPRKKSGPPRILILTPTRELAMQVSDHARELAKHTHLDIATITGGVAYMNHA
EVFSENQDIVVATTGRLLQYIKEENFDCRAVETLILDEADRMLDMGFAQDIEHIAGETRW
RKQTLLFSATLEGDAIQDFAERLLEDPVEVSANPSTRERKKIHQWYYRADDLEHKTALLV
HLLKQPEATRSIVFVRKRERVHELANWLREAGINNCYLEGEMVQGKRNEAIKRLTEGRVN
VLVATDVAARGIDIPDVSHVFNFDMPRSGDTYLHRIGRTARAGRKGTAISLVEAHDHLLL
GKVGRYIEEPIKARVIDELRPKTRAPSEKQTGKPSKKVLAKRAEKKKAKEKEKPRVKKRH
RDTKNIGKRRKPSGTGVPPQTTEE",SrmB,-,-,444aa(1-444),P21507,PhaSepDB,http://db.phasep.pro/browse/,[389-444],"[7-17],[29-38],[396-419]",In vitro,1.5µl 2mg/ml[polyU];|3µl 50µM[SrmB],-,"18.5 µl LSB-50(50 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase?separated droplets in vitro.",0
144,367,PMID: 31435012,RNAPS0000338,https://pubmed.ncbi.nlm.nih.gov/31435012,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P25888|RHLE_ECOLI ATP-dependent RNA helicase RhlE OS=Escherichia coli (strain K12) OX=83333 GN=rhlE PE=1 SV=3
MSFDSLGLSPDILRAVAEQGYREPTPIQQQAIPAVLEGRDLMASAQTGTGKTAGFTLPLL
QHLITRQPHAKGRRPVRALILTPTRELAAQIGENVRDYSKYLNIRSLVVFGGVSINPQMM
KLRGGVDVLVATPGRLLDLEHQNAVKLDQVEILVLDEADRMLDMGFIHDIRRVLTKLPAK
RQNLLFSATFSDDIKALAEKLLHNPLEIEVARRNTASDQVTQHVHFVDKKRKRELLSHMI
GKGNWQQVLVFTRTKHGANHLAEQLNKDGIRSAAIHGNKSQGARTRALADFKSGDIRVLV
ATDIAARGLDIEELPHVVNYELPNVPEDYVHRIGRTGRAAATGEALSLVCVDEHKLLRDI
EKLLKKEIPRIAIPGYEPDPSIKAEPIQNGRQQRGGGGRGQGGGRGQQQPRRGEGGAKSA
SAKPAEKPSRRLGDAKPAGEQQRRRRPRKPAAA",RhlE,-,-,453aa(1-453),P25888,-,-,-,"[334-343],[390-430],[441-453]",In vitro,1.5µl 2mg/ml[polyU];|2µl 50µM[RhlE],-,"18.5 µl LSB-100(100 mM KCl, 30 mM HEPES-KOH pH 7.4, 2 mM MgCl2),1 µl CKM（40 mM ATP, 40 mM MgCl2, 200 mM creatine phosphate, 70 U ml−1 creatine kinase）,1 µl BSA 10mg/ml,1 µl Hepes 1M pH 6.8",RT,-,-,"Wide-field microscopy,FISH,Immunofluorescence microscopy",liquid,"Recombinant Ded1, Dbp1 and Dbp2 all readily undergo LLPS and form droplets in the presence of ATP and RNA.To examine whether DDX-mediated phase separation is conserved, we next analysed DDX6 and DDX3X, the human orthologues of Dhh1 and Ded1. Although the sequences of the unstructured tails have diverged considerably between yeast and human , both recombinant DDX6 and DDX3X still form phase-separated droplets in vitro.",0
145,368,PMID: 31586050,RNAPS0000339,https://pubmed.ncbi.nlm.nih.gov/31586050,RNA + protein,-,-,(GA-rich)30,30nt,GGAGGAGAGGAAGGUAAGGGAAGAAAGAAG,nucleotide rich RNA,-,"sp|Q96F86|EDC3_HUMAN Enhancer of mRNA-decapping protein 3 OS=Homo sapiens OX=9606 GN=EDC3 PE=1 SV=1
MATDWLGSIVSINCGDSLGVYQGRVSAVDQVSQTISLTRPFHNGVKCLVPEVTFRAGDIT
ELKILEIPGPGDNQHFGDLHQTELGPSGAGCQVGINQNGTGKFVKKPASSSSAPQNIPKR
TDVKSQDVAVSPQQQQCSKSYVDRHMESLSQSKSFRRRHNSWSSSSRHPNQATPKKSGLK
NGQMKNKDDECFGDDIEEIPDTDFDFEGNLALFDKAAVFEEIDTYERRSGTRSRGIPNER
PTRYRHDENILESEPIVYRRIIVPHNVSKEFCTDSGLVVPSISYELHKKLLSVAEKHGLT
LERRLEMTGVCASQMALTLLGGPNRLNPKNVHQRPTVALLCGPHVKGAQGISCGRHLANH
DVQVILFLPNFVKMLESITNELSLFSKTQGQQVSSLKDLPTSPVDLVINCLDCPENVFLR
DQPWYKAAVAWANQNRAPVLSIDPPVHEVEQGIDAKWSLALGLPLPLGEHAGRIYLCDIG
IPQQVFQEVGINYHSPFGCKFVIPLHSA",EDC3,-,-,508aa(1-508),Q96F86,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1241,"[95-189],[192-192],[203-258],[",[154-167],In vitro,150 µM Edc3 protein,25 mM NaCl,"25 mM HEPES, pH 7.3",RT,≤ 180 min,-,ssNMR,liquid,"In conclusion, our ssNMR data suggest that RNA is recruited to the dynamic and unstructured IDR in Edc3, which results in decreased internal mobility.",30
146,369,PMID: 31630970,RNAPS0000340,https://pubmed.ncbi.nlm.nih.gov/31630970,RNA + protein,-,-,polyrU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1µM poly(rU)40;|1µM FUS,100mM NaCl,"100mM Tris-HCl,pH 7.5,1mM EDTA,1mM DTT",RT,≤ 6 h,-,FRAP,"solute, liquid","The size of condensates was determined over the course of six hours; whereas WT-FUS, NLS, and G mutant FUS form small droplets (area of ~1.5μm2, R) R mutants grow much larger (area ~ 3-6 μm2) (Fig. 6B). Even after three hours, a stark difference in droplet size is observed (Fig 6C).",40
147,370,PMID: 31677973,RNAPS0000342,https://pubmed.ncbi.nlm.nih.gov/31677973,RNA + protein,-,-,"MajSAT RNA (Huo,2020)",231nt,GGACCUGGAAUAUGGCGAGAAAACUGAAAAUCACGGAAAAUGAGAAAUACACACUUUAGGACGUGAAAUAUGGCGAGGAAAACUGAAAAAGGUGGAAAAUUUAGAAAUGUCCACUGUAGGUCGUGGAAUAUGGCAAGAAAACUGAAAAUCAUGGAAAAUGAGAAACAUCCACUUGACGACUUGAAAAAUGACGAAAUCACUAAAAAACGUGAAAAAUGAGAAAUGCACACUGAA,irregular RNA,-,"sp|Q15424|SAFB1_HUMAN Scaffold attachment factor B1 OS=Homo sapiens OX=9606 GN=SAFB PE=1 SV=4
MAETLSGLGDSGAAGAAALSSASSETGTRRLSDLRVIDLRAELRKRNVDSSGNKSVLMER
LKKAIEDEGGNPDEIEITSEGNKKTSKRSSKGRKPEEEGVEDNGLEENSGDGQEDVETSL
ENLQDIDIMDISVLDEAEIDNGSVADCVEDDDADNLQESLSDSRELVEGEMKELPEQLQE
HAIEDKETINNLDTSSSDFTILQEIEEPSLEPENEKILDILGETCKSEPVKEESSELEQP
FAQDTSSVGPDRKLAEEEDLFDSAHPEEGDLDLASESTAHAQSSKADSLLAVVKREPAEQ
PGDGERTDCEPVGLEPAVEQSSAASELAEASSEELAEAPTEAPSPEARDSKEDGRKFDFD
ACNEVPPAPKESSTSEGADQKMSSPEDDSDTKRLSKEEKGRSSCGRNFWVSGLSSTTRAT
DLKNLFSKYGKVVGAKVVTNARSPGARCYGFVTMSTAEEATKCINHLHKTELHGKMISVE
KAKNEPVGKKTSDKRDSDGKKEKSSNSDRSTNLKRDDKCDRKDDAKKGDDGSGEKSKDQD
DQKPGPSERSRATKSGSRGTERTVVMDKSKGVPVISVKTSGSKERASKSQDRKSASREKR
SVVSFDKVKEPRKSRDSESHSRVRERSEREQRMQAQWEREERERLEIARERLAFQRQRLE
RERMERERLERERMHVEHERRREQERIHREREELRRQQELRYEQERRPAVRRPYDLDRRD
DAYWPEAKRAALDERYHSDFNRQDRFHDFDHRDRGRYPDHSVDRREGSRSMMGEREGQHY
PERHGGPERHGRDSRDGWGGYGSDKRMSEGRGLPPPPRRDWGDHGRREDDRSWQGTADGG
MMDRDHKRWQGGERSMSGHSGPGHMMNRGGMSGRGSFAPGGASRGHPIPHGGMQGGFGGQ
SRGSRPSDARFTRRY",SAFB,-,-,915aa(1-915),Q15424,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2609,http://db.phasep.pro/browse/",-,"[5-24],[83-94],[96-108],[201-215],[319-347],[514-541],[614-707],[739-756],[863-876],[891-905]",In vitro,0-3.75µM MajSAT RNA;|5µM SAFB-GEP,50mM NaCl,"50mM Tris pH 7.5, 5mM DTT",25˚C,10 min,"other_molecular:10% 1,6-hexanediol, 0.1% Triton",FRAP,"solute, liquid","When no RNAs were added, SAFB-GFP formed condensed droplets under 50 mM NaCl concentration. Surprisingly, by adding MajSAT RNAs, SAFB-GFP formed larger “droplet clusters,” whose sizes enlarged with the increase in concentrations of MajSAT RNAs (Figures 6E and 6F).",231
148,371,PMID: 31677973,RNAPS0000343,https://pubmed.ncbi.nlm.nih.gov/31677973,RNA + protein,-,-,"U1 RNA (Huo,2020)",156nt,AUACUUACCUGGCAGGGGAGAUACCAUGAUCACGAAGGUGGUUUUCCCAGGGCGAGGCUUAUCCAUUGCACUCCGGAUGUGCUGACCCCUGCGAUUUCCCCAAAUGCGGGAAACUCGACUGCAUAAUUUGUGGUAGUGGGGGACUGCGUUCGCGCU,irregular RNA,-,"sp|Q15424|SAFB1_HUMAN Scaffold attachment factor B1 OS=Homo sapiens OX=9606 GN=SAFB PE=1 SV=4
MAETLSGLGDSGAAGAAALSSASSETGTRRLSDLRVIDLRAELRKRNVDSSGNKSVLMER
LKKAIEDEGGNPDEIEITSEGNKKTSKRSSKGRKPEEEGVEDNGLEENSGDGQEDVETSL
ENLQDIDIMDISVLDEAEIDNGSVADCVEDDDADNLQESLSDSRELVEGEMKELPEQLQE
HAIEDKETINNLDTSSSDFTILQEIEEPSLEPENEKILDILGETCKSEPVKEESSELEQP
FAQDTSSVGPDRKLAEEEDLFDSAHPEEGDLDLASESTAHAQSSKADSLLAVVKREPAEQ
PGDGERTDCEPVGLEPAVEQSSAASELAEASSEELAEAPTEAPSPEARDSKEDGRKFDFD
ACNEVPPAPKESSTSEGADQKMSSPEDDSDTKRLSKEEKGRSSCGRNFWVSGLSSTTRAT
DLKNLFSKYGKVVGAKVVTNARSPGARCYGFVTMSTAEEATKCINHLHKTELHGKMISVE
KAKNEPVGKKTSDKRDSDGKKEKSSNSDRSTNLKRDDKCDRKDDAKKGDDGSGEKSKDQD
DQKPGPSERSRATKSGSRGTERTVVMDKSKGVPVISVKTSGSKERASKSQDRKSASREKR
SVVSFDKVKEPRKSRDSESHSRVRERSEREQRMQAQWEREERERLEIARERLAFQRQRLE
RERMERERLERERMHVEHERRREQERIHREREELRRQQELRYEQERRPAVRRPYDLDRRD
DAYWPEAKRAALDERYHSDFNRQDRFHDFDHRDRGRYPDHSVDRREGSRSMMGEREGQHY
PERHGGPERHGRDSRDGWGGYGSDKRMSEGRGLPPPPRRDWGDHGRREDDRSWQGTADGG
MMDRDHKRWQGGERSMSGHSGPGHMMNRGGMSGRGSFAPGGASRGHPIPHGGMQGGFGGQ
SRGSRPSDARFTRRY",SAFB,-,-,915aa(1-915),Q15424,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2609,http://db.phasep.pro/browse/",-,"[5-24],[83-94],[96-108],[201-215],[319-347],[514-541],[614-707],[739-756],[863-876],[891-905]",In vitro,"0-3.75µM U1 RNA (Huo,2020);|5µM SAFB-GEP",50mM NaCl,"50mM Tris pH 7.5, 5mM DTT",25˚C,10 min,"other_molecular:10% 1,6-hexanediol, 0.1% Triton",FRAP,"liquid, solute","When no RNAs were added, SAFB-GFP formed condensed droplets under 50 mM NaCl concentration. Surprisingly, by adding MajSAT RNAs, SAFB-GFP formed larger “droplet clusters,” whose sizes enlarged with the increase in concentrations of MajSAT RNAs (Figures 6E and 7F).",156
149,373,PMID: 31975687,RNAPS0000039,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,NCBI ID:174158,https://www.ncbi.nlm.nih.gov/gene/174158,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,Caenorhabditis elegans,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [nos-2];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as efficient as longer RNAs at stimulating MEG-3 condensation.",30
150,382,PMID: 31975687,RNAPS0000091,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(30),30nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U30];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as efficient as longer RNAs at stimulating MEG-3 condensation.",30
151,383,PMID: 31975687,RNAPS0000377,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(100),100nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U100];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as effi cient as longer RNAs at stimulating MEG-3 condensation",100
152,384,PMID: 31975687,RNAPS0000378,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(200),200nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U200];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as effi cient as longer RNAs at stimulating MEG-3 condensation",200
153,385,PMID: 31975687,RNAPS0000379,https://pubmed.ncbi.nlm.nih.gov/31975687,RNA + protein,-,-,polyU(300),300nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"tr|Q9TXM1|Q9TXM1_CAEEL Uncharacterized protein OS=Caenorhabditis elegans OX=6239 GN=meg-3 PE=4 SV=1
MSSSKPYPSGLPNSRRKRGGRRSSSRSNQESASNNMEHQITLDELFNPIAKQDSAQSTSR
EYGAKSGISHHGSVSFNGNTFMNGQQLNHSMTRHGRVFNQSMHAAQGNGSNAFNSIPPTA
PVFSADFRRNLQTRNSSSWYERRFPVSTDQDDVQQSNTRRSRSRQNGQHGLSFSDGSNNY
GHAGNKSFSVSSVPVGFQKQENNSKKLRQTNVHQQCLGNKSFNAQAGVHGHAFKKGHKDN
KNASGKEVINSSLVQKHDAIKSRNLNQSFSGFPTHETSSMKNQQQKSRNDRKKSRGSSNF
QDRTYFNTNDDELTDDVFIDDSMDAARGRRSRSVTKKLQQSTYSKQNAGSKQLTEKCKSS
EEAAKRNLVSNVFSKDGTELSIEQLLEIVSMKIGQQIHLPSSSHGECSNLNRTLPASDLN
CSIGEDFDSSFVDANNQTLPVSLPKKTSLSIKRRGSSRSASRLASLDVTLETVEEDEEPT
PSPQPSSPPKISRRKWTGTFDANVEEMRRLLHGDPEMPKSANRASSSKDQINRNNVDVKR
TPSSSIIPTPKALIGERCLTSSSKSSKLNKSLGVVDSKATKSPMYSVTVSGKETASGKRI
AQKLTPKVVALESSYITGIPVSTDCNGCPTPKRSGINCEIRAAEVYNQAGKWPFEITSDP
APLPCESADRIEYPSQDCTQDPASTSPPPRISESLTAFLEAQQDFNDYIDTNYKEKTQLL
KVNLNIHGMSPERWLYLNYFCTETIPRLDGPYADDPRVPPVRNMFRKWFLRFAEACLGNP
HQLAVMQEIAATFVQARLDDTSSSTDSTNMLYMLWKECIGQKNIIAIADACLLAHLRKSD
PIKYLNVKRDWLESIFDPPRDQ",meg-3,-,-,862aa(1-862),Q9TXM1,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q9TXM1,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-2080,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0145,http://db.phasep.pro/browse/","[1-37],[52-71],[141-187],[259-307],[326-352],[446-495],[510-534]","[14-27],[154-168],[456-492],[559-572],[799-808]",In vitro,20 ng/µL [U300];|500 nM [meg-3],"150 mM (37.5 mM
KCl, 112.5 mM NaCl)",25 mM HEPES (pH 7.4),RT,30 min,-,"FISH,FRAP",liquid,"To determine whether RNA length affects MEG-3 condensation behavior, we tested RNAs of varying sizes in the condensation assay. We found that short RNAs (30 and 100 nt) were not as effi cient as longer RNAs at stimulating MEG-3 condensation",300
154,387,PMID: 32513655,RNAPS0000391,https://pubmed.ncbi.nlm.nih.gov/32513655,RNA + protein,-,-,polyA(15),15nt,AAAAAAAAAAAAAAA,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|residues=296-754
TEDPYNEDFYFQVYKIIQRGGITSESNKGLIARAYLEHSGHRLGGRYKRTDIALQRMQSQVEKA
VTVAKERPSKLKDQQAAAGNSSQDNKQANTVLGKISSTLNSKNPRRQLQIPRQQPSDPDA
LKDVTDSLTNVDLASSGSSSTGSSAAAVASKQRRRSSYAFNNGNGATNLNKSGGKKFILE
LIETVYEEILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIF
NFLDKQQKLKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLS
NNSNFIEIMGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEIS
TWNEIYDKLFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQ
RIIIDEVRDEIFATINEAETLQKKEKELSVLPQR;|-",PAT1;|Dcp1-Dcp2,M+C-term,-;|-,458aa(296-754),"P25644;Q12517,P53550 ","DrLLPS,LLPSDB,PhaSepDB;Dcp-1:DrLLPS,PhaSepDB,
Dcp-2:PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/;http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0754,http://db.phasep.pro/browse/;http://db.phasep.pro/browse/","[1-4],[5-24],[55-79],[164-200],[365-421],[422-469];|-","[59-74],[111-137],[149-157],[165-183],[187-224],[404-415],[434-450],[545-555],[571-583];|-",In vitro,13.4 ng/µl [polyA];|2.5µM [Pat1];|2.5µM Dcp1/Dcp2Ext,60 mM NaCl,"20 mM HEPES pH 7.0, 1 mM DTT",RT,20 min,-,"Bright-field microscopy,Fluorescence microscopy",liquid,"PatMC and Dcp2 both weakly interact with RNA, which can trigger or potentiate liquid-liquid phase separation with oligomeric RNA binding proteins (RBPs)The PatMC/Dcp1/Dcp2Ext droplets were able to incorporate A15 RNA,though A15 RNA did not change the critical concentration required for phase separation However, neither short A15 RNAs nor polyA RNA promoted droplet formation with either PatMC",15
155,388,PMID: 32513655,RNAPS0000391,https://pubmed.ncbi.nlm.nih.gov/32513655,RNA + protein,-,-,polyA(15),15nt,AAAAAAAAAAAAAAA,poly RNA,-,"sp|P25644|PAT1_YEAST DNA topoisomerase 2-associated protein PAT1 OS=Saccharomyces cerevisiae (strain ATCC 204508 / S288c) OX=559292 GN=PAT1 PE=1 SV=4|residues=296-754
TEDPYNEDFYFQVYKIIQRGGITSESNKGLIARAYLEHSGHRLGGRYKRTDIALQRMQSQVEKA
VTVAKERPSKLKDQQAAAGNSSQDNKQANTVLGKISSTLNSKNPRRQLQIPRQQPSDPDA
LKDVTDSLTNVDLASSGSSSTGSSAAAVASKQRRRSSYAFNNGNGATNLNKSGGKKFILE
LIETVYEEILDLEANLRNGQQTDSTAMWEALHIDDSSYDVNPFISMLSFDKGIKIMPRIF
NFLDKQQKLKILQKIFNELSHLQIIILSSYKTTPKPTLTQLKKVDLFQMIILKIIVSFLS
NNSNFIEIMGLLLQLIRNNNVSFLTTSKIGLNLITILISRAALIKQDSSRSNILSSPEIS
TWNEIYDKLFTSLESKIQLIFPPREYNDHIMRLQNDKFMDEAYIWQFLASLALSGKLNHQ
RIIIDEVRDEIFATINEAETLQKKEKELSVLPQR",PAT1,M+C-term,-,458aa(296-754),P25644,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Sac-0330,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0246,http://db.phasep.pro/browse/","[1-4],[5-24],[55-79],[164-200],[365-421],[422-469]","[59-74],[111-137],[149-157],[165-183],[187-224],[404-415],[434-450],[545-555],[571-583]",In vitro,13.4 ng/µl [polyA];|2.5µM [Pat1],60 mM NaCl,"20 mM HEPES pH 7.0, 1 mM DTT",RT,20 min,-,"Bright-field microscopy,Fluorescence microscopy",solute,"PatMC and Dcp2 both weakly interact with RNA, which can trigger or potentiate liquid-liquid phase separation with oligomeric RNA binding proteins (RBPs)The PatMC/Dcp1/Dcp2Ext droplets were able to incorporate A15 RNA,though A15 RNA did not change the critical concentration required for phase separation However, neither short A15 RNAs nor polyA RNA promoted droplet formation with either PatMC",15
156,389,PMID: 32561643,RNAPS0000392,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,OIOOASVEELTEVPGIGPOLAOOILEOLA,Precursor-Orn,-,-,29aa,-,-,-,-,-,In vitro,1.2 mg/mL [polyU];|240 µM [Precursor-Orn];|1.2 µM [fluorescein-labeled Precursor-Orn],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,liquid,"On mixing with polyU, both Precursor-Orn and -Arg formed coacervates  as did Ancestor- (HhH)2 (SI Appendix, Fig. S10). Neither polypeptide formed droplets in the absence of polyU. Further, precursor-Arg consistently made larger droplets than Precursor-Orn, and at lower concen trations. Thus, by increasing the coacervate forming potential, statistical modification of ornithine to arginine could also provide an advantage at this early stage",0
157,390,PMID: 32561643,RNAPS0000393,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,RIRRASVEELTEVPGIGPRLARRILERLA,Precursor-Arg,-,-,29aa,-,-,-,-,-,In vitro,1.4 mg/mL [polyU];|190 µM [Precursor-Arg];|20 µM [fluorescein-labeled Precursor-Arg],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,liquid,"On mixing with polyU, both Precursor-Orn and -Arg formed coacervates  as did Ancestor- (HhH)2 (SI Appendix, Fig. S10). Neither polypeptide formed droplets in the absence of polyU. Further, precursor-Arg consistently made larger droplets than Precursor-Orn, and at lower concen trations. Thus, by increasing the coacervate forming potential, statistical modification of ornithine to arginine could also provide an advantage at this early stage",0
158,391,PMID: 32561643,RNAPS0000394,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,GRVRRSEIPLGIELEAGTLRLARRPEIRVA,all residues except arginine(Scrambled),-,-,30aa,-,-,-,"[1-2],[4-6],[8-8],[12-30]",-,In vitro,1 mg/mL [polyU];|200 µM [Scrambled];|8 µM [fluorescein-labeled Scrambled],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,solid,"Phase separation of these polypeptides is perhaps un surprising, given that arginine-rich peptides have been shown to phase-separate on the addition of RNA or crowding agents . However, scrambling the sequence of the Precursor-Arg—either completely or while preserving only the positions of the arginine residues (scrambled 1 and 2, respectively)—resulted in amor phous aggregate on polyU addition (Fig. 4B). Thus, basic amino acids are likely necessary but not sufficient to encode phase separation.",0
159,392,PMID: 32561643,RNAPS0000395,https://pubmed.ncbi.nlm.nih.gov/32561643,RNA + protein,-,-,polyU,-,-,poly RNA,-,GEPAIRSEPIRLRLEGVRALRTEVGLRIRA,Precursor-Arg(Scrambled),-,-,30aa,-,-,-,"[1-10],[16-26],[28-30]",-,In vitro,1 mg/mL [polyU];|200 µM [Scrambled];|8 µM [fluorescein-labeled Scrambled],-,50 mM MES pH 5.6,RT,-,-,Fluorescence microscopy,solid,"Phase separation of these polypeptides is perhaps un surprising, given that arginine-rich peptides have been shown to phase-separate on the addition of RNA or crowding agents . However, scrambling the sequence of the Precursor-Arg—either completely or while preserving only the positions of the arginine residues (scrambled 1 and 2, respectively)—resulted in amor phous aggregate on polyU addition (Fig. 4B). Thus, basic amino acids are likely necessary but not sufficient to encode phase separation.",0
160,411,PMID: 32637943,RNAPS0000405,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,318nt(PS-318),UAGCUUGUGCUGGUCCCUUUGAAGGUGUUAGACCUUUGACUGAACCUUCUGUUAUUAAAACACCAUUACGGGCGUUUCUAAAAAGGUCUACCUGUCCUUCCACUCUACCAUCAAACAAGACAGUAAGUGAAGAACAAGCACUCUCAGUAGGUUUCUUGGCAAUGUCAGUCAUUGUGCAGACACCUAUUGUAGAUACAUGUGCUGGGGCUUCUCUUUUGUAGUCCCAGAUGUACAGUAUUAGCAGCGAUAUCAACACCCAAAUUAUUGAGUAUCUUAAUCUCUGGCACUGGUUUAAUGUUACGCUUAGCCCAAAGCUCA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:R10D,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,15 min,-,Negative-stain electron microscopy,solid,"We used negative-stain electron microscopy to further analyze mixtures of 10 µM N protein and  1 µM RNA.These images represent the saturated protein-RNA solution surrounding  condensates. Unmodified wild-type protein and viral RNA formed uniform particles of ~20 nm diameter, reminiscent of structures seen in previous studies of partially disrupted MHV  nucleocapsids.Thus, the gel filamentous condensates of the unmodified protein – and possibly the nucleocapsid – are likely to be assembled on a foundation of discrete structural  building blocks. In contrast, the mixture of 10D mutant and RNA formed nonuniform, diffuse chains",318
161,412,PMID: 32637943,RNAPS0000405,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,318nt(PS-318),UAGCUUGUGCUGGUCCCUUUGAAGGUGUUAGACCUUUGACUGAACCUUCUGUUAUUAAAACACCAUUACGGGCGUUUCUAAAAAGGUCUACCUGUCCUUCCACUCUACCAUCAAACAAGACAGUAAGUGAAGAACAAGCACUCUCAGUAGGUUUCUUGGCAAUGUCAGUCAUUGUGCAGACACCUAUUGUAGAUACAUGUGCUGGGGCUUCUCUUUUGUAGUCCCAGAUGUACAGUAUUAGCAGCGAUAUCAACACCCAAAUUAUUGAGUAUCUUAAUCUCUGGCACUGGUUUAAUGUUACGCUUAGCCCAAAGCUCA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,15 min,-,Negative-stain electron microscopy,gel,"We used negative-stain electron microscopy to further analyze mixtures of 10 µM N protein and  1 µM RNA.These images represent the saturated protein-RNA solution surrounding  condensates. Unmodified wild-type protein and viral RNA formed uniform particles of ~20 nm diameter, reminiscent of structures seen in previous studies of partially disrupted MHV  nucleocapsids.Thus, the gel filamentous condensates of the unmodified protein – and possibly the nucleocapsid – are likely to be assembled on a foundation of discrete structural  building blocks. In contrast, the mixture of 10D mutant and RNA formed nonuniform, diffuse chains",318
162,413,PMID: 32637943,RNAPS0000405,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,318nt(PS-318),UAGCUUGUGCUGGUCCCUUUGAAGGUGUUAGACCUUUGACUGAACCUUCUGUUAUUAAAACACCAUUACGGGCGUUUCUAAAAAGGUCUACCUGUCCUUCCACUCUACCAUCAAACAAGACAGUAAGUGAAGAACAAGCACUCUCAGUAGGUUUCUUGGCAAUGUCAGUCAUUGUGCAGACACCUAUUGUAGAUACAUGUGCUGGGGCUUCUCUUUUGUAGUCCCAGAUGUACAGUAUUAGCAGCGAUAUCAACACCCAAAUUAUUGAGUAUCUUAAUCUCUGGCACUGGUUUAAUGUUACGCUUAGCCCAAAGCUCA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"We first analyzed the effects of three mid-sized viral RNA fragments: (1) 5’-400, containing the 400 nt at the 5’ end of the SARS-CoV-2 genome, which is thought to include multiple secondary  structure elements and the leader TRS51-53; (2) PS-318, a sequence near the end of ORF1b in  SARS-CoV, proposed as a packaging sequence54,55 but of unknown function51,56; and (3) N- 1260, containing the open reading frame of the N gene near the 3’ end of the SARS-CoV-2  genome. RNA encoding firefly luciferase (Luc-1710) was a nonviral control. N protein structures were analyzed by microscopy 30 minutes after addition of RNA at room temperature",318
163,414,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:R10D,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"solute, solid","We explored the role of phosphorylation in depth with studies of a phosphomimetic mutant in  which the ten serines and threonines in the SR region were replaced with aspartate (the 10D  mutant). When combined with the 5’-400 viral RNA, the 10D protein rapidly formed condensates with a spherical droplet morphology that was clearly distinct from the filamentous structures of  the wild-type protein",10
164,415,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"liquid, solid","We tested the importance of multivalent RNA binding by measuring the effects of a 10- nucleotide RNA carrying the TRS sequence of SARS-CoV-2. The TRS sequence is thought to  bind primarily to the NTD, with some contribution from the adjacent SR region57,58. Surprisingly,  addition of the TRS RNA triggered the rapid formation of droplets, without the filamentous  structures seen with longer viral RNAs",10
165,416,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1.25-20 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"We tested the importance of multivalent RNA binding by measuring the effects of a 10- nucleotide RNA carrying the TRS sequence of SARS-CoV-2. The TRS sequence is thought to  bind primarily to the NTD, with some contribution from the adjacent SR region57,58. Surprisingly,  addition of the TRS RNA triggered the rapid formation of droplets, without the filamentous  structures seen with longer viral RNAs",10
166,417,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-246,280-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CBP,-,"386aa(1-246,280-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-246],[365-391]","[175-208],[211-230],[236-246],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",10
167,418,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-364
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△CTE,-,364aa(1-364),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",10
168,419,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-419
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTE,-,375aa(45-419),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy","solute, liquid","When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",10
169,420,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-364
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△NTE+△CTE,-,320aa(45-364),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy","solute, liquid","When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",10
170,421,PMID: 32637943,RNAPS0000406,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,10nt(TRS),UCUAAACGAA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-175,207-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEG
PARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△SR,-,"388aa(1-175,207-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[207-212],[233-247],[249-256],[365-391]","[175-175],[207-207],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",solid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",10
171,423,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-364|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△CTE,protein_mutation:R10D,364aa(1-364),P0DTC9,-,-,"[1-43],[73-102],[145-149],[152-160],[172-215],[235-271]",-,In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"All three large viral RNAs were effective in driving droplet  formation, although N-1260 appeared to reduce the saturating concentration (Extended Data  Fig. 4a). NTE deletion in the 10D protein reduced droplet formation, showing once again the  positive role of this region",400
172,424,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-419|mutation:T10D
LPNNTASWFDALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTE,protein_mutation:T10D,375aa(45-419),P0DTC9,-,-,"[45-46],[73-102],[145-149],[152-160],[172-215],[235-271],[365-387],[409-419]",-,In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"All three large viral RNAs were effective in driving droplet  formation, although N-1260 appeared to reduce the saturating concentration (Extended Data  Fig. 4a). NTE deletion in the 10D protein reduced droplet formation, showing once again the  positive role of this region",400
173,425,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-364|mutation:T10D
LPNNTASWFDALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△NTE+△CTE,protein_mutation:T10D,320aa(45-364),P0DTC9,-,-,"[45-46],[73-102],[145-149],[152-160],[172-215],[235-271]",-,In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"All three large viral RNAs were effective in driving droplet  formation, although N-1260 appeared to reduce the saturating concentration (Extended Data  Fig. 4a). NTE deletion in the 10D protein reduced droplet formation, showing once again the  positive role of this region",400
174,426,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|mutation:R10D
MSDNGPQNQDNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,protein_mutation:R10D,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"solute, liquid","We explored the role of phosphorylation in depth with studies of a phosphomimetic mutant in  which the ten serines and threonines in the SR region were replaced with aspartate (the 10D  mutant). When combined with the 5’-400 viral RNA, the 10D protein rapidly formed condensates with a spherical droplet morphology that was clearly distinct from the filamentous structures of  the wild-type protein",400
175,427,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.125-2 µM [SARS-CoV-2];|10 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,"liquid, solid","We tested the importance of multivalent RNA binding by measuring the effects of a 10- nucleotide RNA carrying the TRS sequence of SARS-CoV-2. The TRS sequence is thought to  bind primarily to the NTD, with some contribution from the adjacent SR region57,58. Surprisingly,  addition of the TRS RNA triggered the rapid formation of droplets, without the filamentous  structures seen with longer viral RNAs",400
176,428,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-246,280-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△CBP,-,"386aa(1-246,280-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-246],[365-391]","[175-208],[211-230],[236-246],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",400
177,429,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-364
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△CTE,-,364aa(1-364),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy","liquid, solid","When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",400
178,430,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-419
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△NTE,-,375aa(45-419),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",400
179,431,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=45-364
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,△NTE+△CTE,-,320aa(45-364),P0DTC9,-,-,"[45-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",400
180,432,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residue=1-175,207-419
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEG
PARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,△SR,-,"388aa(1-175,207-419)",P0DTC9,-,-,"[1-40],[44-49],[174-174],[207-212],[233-247],[249-256],[365-391]","[175-175],[207-207],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,"Turbidity measurement,Microscopy",liquid,"When combined with viral 5’-400 RNA, none of the deletions completely prevented droplet  formation at high protein concentrations (Fig. 2a), indicating that no single disordered segment  is essential for the interactions that mediate droplet formation. CTE deletion stimulated the  formation of abundant filaments, suggesting that this region normally inhibits interactions.  Deletion of the NTE or CBP abolished filaments. Droplets were also observed after deletion of  both the NTE and CTE, showing that the central regions are sufficient for droplet formation.",400
181,433,PMID: 32637943,RNAPS0000408,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,400nt(1-400),AUGUUGACGUGCCUCUGAUAAGACCUCCUCCACGGAGUCUCCAAAGCCACGUACGAGCACGUCGCGAACCUGUAAAACAGGCAAACUGAGUUGGACGUGUGUUUUCUCGUUGAAACCAGGGACAAGGCUCUCCAUCUUACCUUUCGGUCACACCCGGACGAAACCUAGAUGUGCUGAUGAUCGGCUGCAACACGGACGAAACCGUAAGCAGCCUGCAGAAGAUAGACGAGUUACUCGUGUCCUGUCAACGACAGUAAUUAGUUAUUAAUUAUACUGCGUGAGUGCACUAAGCAUGCAGCCGAGUGACAGCCACACAGAUUUUAAAGUUCGUUUAGAGAACAGAUCUACAAGAGAUCGAAAGUUGGUUGGUUUGUUACCUGGGAAGGUAUAAACCUUUAAU,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1 µM [SARS-CoV-2];|5-25 µM [SARS-CoV-2 N protein],70 mM KCl,25 mM Hepes pH 7.5,RT,30 min,-,Microscopy,liquid,"We first analyzed the effects of three mid-sized viral RNA fragments: (1) 5’-400, containing the 400 nt at the 5’ end of the SARS-CoV-2 genome, which is thought to include multiple secondary  structure elements and the leader TRS51-53; (2) PS-318, a sequence near the end of ORF1b in  SARS-CoV, proposed as a packaging sequence54,55 but of unknown function51,56; and (3) N- 1260, containing the open reading frame of the N gene near the 3’ end of the SARS-CoV-2  genome. RNA encoding firefly luciferase (Luc-1710) was a nonviral control. N protein structures were analyzed by microscopy 30 minutes after addition of RNA at room temperature",400
182,449,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
183,450,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-364
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,-,-,364aa(1-364),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
184,451,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-419
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,370aa(49-419),P0DTC9,-,-,"[49-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
185,452,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-364
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKK",SARS-CoV-2 Nucleoprotein,-,-,316aa(49-364),P0DTC9,-,-,"[49-49],[174-174],[181-212],[233-247],[249-256]","[175-208],[211-230],[236-249],[361-364]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
186,453,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-246
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTV
",SARS-CoV-2 Nucleoprotein,-,-,246aa(1-246),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-246]","[175-208],[211-230],[236-246]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
187,454,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=247-419
TKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,173aa(247-419),P0DTC9,-,-,"[247-247],[249-256],[365-391]","[247-249],[361-379]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
188,455,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-264
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTV",SARS-CoV-2 Nucleoprotein,-,-,198aa(49-246),P0DTC9,-,-,"[49-49],[174-174],[181-212],[233-246]","[175-208],[211-230],[236-246]",In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",liquid,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
189,456,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-209
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPAR",SARS-CoV-2 Nucleoprotein,-,-,161aa(49-209),P0DTC9,-,-,"[49-49],[174-174],[181-209]",[175-208],In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
190,457,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=1-174
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-,-,174aa(1-174),P0DTC9,-,-,"[1-40],[44-49],[174-174]",-,In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
191,458,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=49-174
TASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAE
",SARS-CoV-2 Nucleoprotein,-,-,126aa(49-174),P0DTC9,-,-,"[49-49],[174-174]",-,In vitro,2µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Turbidity measurement,Differential interference contrast microscopy,Electron microscopy",solute,"With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
192,459,PMID: 32766587,RNAPS0000412,https://pubmed.ncbi.nlm.nih.gov/32766587,RNA + protein,-,-,"17-mer RNA(Lu,2020)",17nt,AAGCAGCUAAGAGCGAA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]",-,In vitro,0-5µM 17-mer RNA;|10µM N protein,80mM KCl,"5 mM HEPES, pH 7.5",20˚C,10–20 min,-,"Differential interference contrast microscopy,FRAP","solute, liquid","With 10 μM N protein, maximal phase separation occurred in the presence of 5 μM 17-mer RNA (85 μM nucleotide), above which phase separation was inhibited. The central intrinsic disordered region is required for RNA-dependent phase separation of N protein. (Fig.3K) Summary of phase separation behaviors of N protein variants shown in (A-J). Domain schematic of the SARS-CoV-2 N protein, with known domains marked. Gray shading indicates the region implicated in N+RNA phase separation.",17
193,460,PMID: 32870271,RNAPS0000414,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE11 cis-acting element RNA (H. Ryan,2020)",11nt,GCCAAGGAGCC,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,-,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur.",11
194,461,PMID: 32870271,RNAPS0000414,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE11 cis-acting element RNA (H. Ryan,2020)",11nt,GCCAAGGAGCC,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,protein_mutation:D290V,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur.",11
195,462,PMID: 32870271,RNAPS0000414,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE11 cis-acting element RNA (H. Ryan,2020)",11nt,GCCAAGGAGCC,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,protein_mutation:D298L,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur.",11
196,463,PMID: 32870271,RNAPS0000415,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE21 two overlapping tandem A2REs RNA (H. Ryan,2020)",21nt,GCCAAGGAGCCAGAGAGCAUG,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,-,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur.",21
197,464,PMID: 32870271,RNAPS0000415,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE21 two overlapping tandem A2REs RNA (H. Ryan,2020)",21nt,GCCAAGGAGCCAGAGAGCAUG,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,protein_mutation:D290V,-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur.",21
198,465,PMID: 32870271,RNAPS0000415,https://pubmed.ncbi.nlm.nih.gov/32870271,RNA + protein,-,-,"rA2RE21 two overlapping tandem A2REs RNA (H. Ryan,2020)",21nt,GCCAAGGAGCCAGAGAGCAUG,irregular RNA,Homo sapiens,"sp|P22626|ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens OX=9606 GN=HNRNPA2B1 PE=1 SV=2
MEKTLETVPLERKKREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKR
SRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIK
EDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGH
NAEVRKALSRQEMQEVQSSRSGRGGNFGFGDSRGGGGNFGPGPGSNFRGGSDGYGSGRGF
GDGYNGYGGGPGGGNFGGSPGYGGGRGGYGGGGPGYGNQGGGYGGGYDNYGGGNYGSGNY
NDFGNYNQQPSNYGPMKSGNFGGSRNMGGPYGGGNYGPGGSGGSGGYGGRSRY",HNRNPA2B1,C,"protein_mutation:D298L,",-,P22626,"DrLLPS,LLPSDB,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2608,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0117,http://db.phasep.pro/browse/","[190-341],[342-353]","[11-22],[198-307],[322-352]",In vitro,15 µM [A2RE];|15 µM [HNRNPA2B1],50mM NaCl or 150mM NaCl,20 mM Tris pH 7.5,RT,≤ 120 min,-,Differential interference contrast microscopy,solute,"rA2RE11 and rA2RE21 prevent phase separation and aggregation of full-length hnRNPA2 WT and mutants.After cleavage of a C-terminal maltose binding protein solubility tag by TEV protease, hnRNPA2 FL D290V (B) and P298L (C) undergo LLPS followed by aggregation. In the presence of either rA2RE11 or rA2RE21, neither phase separation nor aggregation occur.",21
199,469,PMID: 32901111,RNAPS0000420,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,"H20 RNA(Chen,2020)",20nt,AGAUUCAACUGGCAGUAACC,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.2-10µM [H20];|1-40µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy","liquid, solute","To further quantify the properties of N protein/RNA LLPS, we established the phase diagram of Alexa-647-labeled N protein (647-N) with another 20-nt ssRNA labeled with HEX (H20). Phase diagram of a 20-nt RNA H20 separating with N protein of SARS CoV-2. The histogram shows the percentage of area occupied by N protein/H20 droplets.",20
200,470,PMID: 32901111,RNAPS0000421,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,"A20 RNA(Chen,2020)A20 RNA(Chen,2020)",20nt,UAGCUUAUCAGACUGAUGUU,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.2-10µM [A20];|1-40µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,Fluorescence microscopy,"liquid, solute","We observed formation of liquid-like droplets when N protein or RNA concentration was higher than certain thresholds.Phase diagram of N protei-20 RNA LLPS in the presence of 2.5% PEG8000, N protein is labeled with Alexa-488.",20
201,471,PMID: 32901111,RNAPS0000422,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,"A85 RNA(Chen,2020)",85nt,GGCGCAUAAAGAUGAGACGCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGUUCG,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.1-5µM [A85];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Representative fluorescence and DIC images of LLPS formed by N protein (green) with 85-nt RNA A85 at the indicated concentrations. Representative fluorescence and DIC images of LLPS formed by N protein (red) with the positive strand RNA of N protein (N1541, 1541 nt) at the indicated concentrations.",85
202,472,PMID: 32901111,RNAPS0000423,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(10),10nt,UUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10µM[U10];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated",10
203,473,PMID: 32901111,RNAPS0000424,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(20),20nt,UUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5µM[U20];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"When inducing N protein/RNA LLPS by using these poly-U oligos with the same mass and the same concentrations of N protein, we found that the longest ssRNA, U60, could phase separate with N protein to form much larger droplets compared with other shorter oligoes (Supplementary information, Fig. S5a), confirming that the LLPS is indeed dependent on ssRNA length.Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated.",20
204,474,PMID: 32901111,RNAPS0000425,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,2.5µM[U40];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"When inducing N protein/RNA LLPS by using these poly-U oligos with the same mass and the same concentrations of N protein, we found that the longest ssRNA, U60, could phase separate with N protein to form much larger droplets compared with other shorter oligoes (Supplementary information, Fig. S5a), confirming that the LLPS is indeed dependent on ssRNA length.Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated.",40
205,475,PMID: 32901111,RNAPS0000426,https://pubmed.ncbi.nlm.nih.gov/32901111,RNA + protein,-,-,polyU(60),60nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,1.67µM[U60];|20µM [N protein],-,"1× PBS, pH 7.4",RT,> 1 h,crowding agent:2.5% PEG8000,"Differential interference contrast microscopy,Fluorescence microscopy",liquid,"When inducing N protein/RNA LLPS by using these poly-U oligos with the same mass and the same concentrations of N protein, we found that the longest ssRNA, U60, could phase separate with N protein to form much larger droplets compared with other shorter oligoes (Supplementary information, Fig. S5a), confirming that the LLPS is indeed dependent on ssRNA length.Representative fluorescence images of LLPS formed by RNA (orange) of different lengths mixed  with N protein (red). In the experiments, the RNA oligoes of the same mass were used, and the  corresponding molar concentrations are also indicated.",60
206,476,PMID: 32909564,RNAPS0000427,https://pubmed.ncbi.nlm.nih.gov/32909564,RNA + protein,-,-,polyU(20),20nt,UUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,5 or 10 µM[polyU];|5 µM[laf-1],-,"20 mM Tris–HCl, 5 mM TCEP, pH 7.4",25˚C,-,-,Microscopy,liquid,"Light microscopy snapshots of (A) LAF-1 (5 μM) + polyU20 RNA (5 μM), (B) LAF-1 (5 μM) + polyU20 RNA (10 μM), (C) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (50 μM), (D) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (500 μM), at 25˚C in buffer (20 mM Tris–HCl, 5 mM TCEP, pH 7.4). (Scale bar, 30 µm).",20
207,477,PMID: 32909564,RNAPS0000427,https://pubmed.ncbi.nlm.nih.gov/32909564,RNA + protein,-,-,polyU(20),20nt,UUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|D0PV95|DDX3_CAEEL ATP-dependent RNA helicase laf-1 OS=Caenorhabditis elegans OX=6239 GN=laf-1 PE=1 SV=1
MESNQSNNGGSGNAALNRGGRYVPPHLRGGDGGAAAAASAGGDDRRGGAGGGGYRRGGGN
SGGGGGGGYDRGYNDNRDDRDNRGGSGGYGRDRNYEDRGYNGGGGGGGNRGYNNNRGGGG
GGYNRQDRGDGGSSNFSRGGYNNRDEGSDNRGSGRSYNNDRRDNGGDGQNTRWNNLDAPP
SRGTSKWENRGARDERIEQELFSGQLSGINFDKYEEIPVEATGDDVPQPISLFSDLSLHE
WIEENIKTAGYDRPTPVQKYSIPALQGGRDLMSCAQTGSGKTAAFLVPLVNAILQDGPDA
VHRSVTSSGGRKKQYPSALVLSPTRELSLQIFNESRKFAYRTPITSALLYGGRENYKDQI
HKLRLGCHILIATPGRLIDVMDQGLIGMEGCRYLVLDEADRMLDMGFEPQIRQIVECNRM
PSKEERITAMFSATFPKEIQLLAQDFLKENYVFLAVGRVGSTSENIMQKIVWVEEDEKRS
YLMDLLDATGDSSLTLVFVETKRGASDLAYYLNRQNYEVVTIHGDLKQFEREKHLDLFRT
GTAPILVATAVAARGLDIPNVKHVINYDLPSDVDEYVHRIGRTGRVGNVGLATSFFNDKN
RNIARELMDLIVEANQELPDWLEGMSGDMRSGGGYRGRGGRGNGQRFGGRDHRYQGGSGN
GGGGNGGGGGFGGGGQRSGGGGGFQSGGGGGRQQQQQQRAQPQQDWWS",laf-1,-,-,708aa(1-708),D0PV95,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/D0PV95,http://llps.biocuckoo.cn/view.php?id=LLPS-Cae-0337,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0001,http://db.phasep.pro/browse/",-,-,In vitro,5 or 10 µM[polyU];|5 µM[laf-1],-,"20 mM Tris–HCl, 5 mM TCEP, pH 7.4",25˚C,-,other_molecular:50 μM LL-III200 μM LL-III500 μM LL-III,Microscopy,liquid,"Light microscopy snapshots of (A) LAF-1 (5 μM) + polyU20 RNA (5 μM), (B) LAF-1 (5 μM) + polyU20 RNA (10 μM), (C) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (50 μM), (D) LAF-1 (5 μM) + polyU20 RNA (5 μM) + LL-III (500 μM), at 25˚C in buffer (20 mM Tris–HCl, 5 mM TCEP, pH 7.4). (Scale bar, 30 µm).",20
208,500,PMID: 32995779,RNAPS0000435,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-5000 ng/µL [polyU];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Microscopy,"liquid, solute","Similar to polyC RNA, polyA and polyU RNA substrates produced spherical condensates at micromolar  concentrations of the N protein (Figure 2A). However, combining N protein with polyG that forms G quadruplexes or polyAU that forms base-pair interactions led to the formation of non-spherical condensates",0
209,501,PMID: 32995779,RNAPS0000436,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyG,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-5000 ng/µL [polyG];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Microscopy,solid,"Similar to polyC RNA, polyA and polyU RNA substrates produced spherical condensates at micromolar  concentrations of the N protein (Figure 2A). However, combining N protein with polyG that forms G quadruplexes or polyAU that forms base-pair interactions led to the formation of non-spherical condensates",0
210,502,PMID: 32995779,RNAPS0000437,https://pubmed.ncbi.nlm.nih.gov/32995779,RNA + protein,-,-,polyA,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,5-5000 ng/µL [polyA];|18.5 µM [N protein],"150 mM NaCl, 5 mM MgCl2","50 mM HEPES pH 7.4, 1 mM EGTA, 1 mM DTT, 1% pluronic",RT,> 25 min,-,Microscopy,"liquid, solute","Similar to polyC RNA, polyA and polyU RNA substrates produced spherical condensates at micromolar  concentrations of the N protein (Figure 2A). However, combining N protein with polyG that forms G quadruplexes or polyAU that forms base-pair interactions led to the formation of non-spherical condensates",0
211,506,PMID: 33200826,RNAPS0000435,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-U];|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N.",0
212,507,PMID: 33200826,RNAPS0000436,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyG,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-G];|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",solid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N.",0
213,508,PMID: 33200826,RNAPS0000437,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyA,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-A];|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N.",0
214,509,PMID: 33200826,RNAPS0000440,https://pubmed.ncbi.nlm.nih.gov/33200826,RNA + protein,-,-,polyC,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.5 mg/ml[ploy-C;|50 µM [N protein],70 mM NaCl,50 mM Tris pH 7.4,25˚C,≤ 2 h,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"To compare the effect of homopolymeric RNAs on nucleocapsid phase separation, we first performed turbidity measurements at condi tions where N phase separates alone. Importantly, the homopoly meric RNA stock solutions are all buffer exchanged via a spin desalting column and therefore are soluble in these conditions alone. Like torula yeast RNA, all homopolymeric RNAs enhanced the turbidity of solutions of N (Fig 6A), suggesting that particular sequences or RNA structures are not essential for interaction with N.",0
215,521,PMID: 33279579,RNAPS0000443,https://pubmed.ncbi.nlm.nih.gov/33279579,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|residues=255-441
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,20 µM[2N4R];|40 µg/mL[polyU],5 mM NaCl,-,RT,10 min,"other_molecular:0 or 4 wt% 1,6-hexanediol",Transmission electron microscopy,liquid,"We prepared tau LLPS-ED in two ways: by mixing tau187 with  RNA by the complex coacervation mechanism, or by lowering the ionic strength of the solution  containing 2N4R (< 10 mM, referred to as low-salt droplets) that induces simple coacervation  (Figure 1D). When adding 4% 1,6-HD, neither form of tau LLPS-ED, tau-RNA droplets formed  by complex coacervation or tau low-salt droplets formed by simple coacervation, dissolved  (Figure 1D).",0
216,522,PMID: 33279579,RNAPS0000443,https://pubmed.ncbi.nlm.nih.gov/33279579,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|residues=255-441
NVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,187aa(255-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[257-264],[280-282],[284-286],[291-299],[340-350],[396-436]",-,In vitro,100 µM[tau];|40 µg/mL[polyU],4.75M NaCl,-,RT,10 min,-,Transmission electron microscopy,liquid,"We prepared tau LLPS-ED in two ways: by mixing tau187 with  RNA by the complex coacervation mechanism, or by lowering the ionic strength of the solution  containing 2N4R (< 10 mM, referred to as low-salt droplets) that induces simple coacervation  (Figure 1D). When adding 4% 1,6-HD, neither form of tau LLPS-ED, tau-RNA droplets formed  by complex coacervation or tau low-salt droplets formed by simple coacervation, dissolved  (Figure 1D).",0
217,545,PMID: 33452693,RNAPS0000443,https://pubmed.ncbi.nlm.nih.gov/33452693,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P10636-8|TAU_HUMAN Isoform Tau-F of Microtubule-associated protein tau OS=Homo sapiens OX=9606 GN=MAPT|
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPK
TPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAK
SRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHV
PGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNI
THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMV
DSPQLATLADEVSASLAKQGL",MAPT,-,-,441aa(1-441),P10636,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2853,http://db.phasep.pro/browse/","[125-375],[395-441]","[216-226],[323-340],[380-403]",In vitro,60nM[polyU];|60µM[tau],50 mM KCl ,"50 mM HEPES pH 7.4, 1 mM DTT",RT,immediately or 20 - 30 min,other_molecular:2.5% dextran,"Differential interference contrast microscopy,FRAP",liquid,"We therefore formed droplets by mixing tau (50 μM) with polyU RNA (60 nM). To increase the stabil ity of the droplets, we additionally added 2.5% dextranWe then added 10 μM of aSyn to the preformed tau droplets such that the tau concentration was fivefold higher when compared to aSyn. aSyn alone did not form droplets (Figure S1). Fluorescence microscopy showed that aSyn concentrates inside the tau droplets independent of the presence of RNA",0
218,546,PMID: 33477032,RNAPS0000456,https://pubmed.ncbi.nlm.nih.gov/33477032,RNA + protein,-,-,polyA(24),24nt,AAAAAAAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,Molar Ratio of N protein and A24 from 1:0.5 to 1:1000,70 mM KCl,25 mM HEPES pH 7.5,RT,-,-,Turbidity measurement,liquid,"Indeed, here we found that A24 also biphasically modulated LLPS of the N protein as ATP but the ratios required to induce and dissolve droplets were much lower than those of ATP. Addition of A24 even at 1:0.5 resulted a turbidity value of 0.97 (Fig. 1C)",24
219,547,PMID: 33477032,RNAPS0000456,https://pubmed.ncbi.nlm.nih.gov/33477032,RNA + protein,-,-,polyA(24),24nt,AAAAAAAAAAAAAAAAAAAAAAAA,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM[polyA];|20 µM[SARS-CoV-2 Nucleoprotein],70 mM KCl,25 mM HEPES pH 7.5,RT,-,other_molecular:0-8000 µM ATP,Differential interference contrast microscopy,-,"Indeed, here we found that A24 also biphasically  modulated LLPS of the N protein as ATP but the ratios required to  induce and dissolve droplets were much lower than those of ATP.  Addition of A24 even at 1:0.5 resulted a turbidity value of 0.97 as well as the formation of a large number of dynamic  droplets with the diameter of some even close to ~2 mm",24
220,554,PMID: 33523882,RNAPS0000460,https://pubmed.ncbi.nlm.nih.gov/33523882,RNA + protein,-,-,(CGG)99,297nt,CGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG,repeat RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,20 ng/µl [(CGG)99];|9 µM [FMRpolyG],"25 mM NaCl, 10 mM MgCl2","10 mM tris-HCl buffer pH 7.5,12% (w/v) glycerol",23˚C,1 h,-,FRAP,liquid,We next investigated whether PpIX affects the LLPS of FMRpolyG  in vitro. The phase-separated liquid droplets and hydrogels of com plexes of fluorescein-FMRpolyG and CX rhodamine–CGG99 formed  substantially smaller droplets after PpIX treatment compared to un treated controls,297
221,555,PMID: 33523882,RNAPS0000460,https://pubmed.ncbi.nlm.nih.gov/33523882,RNA + protein,-,-,(CGG)99,297nt,CGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG,repeat RNA,-,"sp|Q06787|FMR1_HUMAN Synaptic functional regulator FMR1 OS=Homo sapiens OX=9606 GN=FMR1 PE=1 SV=1
MEELVVEVRGSNGAFYKAFVKDVHEDSITVAFENNWQPDRQIPFHDVRFPPPVGYNKDIN
ESDEVEVYSRANEKEPCCWWLAKVRMIKGEFYVIEYAACDATYNEIVTIERLRSVNPNKP
ATKDTFHKIKLDVPEDLRQMCAKEAAHKDFKKAVGAFSVTYDPENYQLVILSINEVTSKR
AHMLIDMHFRSLRTKLSLIMRNEEASKQLESSRQLASRFHEQFIVREDLMGLAIGTHGAN
IQQARKVPGVTAIDLDEDTCTFHIYGEDQDAVKKARSFLEFAEDVIQVPRNLVGKVIGKN
GKLIQEIVDKSGVVRVRIEAENEKNVPQEEEIMPPNSLPSNNSRVGPNAPEEKKHLDIKE
NSTHFSQPNSTKVQRVLVASSVVAGESQKPELKAWQGMVPFVFVGTKDSIANATVLLDYH
LNYLKEVDQLRLERLQIDEQLRQIGASSRPPPNRTDKEKSYVTDDGQGMGRGSRPYRNRG
HGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRG
QGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTDGSLQIRVDCNNERSVHTKTLQNTSS
EGSRLRTGKDRNQKKEKPDSVDGQQPLVNGVP",FMR1,-,-,632aa(1-632),Q06787,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q06787,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-2426,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0024,http://db.phasep.pro/browse/","[281-422],[443-515],[516-632]","[492-504],[527-549]",In vitro,20 ng/µl [(CGG)99];|9 µM [FMRpolyG],"25 mM NaCl, 10 mM MgCl2","10 mM tris-HCl buffer pH 7.5,12% (w/v) glycerol",23˚C,1 h,drug:PpIX (50µM),FRAP,liquid,We next investigated whether PpIX affects the LLPS of FMRpolyG  in vitro. The phase-separated liquid droplets and hydrogels of com plexes of fluorescein-FMRpolyG and CX rhodamine–CGG99 formed  substantially smaller droplets after PpIX treatment compared to un treated controls,297
222,556,PMID: 33558506,RNAPS0000465,https://pubmed.ncbi.nlm.nih.gov/33558506,RNA + protein,-,-,polyrU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1|residues=471-510
DRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGK",FUS,RGG3,-,40aa(471-510),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,0.2 mg/ml µM[GLS1];|0.2 µM [GIRGL];|1 mg/ml µM [FUS],150 mM NaCl,"25 mM Tris-HCl (pH = 7.5), 20 mM DTT",RT,-,-,Confocal fluorescence microscopy,liquid,"MD simulations similar to those in Fig. 1d but now including π-rich FUSPLP as a client (Table S2) revealed enhanced surface recruitment of PLP chains into RRP-RNA droplets only at low-RNA conditions(Fig. 1f, Fig. S9), thereby lending support to this idea. To test this experimentally, we utilized PLPs from two different RNPs, EWS and FUS, and quantified their partitioning in FUSRGG3-poly(rU) condensates.",40
223,557,PMID: 33558506,RNAPS0000465,https://pubmed.ncbi.nlm.nih.gov/33558506,RNA + protein,-,-,polyrU(40),40nt,UUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,2.5 mg/ml µM[GLS1];|0.2 µM [GIRGL];|1 mg/ml µM [FUS],150 mM NaCl,"25 mM Tris-HCl (pH = 7.5), 20 mM DTT",RT,-,-,Confocal fluorescence microscopy,liquid,"MD simulations similar to those in Fig. 1d but now including π-rich FUSPLP as a client (Table S2) revealed enhanced surface recruitment of PLP chains into RRP-RNA droplets only at low-RNA conditions(Fig. 1f, Fig. S9), thereby lending support to this idea. To test this experimentally, we utilized PLPs from two different RNPs, EWS and FUS, and quantified their partitioning in FUSRGG3-poly(rU) condensates.",40
224,558,PMID: 33597515,RNAPS0000466,https://pubmed.ncbi.nlm.nih.gov/33597515,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1.25 mg/mL [PolyU];|4.5 µM [FUS],2.7 M KCl,50 mM Tris-HCl (pH 7.2) ,RT,-,"other_molecular:10% 1,6-hexanediol,12.5 mM ATP",Fluorescence microscopy,"liquid, solute","To test this hypothesis, we probed the ability of pre-formed FUS condensates to dissociate when exposed to a range of additional components acting as phase separation disruptors, as shown in Fig. 3a. We selected a representative set of compounds with the ability to modulate both electrostatic interactions, such as poly-uridine (PolyU) RNA and ATP, both highly negatively charged molecules previously described to disrupt phase separation20,64,65, as well as 1,6-hexanediol, an aliphatic alcohol known to disrupt weak protein–protein hydrophobic interactions and selectively dissolve liquid condensates but not solid ones70. At low-salt concentrations, PolyU RNA, ATP, and 1,6-hexanediol were all able to dissolve FUS condensates, confirming that both hydrophobic and electrostatic interactions contribute to the stability of FUS condensates in the low-salt regime. At high-salt conditions, 1,6-hexanediol was the only disruptor that could dissolve FUS condensates, while the addition of PolyU RNA and ATP did not show any effects. These observations, summarized in Fig. 3b, suggest that reentrant high-salt phase separation of proteins is indeed primarily a hydrophobically driven process where electrostatics are screened out.",0
225,559,PMID: 33597515,RNAPS0000466,https://pubmed.ncbi.nlm.nih.gov/33597515,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P35637|FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens OX=9606 GN=FUS PE=1 SV=1
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYE
PRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIES
VADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFS
GNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQ
QRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYD
RGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY",FUS,-,-,526aa(1-526),P35637,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/","[1-507],[508-512]","[17-104],[106-261],[371-425],[450-507]",In vitro,1.25 mg/mL [PolyU];|4.5 µM [FUS],50 mM KCl,50 mM Tris-HCl (pH 7.2) ,RT,-,"other_molecular:10% 1,6-hexanediol,12.5 mM ATP",Fluorescence microscopy,solute,"To test this hypothesis, we probed the ability of pre-formed FUS condensates to dissociate when exposed to a range of additional components acting as phase separation disruptors, as shown in Fig. 3a. We selected a representative set of compounds with the ability to modulate both electrostatic interactions, such as poly-uridine (PolyU) RNA and ATP, both highly negatively charged molecules previously described to disrupt phase separation20,64,65, as well as 1,6-hexanediol, an aliphatic alcohol known to disrupt weak protein–protein hydrophobic interactions and selectively dissolve liquid condensates but not solid ones70. At low-salt concentrations, PolyU RNA, ATP, and 1,6-hexanediol were all able to dissolve FUS condensates, confirming that both hydrophobic and electrostatic interactions contribute to the stability of FUS condensates in the low-salt regime. At high-salt conditions, 1,6-hexanediol was the only disruptor that could dissolve FUS condensates, while the addition of PolyU RNA and ATP did not show any effects. These observations, summarized in Fig. 3b, suggest that reentrant high-salt phase separation of proteins is indeed primarily a hydrophobically driven process where electrostatics are screened out.",0
226,560,PMID: 33621982,RNAPS0000467,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53,14nt(site1),UUUUUUACCUUGUA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,1 µM [p53];|5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,≤ 20 min,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"We therefore tested whether these individual sites were sufficient for inducing TIA-1 condensation in vitro using oligonucleotides repre senting either the short 14-nt TIA-1 binding site (p53 site 1) or the longer 27-nt TIA-1 binding site (p53 site 2). P53 site 1 did not induce self-association of TIA-1 either through phase separation or fibril formation as shown by DIC, tur bidity and ThT fluorescence assay respectively.In con trast, the presence of UC5 resulted in a dramatic increase in ThT fluorescence, after a lag time of ∼6 h",14
227,561,PMID: 33621982,RNAPS0000468,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53,27nt(site2),UUUUUUUUUUUUUUACCCCUUUUUAUA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,1 µM [p53];|5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,≤ 20 min,-,"Turbidity measurement,Differential interference contrast microscopy",liquid,"We therefore tested whether these individual sites were sufficient for inducing TIA-1 condensation in vitro using oligonucleotides repre senting either the short 14-nt TIA-1 binding site (p53 site 1) or the longer 27-nt TIA-1 binding site (p53 site 2). P53 site 1 did not induce self-association of TIA-1 either through phase separation or fibril formation as shown by DIC, tur bidity and ThT fluorescence assay respectively.In con trast, the presence of UC5 resulted in a dramatic increase in ThT fluorescence, after a lag time of ∼6 h",27
228,562,PMID: 33621982,RNAPS0000469,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53,326nt(3'UTR),GGGUCCCUUCUGCUGCCUUUUUUACCUUGUAGCUAG GGCUCAGCCCCCUCUCUGAGUAGUGGUUCCUGGCCCAAGUUGGGGAAUAGGUUGAUAGUU GUCAGGUCUCUGCUGGCCCAGCGAAAUUCUAUCCAGCCAGUUGUUGGACCCUGGCACCUA CAAUGAAAUCUCACCCUACCCCACACCCUGUAAGAUUCUAUCUUGGGCCCUCAUAGGGUC CAUAUCCUCCAGGGCCUACUUUCCUUCCAUUCUGCAAAGCCUGUCUGCAUUUAUCCACCC CCCACCCUGUCUCCCUCUUUUUUUUUUUUUUACCCCUUUUUAUAUAUCAA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [p53];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,Next we tested whether these TIA-1 binding sites also drove TIA-1 condensation in the context of the p53 3  UTR. Wild type p53 3  UTR RNA induced phase separation of TIA-1 in turbidity assay and fibril formation in the ThT assay,326
229,563,PMID: 33621982,RNAPS0000470,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,p53_mut,326nt(3'UTR),GGGUCCCUUCUGCUGCCUAUGUAACCUAGUAGCUAG GGCUCAGCCCCCUCUCUGAGUAGUGGUUCCUGGCCCAAGUUGGGGAAUAGGUUGAUAGUU GUCAGGUCUCUGCUGGCCCAGCGAAAUUCUAUCCAGCCAGUUGUUGGACCCUGGCACCUA CAAUGAAAUCUCACCCUACCCCACACCCUGUAAGAUUCUAUCUUGGGCCCUCAUAGGGUC CAUAUCCUCCAGGGCCUACUUUCCUUCCAUUCUGCAAAGCCUGUCUGCAUUUAUCCACCC CCCACCCUGUCUCCCUCUAUGUAUGUAUGUAACCCCUGAUUAUAUAUCAA,mRNA,Mus musculus,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [p53];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,Next we tested whether these TIA-1 binding sites also drove TIA-1 condensation in the context of the p53 3  UTR. Wild type p53 3  UTR RNA induced phase separation of TIA-1 in turbidity assay and fibril formation in the ThT assay,326
230,564,PMID: 33621982,RNAPS0000471,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,(UUUUUACUCCAA)4+UUUUUACUCC,58nt,UUUUUACUCCAAUUUUUACUCCAAUUUUUACUCCAAUUUUUACUCCAAUUUUUACUCC,repeat RNA,-,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [RNA];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,"To directly test the ability of the oligonucleotide con centration with specific binding sites to modulate TIA-1 condensation, we varied the concentration of TC5 between 0.125 and 5  M and monitored spontaneous phase sepa ration and fibril formation over time of TIA-1 at 2.5  M",58
231,565,PMID: 33621982,RNAPS0000472,https://pubmed.ncbi.nlm.nih.gov/33621982,RNA + protein,-,-,"UC RNA(Loughlin,2021)",10nt,UUUUUACUCC,irregular RNA,-,"sp|P31483|TIA1_HUMAN Nucleolysin TIA-1 isoform p40 OS=Homo sapiens OX=9606 GN=TIA1 PE=1 SV=3
MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAA
AALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTE
DIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTN
WATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQI
MEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQI
GYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGV
QPPQGQNGSMLPNQPSGYRVAGYETQ",TIA-1,-,-,386aa(1-386),P31483,"PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/P31483,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0303,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0007,http://db.phasep.pro/browse/",[354-386],"[59-65],[82-104]",In vitro,0.25 µM [RNA];|2.5 µM [TIA-1],50 mM NaCl,"20 mM HEPES
pH 7, 40 mM Arginine",RT,10 min,-,Turbidity measurement,liquid,"To directly test the ability of the oligonucleotide con centration with specific binding sites to modulate TIA-1 condensation, we varied the concentration of TC5 between 0.125 and 5  M and monitored spontaneous phase sepa ration and fibril formation over time of TIA-1 at 2.5  M",10
232,567,PMID: 33688654,RNAPS0000474,https://pubmed.ncbi.nlm.nih.gov/33688654,RNA + protein,-,-,SARS-CoV-2 virus RNA,211nt(84-294),CUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,LCD,-,-,P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,7.5µM [SARS-CoV-2];|30 µM [SARS-CoV-2 N protein],300 mM NaCl,"20 mM Tris, pH 8.0",37˚C,≤ 24 h,-,FRAP,"liquid, solid","The LCD segment, as opposed to the full length NCAP, form fibrils in lower protein:RNA ratios.  Whereas we observed no LLPS or amyloid formation of the LCD in the 40:1 protein: RNA (0.75  µM) molar ratio, ThS and PI positive LLPS droplets of roughly 3-10 µm in diameter appeared in  the 4:1 (7.5 µM RNA) molar ratio mixture during 17 h of incubation (Figure 4B & S4). 24 h of incubation led to the formation of gel particles of intense ThS signal",211
233,568,PMID: 33688654,RNAPS0000474,https://pubmed.ncbi.nlm.nih.gov/33688654,RNA + protein,-,-,SARS-CoV-2 virus RNA,211nt(84-294),CUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.75 µM [SARS-CoV-2];|30 µM [SARS-CoV-2 N protein],300 mM NaCl,"20 mM Tris, pH 8.0",37˚C,17 h,-,Fluorescence microscopy,solid,"Amyloid and LLPS formation are correlated in mixtures of NCAP, and its LCD, with appropriate Site2hp RNA concentrations, as visualized in vitro by fluorescence microscopy with the amyloid  fluorescent dye Thioflavin-S (ThS). ThS positive LLPS droplets of ~2-5 µm in diameter were  observed of the NCAP protein when mixed with Site2hp RNA in 40:1 protein:RNA molar ratio (0.75 µM RNA). Those droplets were also positive to propidium iodide (PI), a nucleic acid  indicator, demonstrating that the protein fibrils and RNA are co-localized into those droplets",211
234,569,PMID: 33688654,RNAPS0000474,https://pubmed.ncbi.nlm.nih.gov/33688654,RNA + protein,-,-,SARS-CoV-2 virus RNA,211nt(84-294),CUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGA,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,7.5 µM [SARS-CoV-2];|30 µM [SARS-CoV-2 N protein],300 mM NaCl,"20 mM Tris, pH 8.0",37˚C,17 h,-,Fluorescence microscopy,"liquid, solid","Amyloid and LLPS formation are correlated in mixtures of NCAP, and its LCD, with appropriate Site2hp RNA concentrations, as visualized in vitro by fluorescence microscopy with the amyloid  fluorescent dye Thioflavin-S (ThS). ThS positive LLPS droplets of ~2-5 µm in diameter were  observed of the NCAP protein when mixed with Site2hp RNA in 40:1 protein:RNA molar ratio (0.75 µM RNA). Those droplets were also positive to propidium iodide (PI), a nucleic acid  indicator, demonstrating that the protein fibrils and RNA are co-localized into those droplets",211
235,572,PMID: 33782395,RNAPS0000479,https://pubmed.ncbi.nlm.nih.gov/33782395,RNA + protein,-,-,polyrU,200–250nt,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10-1000 µM [poly(rU)];|0.5-20 µM [N protein],0 mM NaCl,"50 mM Tris, pH 7.5",RT,-,-,Turbidity measurement,"solute, liquid","In line with this expectation, we observed robust droplet formation with homopolymeric RNA (Fig. 5A, B) under aqueous buffer conditions, both at 50 mM Tris and at a higher salt concentration of 50 mM NaCl. Turbidity assays at different concentrations of protein and poly(rU) (200–250 nucleotides) demonstrate the classical re-entrant phase behavior expected for a system undergoing heterotypic interaction",250
236,573,PMID: 33782395,RNAPS0000479,https://pubmed.ncbi.nlm.nih.gov/33782395,RNA + protein,-,-,polyrU,200–250nt,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10-1000 µM [poly(rU)];|0.5-20 µM [N protein],50 mM NaCl,"50 mM Tris, pH 7.5",RT,-,-,Turbidity measurement,"solute, liquid","In line with this expectation, we observed robust droplet formation with homopolymeric RNA (Fig. 5A, B) under aqueous buffer conditions, both at 50 mM Tris and at a higher salt concentration of 50 mM NaCl. Turbidity assays at different concentrations of protein and poly(rU) (200–250 nucleotides) demonstrate the classical re-entrant phase behavior expected for a system undergoing heterotypic interaction",250
237,582,PMID: 32234784,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/32234784,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1|residue=RGG 90-137
RGYRGGSAGGRGFFRGGRGRGRGFSRGGGDRGYGGNRFESRSGGYGG",CIRBP,RGG,-,47aa(90-137),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[90-137],"[90-125],[130-137]",In vitro,30 µM [CIRBP];|10 µM (UG)12 RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4 pH 7.5,1 mM DTT,2.5% glycerol",25℃,≤ 30 min,-,Differential interference contrast microscopy,liquid,DIC microscopy showed that CIRBPRGG formed liquid-like condensates in the presence of RNA similar to the full-length protein.,24
238,583,PMID: 32234784,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/32234784,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1|residue=RSY 137-172
RSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,RSY,-,46aa(137-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[137-172],[137-167],In vitro,30 µM [CIRBP];|10 µM (UG)12 RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4 pH 7.5,1 mM DTT,2.5% glycerol",25℃,≤ 30 min,-,Differential interference contrast microscopy,liquid,DIC microscopy showed that CIRBPRGG formed liquid-like condensates in the presence of RNA similar to the full-length protein.,24
239,584,PMID: 32234784,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/32234784,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1|residue=RRM 1-67
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAM",CIRBP,RRM,-,67aa(1-67),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",-,-,In vitro,30 µM [CIRBP];|10 µM (UG)12 RNA,75 mM NaCl,"20 mM Na2HPO4/NaH2PO4 pH 7.5,1 mM DTT,2.5% glycerol",25℃,≤ 30 min,-,Differential interference contrast microscopy,liquid,DIC microscopy showed that CIRBPRGG formed liquid-like condensates in the presence of RNA similar to the full-length protein.,24
240,585,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,539aa(isofromA),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-539]",In vitro,4 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A).",24
241,586,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,4 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A).",24
242,587,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,539aa(isofromA),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-539]",In vitro,2 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A).",24
243,588,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,2 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,> 3 h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A).",24
244,589,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,4 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,≤ 24h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A).",24
245,590,PMID: 32328638,RNAPS0000527,https://pubmed.ncbi.nlm.nih.gov/32328638,RNA + protein,-,-,luciferase siRNA,24nt,GCACUCUGAUUGACAAAUACGAUU,siRNA,Xenopus tropicalis,-,fxr1,-,-,677aa(iosformE),Q5BJ56,PhaSepDB,http://db.phasep.pro/browse/,-,"[404-421],[461-496],[523-545],[572-582]",In vitro,2 µM [FXR1];|10 nM luciferase RNA,150 mM KCl,"20 mM Hepes and 1 mM β-mercaptoethanol, pH 7.4",RT,≤ 24h,-,Fluorescence microscopy,liquid,"We observed that in the presence of luciferase RNA, both isoforms E and A had the tendency to slowly aggregate (Fig. 6 A; and Fig. S4 A).",24
246,596,PMID: 34159327,RNAPS0000532,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA,267nt (5′UTR),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAG,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15-50nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,20h,-,Fluorescence microscopy,liquid,"We tested 1-1000nt, 1-267nt (the 5′UTR), 1-500nt, and 500-1000nt fragments at either 15, 25, or 50nM RNA and 3.6µM protein. All tested fragments could drive N-protein LLPS, however some fragments drove LLPS more readily (1-500 or 1-1000).",267
247,598,PMID: 34159327,RNAPS0000534,https://pubmed.ncbi.nlm.nih.gov/34159327,RNA + protein,-,-,SARS-CoV-2 virus RNA,500nt(1-500),GGGUUAAAGGUUUAUACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAUCUGUUCUCUAAACGAACUUUAAAAUCUGUGUGGCUGUCACUCGGCUGCAUGCUUAGUGCACUCACGCAGUAUAAUUAAUAACUAAUUACUGUCGUUGACAGGACACGAGUAACUCGUCUAUCUUCUGCAGGCUGCUUACGGUUUCGUCCGUGUUGCAGCCGAUCAUCAGCACAUCUAGGUUUCGUCCGGGUGUGACCGAAAGGUAAGAUGGAGAGCCUUGUCCCUGGUUUCAACGAGAAAACACACGUCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUCCGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUAGAAGUUGAAAAAGGCGUUUUGCCUCAACUUGAACAGCCCUAUGUGUUCAUCAAACGUUCGGAUGCUCGAACUGC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1|residues=45-364
LPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFP",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,15-50nM [SARS-CoV-2];|3.6 µM [SARS-CoV-2 N protein],150 mM NaCl,20 mM Tris pH 7.5,37°C,20h,-,Fluorescence microscopy,liquid,"We tested 1-1000nt, 1-267nt (the 5′UTR), 1-500nt, and 500-1000nt fragments at either 15, 25, or 50nM RNA and 3.6µM protein. All tested fragments could drive N-protein LLPS, however some fragments drove LLPS more readily (1-500 or 1-1000).",500
248,603,PMID: 32637943,RNAPS0000538,https://pubmed.ncbi.nlm.nih.gov/32637943,RNA + protein,-,-,SARS-CoV-2 virus RNA,61nt(Rsndom-10),UCCAACUCAGUUUGCCUGUUUUACAGGUUCGCGACGUGCUCGUACGUGGCUUUGGAGACUC,virus RNA,SARS-CoV-2 virus,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10 µM [SARS-CoV-2 N protein];|1.25-20 µM [Rsndom-10],70 mM KCl,25 mM HEPES pH 7.5,RT,> 30 min,-,Light microscopy,liquid,"We analyzed the formation and morphology of condensates over a wide range of N protein and 5′-400 RNA concentrations (Figures S3 and ​and1C,1C, top row). At low RNA concentrations, small spherical droplets were seen at multiple N protein concentrations. Higher RNA and protein concentrations led to filamentous structures. Interestingly, at RNA concentrations approaching those of N protein, no structures were formed. Droplets formed when TRS RNA was equimolar with or in excess of N protein (Figure 1C), suggesting that these droplets depend on the binding of a single TRS RNA to each N protein. A 10-nt RNA with a random sequence displayed similar behavior but at higher concentrations, suggesting that specific binding is not entirely responsible for the effects of TRS RNA (Figure 1C).",61
249,604,PMID: 33479198,RNAPS0000539,https://pubmed.ncbi.nlm.nih.gov/33479198,RNA + protein,-,-,"17-mer ssRNA (Lu,2021)",34nt,CGUGGAGGAGGUCUUAUCAGAGGCACGUCAACAUCUUAAAGAUGGCACUUGUGGCUUAGUA,irregular RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10µM [SARS-CoV-2 N protein];|0-10µM [17 mer RNA-3'-6-FAM],80 mM KCl,5 mM HEPES pH 7.5,20 °C,≥ 10 min,-,"Fluorescence microscopy,Differential interference contrast microscopy","liquid, solute","We generated a variant N protein with an N-terminal cysteine for specific labeling, then mixed Cy5-labeled full-length N protein with a nonspecific 17-mer ssRNA labeled with fluorescein (6-FAM). After mixing, we observed formation of spherical phase-separated condensates containing both components (Fig. 1a). Condensates formed in a specific range of RNA concentration, above which phase separation was inhibited (Fig. 1a). This so-called reentrant phase separation behavior is commonly observed in two-component systems, including RNA–protein mixtures, and is related to the ratio of binding sites in the two components in the mixture. With 10 µM N protein, maximal phase separation occurred in the presence of 5 µM 17-mer RNA (85 µM nucleotide), above which phase separation was inhibited (Fig.1a).",34
250,628,PMID: 33650968,RNAPS0000563,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:2857,https://www.ncbi.nlm.nih.gov/gene/2857,GPR34,496nt(3'UTR),GGUAAACAUACUAAAAUGAAUUAUAUAAUGCAGCCUCUUAAUUCUUUGAAGAACUAAAAAAUUAGGAAACAAAGUUCUAGCAUUUACAAAACUCAGAUCUCAAAGCUCUGCUUGUAUUUGUGAUAUUUCAUUUGCUUAACUGUAAACCAUUUCAAGGUACUAACUUUUAAAUCUGUAUGUAAAAUCUUUUCAAAAUACAUUUUUAAGCUAAUACUCUUAACAUAGAUUAUGAAGUUAAGUGAAAUUUAUGGCUCUAACAGCAAAAUAAUUAAAGUGCCAUAGUUUCUCAAGUGACUAAAGUAGUUAUUAAAAUCAAGCACUUGAUACUAAUUUGAAGUGUGUUUAAAAGUAAAUGAUUUGGGAACUGACAAUGUGUCAGAAAAUAUAUGUUCAUUUAUCAUUUUAAAAUCUUGUAUAAUUUGCCACUGUAUUCAUUUAUGCCUAAAUCUCUAUAACAGAUGAAAAGAUAAUUAAUAAAAUCCUAAUUAAAAAAUGA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[GPR34 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network",496
251,629,PMID: 33650968,RNAPS0000564,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:51699,https://www.ncbi.nlm.nih.gov/gene/51699,VPS29,482nt(3'UTR),AGCCAGGCCUGUCUUGAUGAUUUUUGGUUUUUUUUCAUUGUCCUGUUGAAAUCAAGUAAUUAAACAUUUAAGAGCCACAAAAUUGUAUCACUUUUAUAAUAUUUUGCAGUAAAAUAUAAUACCAUCUUCUCUGUUAAUACAUAAUUGCUCCAAGCUUCCUGUAAACUAUAAGAAUAUAUUUAGUUUACAGUAUAUGGAUUCUAUGAAAAAAUGUCCACAACACAGUAAUUGGUCACUUGUUAAGAAAAAUUUAUCCUUGUAAGUAUCUUCAAAGUUGAUAUUUGGAACUUUAUUCCAAAAGUAGUGCAUGUGGAGAAAGAAUCUAGACUUUCUUGUAUACAUUUUUCUCUUCUCCAGUAAUAAACAAUUACCUUUCAUUUAUACUUUGAUAACCUGUAUUUAAUUUAAAAAAAAACAUAAAAAUGAGGAACCAAGUGAAACUACGGAUAUAAAUAUUAAAGUGGACGAGAUGACCUUUCAGA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[VPS29 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,"liquid, gel","We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network",482
252,630,PMID: 33650968,RNAPS0000565,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:4609,https://www.ncbi.nlm.nih.gov/gene/4609,MYC,476nt(3'UTR),GGAAAAGUAAGGAAAACGAUUCCUUCUAACAGAAAUGUCCUGAGCAAUCACCUAUGAACUUGUUUCAAAUGCAUGAUCAAAUGCAACCUCACAACCUUGGCUGAGUCUUGAGACUGAAAGAUUUAGCCAUAAUGUAAACUGCCUCAAAUUGGACUUUGGGCAUAAAAGAACUUUUUUAUGCUUACCAUCUUUUUUUUUUCUUUAACAGAUUUGUAUUUAAGAAUUGUUUUUAAAAAAUUUUAAGAUUUACACAAUGUUUCUCUGUAAAUAUUGCCAUUAAAUGUAAAUAACUUUAAUAAAACGUUUAUAGCAGUUACACAGAAUUUCAAUCCUAGUAUAUAGUACCUAGUAUUAUAGGUACUAUAAACCCUAAUUUUUUUUAUUUAAGUACAUUUUGCUUUUUAAAGUUGAUUUUUUUCUAUUGUUUUUAGAAAAAAUAAAAUAACUGGCAAAUAUAUCAUUGAGCCAAAUCUUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[MYC 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network",476
253,631,PMID: 33650968,RNAPS0000566,https://pubmed.ncbi.nlm.nih.gov/33650968,RNA + protein,NCBI ID:5321,https://www.ncbi.nlm.nih.gov/gene/5321,PLA2G4A,473nt(3'UTR),UUCAUGUACUGGAAAUGGCAGCAGUUUCUGAUGCUGAGGCAGUUUGCAAUCCCAUGACAACUGGAUUUAAAAGUACAGUACAGAUAGUCGUACUGAUCAUGAGAGACUGGCUGAUACUCAAAGUUGCAGUUACUUAGCUGCAUGAGAAUAAUACUAUUAUAAGUUAGGUUGACAAAUGAUGUUGAUUAUGUAAGGAUAUACUUAGCUACAUUUUCAGUCAGUAUGAACUUCCUGAUACAAAUGUAGGGAUAUAUACUGUAUUUUUAAACAUUUCUCACCAACUUUCUUAUGUGUGUUCUUUUUAAAAAUUUUUUUUCUUUUAAAAUAUUUAACAGUUCAAUCUCAAUAAGACCUCGCAUUAUGUAUGAAUGUUAUUCACUGACUAGAUUUAUUCAUACCAUGAGACAACACUAUUUUUAUUUAUAUAUGCAUAUAUAUACAUACAUGAAAUAAAUACAUCAAUAUAAAAAUAA,mRNA,Homo sapiens,"A fusion protein construct[TIS11B RBD]-[FUS IDR]with RBD residues 114-181fused to FUS residues 1-214|length=282aa|residues=114-181/1-214
RYKTELCRPFEENGACKYGDKCQFAHGIHELRSLTRHPKYKTELCRTFHTIGFCPYGPRCHFIHNAEE|
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQ
SQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSS
SYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQD
QSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRG",TIS11B-FUS,RBD;IDR,-,"282aa(1-214,114-181)","Q07352,P35637","TIS11B:PhaSePro,
FUS:PhaSePro,DrLLPS,LLPSDB,PhaSepDB","https://phasepro.elte.hu/entry/Q07352;https://phasepro.elte.hu/entry/P35637,http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1390,http://bio-comp.org.cn/llpsdb/protein.php?protein=p0002,http://db.phasep.pro/browse/",[93-113];[114-181],"[80-92],[201-214];|[114-181]",In vitro,10µM[mGFP-FUS-TIS];|100-750nM[PLA2G4A 3'UTR],"150 mM NaCl,  200 mM ZnCl2","25 mM Tris-Cl, pH 7.4, 1 mM DTT, 2.5% glycerol",RT,16 h,crowding agent:5% dextran T500 [Pharmacosmos],FRAP,liquid,"We observed a strong association between the propensity of an RNA to induce network formation and the predicted ‘unstructured-ness’ of the RNA. For sphere-inducing RNAs, the majority of their nucleotides are predicted to form strong local structures, whereas RNAs with a high propensity for network",473
254,669,PMID: 33895773,RNAPS0000607,https://pubmed.ncbi.nlm.nih.gov/33895773,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,10µM[mCherry-N protein];|10 ng/mL[polyU],-,-,37˚C,20 min,-,FRAP,liquid,We further found that recombinant mCherry-fusion SARS-CoV-2 N protein formed micrometer-sized liquid droplets within 1 min when blended with poly(I:C) or polyU in vitro,0
255,670,PMID: 33895773,RNAPS0000607,https://pubmed.ncbi.nlm.nih.gov/33895773,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|P0DTC9|NCAP_SARS2 Nucleoprotein OS=Severe acute respiratory syndrome coronavirus 2 OX=2697049 GN=N PE=1 SV=1
MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHG
KEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAG
LPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGS
QASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQ
QQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH
WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAY
KTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA",SARS-CoV-2 Nucleoprotein,-,-,419aa(1-419),P0DTC9,-,-,"[1-40],[44-49],[174-174],[181-212],[233-247],[249-256],[365-391]","[175-208],[211-230],[236-249],[361-379]",In vitro,0.25-5µM[mCherry-N protein];|0-50 ng/mL[polyU],-,-,37˚C,-,-,FRAP,"solute, liquid","N protein was able to form liquid-like droplets at the concentration of 1μM with the presence of poly(I: C) or polyU over 5 ng/mL (Fig. 3f, g). Small liquid droplets tended to coalesce and formed larger droplets over time, together with larger equivalent diameter in vitro (Fig. 3h). ",0
256,671,PMID: 33910901,RNAPS0000610,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q94BV4|RH6_ARATH DEAD-box ATP-dependent RNA helicase 6 OS=Arabidopsis thaliana OX=3702 GN=RH6 PE=2 SV=2
MNNNNNNRGRFPPGIGAAGPGPDPNFQSRNPNPPQPQQYLQSRTPFPQQPQPQPPQYLQS
QSDAQQYVQRGYPQQIQQQQQLQQQQQQQQQQQEQQWSRRAQLPGDPSYIDEVEKTVQSE
AISDSNNEDWKATLKLPPRDNRYQTEDVTATKGNEFEDYFLKRDLLRGIYEKGFEKPSPI
QEESIPIALTGSDILARAKNGTGKTGAFCIPTLEKIDPENNVIQAVILVPTRELALQTSQ
VCKELSKYLKIEVMVTTGGTSLRDDIMRLYQPVHLLVGTPGRILDLAKKGVCVLKDCAML
VMDEADKLLSVEFQPSIEELIQFLPESRQILMFSATFPVTVKSFKDRYLKKPYIINLMDQ
LTLMGVTQYYAFVEERQKVHCLNTLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFY
IHAKMVQDHRNRVFHDFRNGACRNLVCTDLFTRGIDIQAVNVVINFDFPRTSESYLHRVG
RSGRFGHLGLAVNLVTYEDRFKMYQTEQELGTEIKPIPSLIDKAIYCQ",RH6,-,-,528aa(1-528),Q94BV4,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Art-0517,-,"[2-41],[45-56],[65-97]",In vitro,300ng/µL[polyU];|8µM[RH6],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,other_moleculer:5mM[ATP];crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",liquid,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro.",0
257,672,PMID: 33910901,RNAPS0000611,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q8RXK6|RH8_ARATH DEAD-box ATP-dependent RNA helicase 8 OS=Arabidopsis thaliana OX=3702 GN=RH8 PE=2 SV=1
MNNRGRYPPGIGAGRGAFNPNPNYQSRSGYQQHPPPQYVQRGNYAQNHQQQFQQAPSQPH
QYQQQQQQQQQWLRRGQIPGGNSNGDAVVEVEKTVQSEVIDPNSEDWKARLKLPAPDTRY
RTEDVTATKGNEFEDYFLKRELLMGIYEKGFERPSPIQEESIPIALTGRDILARAKNGTG
KTAAFCIPVLEKIDQDNNVIQAVIIVPTRELALQTSQVCKELGKHLKIQVMVTTGGTSLK
DDIMRLYQPVHLLVGTPGRILDLTKKGVCVLKDCSVLVMDEADKLLSQEFQPSVEHLISF
LPESRQILMFSATFPVTVKDFKDRFLTNPYVINLMDELTLKGITQFYAFVEERQKIHCLN
TLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMLQDHRNRVFHDFRNGACR
NLVCTDLFTRGIDIQAVNVVINFDFPKNAETYLHRVGRSGRFGHLGLAVNLITYEDRFNL
YRIEQELGTEIKQIPPHIDQAIYCQ",RH8,-,-,505aa(1-505),Q8RXK6,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1431,http://db.phasep.pro/browse/",-,[43-72],In vitro,300ng/µL[polyU];|8µM[RH8],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,other_moleculer:5mM[ATP];crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",liquid,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro.",0
258,673,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,300ng/µL[polyU];|8µM[RH12],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,other_moleculer:5mM[ATP];crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",liquid,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro.",0
259,674,PMID: 33910901,RNAPS0000610,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q94BV4|RH6_ARATH DEAD-box ATP-dependent RNA helicase 6 OS=Arabidopsis thaliana OX=3702 GN=RH6 PE=2 SV=2
MNNNNNNRGRFPPGIGAAGPGPDPNFQSRNPNPPQPQQYLQSRTPFPQQPQPQPPQYLQS
QSDAQQYVQRGYPQQIQQQQQLQQQQQQQQQQQEQQWSRRAQLPGDPSYIDEVEKTVQSE
AISDSNNEDWKATLKLPPRDNRYQTEDVTATKGNEFEDYFLKRDLLRGIYEKGFEKPSPI
QEESIPIALTGSDILARAKNGTGKTGAFCIPTLEKIDPENNVIQAVILVPTRELALQTSQ
VCKELSKYLKIEVMVTTGGTSLRDDIMRLYQPVHLLVGTPGRILDLAKKGVCVLKDCAML
VMDEADKLLSVEFQPSIEELIQFLPESRQILMFSATFPVTVKSFKDRYLKKPYIINLMDQ
LTLMGVTQYYAFVEERQKVHCLNTLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFY
IHAKMVQDHRNRVFHDFRNGACRNLVCTDLFTRGIDIQAVNVVINFDFPRTSESYLHRVG
RSGRFGHLGLAVNLVTYEDRFKMYQTEQELGTEIKPIPSLIDKAIYCQ",RH6,-,-,528aa(1-528),Q94BV4,DrLLPS,http://llps.biocuckoo.cn/view.php?id=LLPS-Art-0517,-,"[2-41],[45-56],[65-97]",In vitro,300ng/µL[polyU];|8µM[RH6],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",solute,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro.",0
260,675,PMID: 33910901,RNAPS0000611,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q8RXK6|RH8_ARATH DEAD-box ATP-dependent RNA helicase 8 OS=Arabidopsis thaliana OX=3702 GN=RH8 PE=2 SV=1
MNNRGRYPPGIGAGRGAFNPNPNYQSRSGYQQHPPPQYVQRGNYAQNHQQQFQQAPSQPH
QYQQQQQQQQQWLRRGQIPGGNSNGDAVVEVEKTVQSEVIDPNSEDWKARLKLPAPDTRY
RTEDVTATKGNEFEDYFLKRELLMGIYEKGFERPSPIQEESIPIALTGRDILARAKNGTG
KTAAFCIPVLEKIDQDNNVIQAVIIVPTRELALQTSQVCKELGKHLKIQVMVTTGGTSLK
DDIMRLYQPVHLLVGTPGRILDLTKKGVCVLKDCSVLVMDEADKLLSQEFQPSVEHLISF
LPESRQILMFSATFPVTVKDFKDRFLTNPYVINLMDELTLKGITQFYAFVEERQKIHCLN
TLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMLQDHRNRVFHDFRNGACR
NLVCTDLFTRGIDIQAVNVVINFDFPKNAETYLHRVGRSGRFGHLGLAVNLITYEDRFNL
YRIEQELGTEIKQIPPHIDQAIYCQ",RH8,-,-,505aa(1-505),Q8RXK6,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1431,http://db.phasep.pro/browse/",-,[43-72],In vitro,300ng/µL[polyU];|8µM[RH8],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",solute,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro.",0
261,676,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,300ng/µL[polyU];|8µM[RH12],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2 μl of 50% PEG8000,"Fluorescence 
microscopy ",solute,"In contrast, RH12, RH6, and RH8 remained dispersed in the absence of RNA or ATP, indicating that these helicases at high concentrations can undergo phase separation in an RNA- and ATP-dependent manner in vitro.",0
262,677,PMID: 33910901,RNAPS0000613,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,-,Turnip mosaic virus Vpg,-,-,-,-,-,-,-,-,In vitro,0-150ng/µL[polyU];|15µM[VPg],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"we found that VPg protein undergoes LLPS in the absence of RNA, and ssRNA (polyU) decreases its phase separation (fig. S12, C to E). VPg directly interacts with RH12 in vitro (Fig. 5D). Although high concentration of RNA inhibits the phase separation of VPg, phase separation of RH12 is dependent on RNA ",0
263,678,PMID: 33910901,RNAPS0000613,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,-,Turnip mosaic virus Vpg,-,-,-,-,-,-,-,-,In vitro,8µM[VPg];|50ng/µL[polyU],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"As expected, the droplet number and size of VPg proteins increased with the addition of RH8 or RH12 proteins under high concentration of RNAs",0
264,679,PMID: 33910901,RNAPS0000611,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q8RXK6|RH8_ARATH DEAD-box ATP-dependent RNA helicase 8 OS=Arabidopsis thaliana OX=3702 GN=RH8 PE=2 SV=1
MNNRGRYPPGIGAGRGAFNPNPNYQSRSGYQQHPPPQYVQRGNYAQNHQQQFQQAPSQPH
QYQQQQQQQQQWLRRGQIPGGNSNGDAVVEVEKTVQSEVIDPNSEDWKARLKLPAPDTRY
RTEDVTATKGNEFEDYFLKRELLMGIYEKGFERPSPIQEESIPIALTGRDILARAKNGTG
KTAAFCIPVLEKIDQDNNVIQAVIIVPTRELALQTSQVCKELGKHLKIQVMVTTGGTSLK
DDIMRLYQPVHLLVGTPGRILDLTKKGVCVLKDCSVLVMDEADKLLSQEFQPSVEHLISF
LPESRQILMFSATFPVTVKDFKDRFLTNPYVINLMDELTLKGITQFYAFVEERQKIHCLN
TLFSKLQINQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMLQDHRNRVFHDFRNGACR
NLVCTDLFTRGIDIQAVNVVINFDFPKNAETYLHRVGRSGRFGHLGLAVNLITYEDRFNL
YRIEQELGTEIKQIPPHIDQAIYCQ",RH8,-,-,505aa(1-505),Q8RXK6,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1431,http://db.phasep.pro/browse/",-,[43-72],In vitro,8µM[RH8];|50ng/µL[polyU],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"As expected, the droplet number and size of VPg proteins increased with the addition of RH8 or RH12 proteins under high concentration of RNAs",0
265,680,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,8µM[RH12];|50ng/µL[polyU],1 μl of 200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,-,"Fluorescence 
microscopy ",liquid,"As expected, the droplet number and size of VPg proteins increased with the addition of RH8 or RH12 proteins under high concentration of RNAs",0
266,681,PMID: 33910901,RNAPS0000612,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,"sp|Q9M2E0|RH12_ARATH DEAD-box ATP-dependent RNA helicase 12 OS=Arabidopsis thaliana OX=3702 GN=RH12 PE=2 SV=1
MNTNRGRYPPGVGTGRGAPPNPDYHQSYRQQQPPQDQQYVQRGYSQNPQQMQLQQQHQQQ
QQQQQWSRRPQLPGNASNANEVVQQTTQPEASSDANGQDWKATLRLPPPDTRYQTADVTA
TKGNEFEDYFLKRDLLKGIYEKGFEKPSPIQEESIPIALTGSDILARAKNGTGKTGAFCI
PVLEKIDPNNNVIQAMILVPTRELALQTSQVCKELSKYLNIQVMVTTGGTSLRDDIMRLH
QPVHLLVGTPGRILDLTKKGVCVLKDCAMLVMDEADKLLSAEFQPSLEELIQFLPQNRQF
LMFSATFPVTVKAFKDRHLRKPYVINLMDQLTLMGVTQYYAFVEERQKVHCLNTLFSKLQ
INQSIIFCNSVNRVELLAKKITELGYSCFYIHAKMVQDHRNRVFHEFRNGACRNLVCTDL
FTRGIDIQAVNVVINFDFPRTSESYLHRVGRSGRFGHLGLAVNLVTYEDRFKMYQTEQEL
GTEIKPIPSNIDQAIYCQ",RH12,-,-,498aa(1-498),Q9M2E0,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Art-1808,http://db.phasep.pro/browse/",-,"[26-42],[46-66]",In vitro,8µM[RH12];|300ng/µL[polyU],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2μl of 50% PEG8000;other_moleculer:5mM[ATP],"Fluorescence 
microscopy ",liquid,"To evaluate whether VPg directly inhibits RH12 phase separation, we mixed VPg and RH12 under high concentration of RNA. VPg proteins remain dispersed at polyU",0
267,682,PMID: 33910901,RNAPS0000613,https://pubmed.ncbi.nlm.nih.gov/33910901,RNA + protein,-,-,polyU,-,-,poly RNA,-,-,Turnip mosaic virus Vpg,-,-,-,-,-,-,-,-,In vitro,10µM[VPg];|300ng/µL[polyU],200 mM MgCl2,1 μl of Hepes-KOH (pH 6.6),-,-,crowding agent:2μl of 50% PEG8000;other_moleculer:5mM[ATP],"Fluorescence 
microscopy ",solute,"To evaluate whether VPg directly inhibits RH12 phase separation, we mixed VPg and RH12 under high concentration of RNA. VPg proteins remain dispersed at polyU",0
268,683,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|1-30µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,-,-,Turbidity measurement,liquid,"titration of (UG)12RNA to a sample with a fixed CIRBP concentration (17 μM) led to a progressive turbidity increase at low RNA concentrations, whereas higher amounts of RNA had a suppressive effect on CIRBP LLPS",24
269,684,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|7.5µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,-,other_moleculer:0-10mM[ATP],Turbidity measurement,liquid,"Addition of increasing amounts of ATP to RNA-bound and phase separated CIRBP led to a concentration-dependent decrease in turbidity, demonstrating that ATP inhibits CIRBP LLPS ",24
270,685,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|7.5µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,5-30 min,other_moleculer:5mM[ATP],Differential interference contrast microscopy,-,"In order to further validate these findings, we monitored CIRBP phase separation by DIC microscopy. In the presence of substoichiometric amounts of RNA, CIRBP immediately formed small condensates that increased in size over time, most likely due to fusion of condensates, and indicating their “liquid-like” behavior ",24
271,686,PMID: 33991007,RNAPS0000526,https://pubmed.ncbi.nlm.nih.gov/33991007,RNA + protein,-,-,(UG)12,24nt,UGUGUGUGUGUGUGUGUGUGUGUG,repeat RNA,-,"sp|Q14011|CIRBP_HUMAN Cold-inducible RNA-binding protein OS=Homo sapiens OX=9606 GN=CIRBP PE=1 SV=1
MASDEGKLFVGGLSFDTNEQSLEQVFSKYGQISEVVVVKDRETQRSRGFGFVTFENIDDA
KDAMMAMNGKSVDGRQIRVDQAGKSSDNRSRGYRGGSAGGRGFFRGGRGRGRGFSRGGGD
RGYGGNRFESRSGGYGGSRDYYSSRSQSGGYSDRSSGGSYRDSYDSYATHNE",CIRBP,-,-,172aa(1-172),Q14011,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-0652,http://db.phasep.pro/browse/",[86-172],"[89-125],[130-167]",In vitro,17µM[CIRBP];|7.5µM[(UG)12],150 mM NaCl,"50 mM NaH2PO4/Na2HPO4,pH 6.5",-,5-30 min,-,Differential interference contrast microscopy,liquid,"In order to further validate these findings, we monitored CIRBP phase separation by DIC microscopy. In the presence of substoichiometric amounts of RNA, CIRBP immediately formed small condensates that increased in size over time, most likely due to fusion of condensates, and indicating their “liquid-like” behavior ",24
272,695,PMID: 34267352,RNAPS0000625,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9,345nt(1-345),GCGGCCCGGGAAUCUACGUCACCCGAAAAGCGACUAUAAACGCCGGCGCCUCCGUCCCCAGCCGCGGCUCGGGAAUCCACCCGAAGAGUGGCUAUAAACGUCCGCGCCUCCAUUGCGCUCUCCUCUUCACUUAGGACACUGGUCCUCCCACGCCUGACACCGACGUCGCCAGGACCGCGGGGUUGGGGGAACUUGGCUGUCCCACGUCUUUCAAAUAAAGCUGUUUUGUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,-,"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,"Differential interference contrast microscopy,Fluorescence microscopy",liquid," To test whether the interaction with SNHG9 induces LATS1 phase separation in vitro, we incubated LATS1-GFP protein with fluorescein-labeled SNHG9 (red). Upon mixing, LATS1 and SNHG9 formed micrometer-sized liquid droplets",345
273,696,PMID: 34267352,RNAPS0000625,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9,345nt(1-345),GCGGCCCGGGAAUCUACGUCACCCGAAAAGCGACUAUAAACGCCGGCGCCUCCGUCCCCAGCCGCGGCUCGGGAAUCCACCCGAAGAGUGGCUAUAAACGUCCGCGCCUCCAUUGCGCUCUCCUCUUCACUUAGGACACUGGUCCUCCCACGCCUGACACCGACGUCGCCAGGACCGCGGGGUUGGGGGAACUUGGCUGUCCCACGUCUUUCAAAUAAAGCUGUUUUGUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,100 nM [SNHG9-sen];|0.01-2µM[LATS1-GFP],"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,Fluorescence microscopy,liquid,"Droplet formation was observed when the protein concentration of LATS1-GFP was 0.1 µM in the presence of SNHG9-sense, while no droplet formed at the same protein concentration in the presence of SNHG9-antisense or in the absence of RNA",345
274,697,PMID: 34267352,RNAPS0000626,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9-antisense,345nt(1-345),AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUGUUUUGUCGAAAUAAACUUUCUGCACCCUGUCGGUUCAAGGGGGUUGGGGCGCCAGGACCGCUGCAGCCACAGUCCGCACCCUCCUGGUCACAGGAUUCACUUCUCCUCUCGCGUUACCUCCGCGCCUGCAAAUAUCGGUGAGAAGCCCACCUAAGGGCUCGGCGCCGACCCCUGCCUCCGCGGCCGCAAAUAUCAGCGAAAAGCCCACUGCAUCUAAGGGCCCGGCG,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,100 nM [SNHG9-as];|0.01-2µM[LATS1-GFP],"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,Fluorescence microscopy,"solute, liquid","Droplet formation was observed when the protein concentration of LATS1-GFP was 0.1 µM in the presence of SNHG9-sense, while no droplet formed at the same protein concentration in the presence of SNHG9-antisense or in the absence of RNA",345
275,698,PMID: 34267352,RNAPS0000625,https://pubmed.ncbi.nlm.nih.gov/34267352,RNA + protein,NCBI ID:735301,https://www.ncbi.nlm.nih.gov/gene/735301,SNHG9,345nt(1-345),GCGGCCCGGGAAUCUACGUCACCCGAAAAGCGACUAUAAACGCCGGCGCCUCCGUCCCCAGCCGCGGCUCGGGAAUCCACCCGAAGAGUGGCUAUAAACGUCCGCGCCUCCAUUGCGCUCUCCUCUUCACUUAGGACACUGGUCCUCCCACGCCUGACACCGACGUCGCCAGGACCGCGGGGUUGGGGGAACUUGGCUGUCCCACGUCUUUCAAAUAAAGCUGUUUUGUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,lncRNA,Homo sapiens,"sp|O95835|LATS1_HUMAN Serine/threonine-protein kinase LATS1 OS=Homo sapiens OX=9606 GN=LATS1 PE=1 SV=1
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTE
DPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVI
QALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKG
SKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPP
QVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGY
PPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQ
NVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNME
LYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQ
PSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNV
TVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENV
DSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHR
KKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVC
LARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYF
VMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDG
HIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAAR
QHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQM
KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLR
QQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTF
RRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV",LATS1,-,-,1130aa(1-1130),O95835,"DrLLPS,PhaSepDB","http://llps.biocuckoo.cn/view.php?id=LLPS-Hos-1421,http://db.phasep.pro/browse/","[1-68],[149-276],[294-321],[365-405],[432-484],[515-601],[1104-1130]","[228-267],[301-314],[434-447],[483-494],[555-560],[1104-1116]",In vitro,0-2nM[SNHG9];|2-8µM[LATS1-GFP],"15 mM NaCl, 130 mM KCl, 5 mM KH2PO4, 1.5 mM MgCl2","20 mM Tris-HCl, pH 7.5",25˚C,2 h,other_molecular:1 mg/mL BSA,Fluorescence microscopy,liquid,"Additionally, our orthogonal experiment suggested that LATS1 underwent phase separation in a dosedependent manner with additional SNHG9",345
